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Summary
The primary purpose o f the present experiments was to elucidate the role of putative 
brain serotonergic and dopaminergic modulators and indices (markers) in ‘central 
fatigue’ during exercise in health and disease, with a concuiTent examination of 
metabolic, cardiovascular and perceptual responses.
In experiments (EXPs) 1 and 2, the subjects undeiwent thi'ee main exercise trials. 
The first, following a pre-exercise high CHO meal (Control trial) and the remaining 
two after a pre-exercise high fat meal with (EC trial) and without (F trial) caffeine. 
The use of fat meals was employed to elevate circulating plasma free fatty acids 
(FFA) levels in an attempt to produce i) a similar muscle metabolic adjustment, and, 
ii) a parallel displacement of plasma Trp from albmnin by plasma FFA and therefore 
similar brain serotonin (5-HT) manipulation in both F and FC trials. Differences on 
brain 5-HT and dopamine (DA) modulators and indices, exercise performance and 
perceptual (RPE), metabolic and cardiovascular responses could be examined by 
ingestion of caffeine. Thus, caffeine would differentiate between peripheral and 
central aspects affecting exercise fatigue and therefore the mechanism(s) associated 
with central fatigue could be evaluated.
Modulators and indices of brain 5-HT and DA functions (i.e. plasma free and total 
tryptophan (Tip), tyi'osine (Tyi'), large neutral amino acids (LNAA), Trp:LNAA 
ratio, fi'ee-[Trp]:[Tyr] ratio, Trp:Tyi- ratio, and prolactin) and exercise performance 
were not different between the trials but RPE was reduced and 
metabolic/cardiovascular responses increased during exercise with caffeine. The 
first two EXPs indicate a differentiation between putative metabolic and CNS 
effects of caffeine during constant-load exercise (since RPE was reduced following 
caffeine ingestion despite an elevation in cardiopulmonary and metabolic 
responses). However, the first two experiments demonstrate a dissociation between 
i) modulators of brain 5-HT function and RPE, ii) RPE and 
metabolic/cardiovascular responses and iii) RPE and exercise performance. 
Consequently, the reduction in RPE per se cannot contribute to enliancing exercise 
perfoimance and the mechanism of this RPE attenuation seems not to be associated 
with brain 5-HT modulators and function during exercise in well-trained humans. 
The EXP 2 showed also that during prolonged exercise in a low temperature (10”C) 
the primary cause of fatigue is muscle glycogen depletion. Consequently, neither
IX
‘central fatigue’ can be developed nor caffeine can contribute in enliancing 
endurance performance by attenuating brain 5-HT function and/or counterbalancing 
brain 5-HT:DA ratio in well-trained humans.
The aim of EXP 3 was to examine the effects of a creatine (Cr) supplementation on 
putative modulators and indices of brain 5-HT and DA fimction and on thennal 
stress dining prolonged exercise in the heat. The Cr was used as a ‘vehicle’ to 
increase hydration and/or reduce thermal stress-induced increase in brain 5-HT 
function. Cr reduced thermoregulatory (e.g. sweat rate, rectal temperature and heart 
rate) and perceptual responses, plasma ffee-[Trp] {P ~  0.001) and free-[Trp]:[Tyr] 
ratio (P = 0.001) and enhanced endurance performance in subjects classified as 
‘responders’ to Cr. The EXP 3 revealed that, the effectiveness o f Cr to alter key 
modulators of brain 5-HT and DA function may have contributed to the reduced 
thermal stress and effort perception during exercise in the heat and to the 
enhancement of endurance performance in the ‘responders’ to Cr supplementation.
In EXP 4, chronic fatigue syndrome (CFS) patients were examined because they are 
reported to have an up-regulation of brain Trp uptake (e.g. Baklieit et al. 1992). The 
aim of the fourth EXP was to elucidate the role of putative modulators (Trp, LNAA, 
Tyi*) of central fatigue in CFS, to evaluate the association between these modulators 
with perceptual and metabolic responses in CFS patients and to compare their 
results to those of matched sedentary controls. It was found that plasma free-[Trp], 
free-[Trp] : [LNAA] ratio and RPE were higher and plasma [Tyi*] and exercise 
tolerance lower in the CFS relative to the sedentary control group. It was concluded 
that the significant differences between patients with CFS and healthy controls 
observed in several key brain 5-HT and DA modulators suggest that central neural 
mechanisms associated possibly with up-regulation of brain 5-HT system may 
contribute to the decreased central motivation (increased RPE) and impaired 
exercise tolerance in CFS.
Taken together, the results across studies imply that putative modulators of brain 
serotonergic and dopaminergic systems (and therefore brain 5-HT and DA function) 
play a key role in pre-exercise central motivation and also in central fatigue process 
of well-trained humans during exercise in the heat (EXP 3) and in the exacerbated 
RPE, exercise intolerance and pathogenesis of CFS (EXP 4). However, under 
physiological conditions this central neural .drive of fatigue associated with
metabolic up-regulation of brain 5-HT does not affect exercise performance of well- 
trained humans (EXPs 1, 2). The exact mechanism(s) therefore for the attenuation of 
RPE with caffeine is unlikely to be a brain 5-HT-mediated but most likely a DA- 
mediated effect. Nevertheless, neither brain 5-HT nor DA systems would appear to 
be implicated in the fatigue process when exercise is performed without significant 
thermoregulatory stress thus enabling fatigue development during exercise to occur 
due to peripheral factors (i.e. glycogen depletion). However, the reduced RPE 
during exercise in the heat following Cr supplementation may be due, in part at 
least, to the reduction in modulators of brain 5-HT function and/or to a concomitant 
elevation in brain DA activation. Finally, the brain 5-HT up-regulation in 
conj miction with the brain DA down-regulation may have contributed in 
exacerbating RPE and reducing exercise tolerance in CFS.
The series of the present EXPs were the first to show;
1. The lack of central neural involvement, associated with brain 5-HT and DA 
modulators and function on the fatigue process during exercise in relatively 
thermoneutral environments in which fatigue occurs due to peripheral 
limiting factors (i.e. cardiovascular stress, glycogen depletion).
2. A possible contribution of Cr supplementation to the reduction in the 
putative modulators of brain 5-HT system and/or a direct contribution to the 
increased brain DA function.
3. Abnormalities in putative modulators of brain serotonergic and 
dopaminergic function in CFS patients, even in resting conditions, 
implicating the involvement of central neural mechanisms in the increased 
RPE and impaired exercise tolerance in CFS.
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Chapter one
General Introduction
1. General Introduction
Fatigue is physiologically characterised by the inability to maintain muscular force 
or power. It may have either a peripheral or a central mechanistic origin (Gandavia, 
1998; Newsholme et al., 1987; 1991). Under physiological conditions, peripheral 
fatigue refers to fatigue that has primarily a skeletal muscle cell malfiinction in 
origin involving an inliibition of actin-myosin cross bridges which reduce muscle 
shortening and therefore power output (Edwards, 1981). Central fatigue implies 
malfunction at central nervous system (CNS) and spinal cord levels (Asmussen, 
1979; Edwards 1981); predominantly, abnoi*malities in neurotransmitter pathways 
co-existing with psychological problems (Lloyd, 1998). Nevertheless, when 
reviewing the literature, one of the main difficulties is how to define fatigue and 
how to discriminate between central and peripheral fatigue. This becomes more 
complicated since several reports suggest that there are not only independent 
peripheral or central factors that contribute in fatigue but both intramuscular 
metabolic abnormalities and central motor-drive failure may simultaneously and 
proportionally contribute to developing general tiredness and muscle fatigue (Kent- 
Braun, 1999; Lewis and Haller, 1991; Swain, 2000). hi addition, fatigue during 
physical activity is influenced by motivation and effort perception (RPE) (Davis and 
Bailey, 1997; Dugan and Frontera, 2000), and its underlying mechanism varies 
according to the type, duration and intensity of exercise as well as the fitness and 
pre-exercise nutritional status of the subjects (Brooks et ah, 2000). Therefore, in 
order to examine central fatigue during exercise, effort perception and peripheral 
aspects that influence tiredness and muscle fatigue, such as metabolic and 
cai'diovasculai* responses, have to be taken into consideration.
According to Layzer (1998), four different types of fatigue can be distinguished in 
physiology and clinical settings. These include objective, subjective, systemic 
fatigue, and asthenia. Objective fatigue is an incapability to maintain a precise force 
and/or work rate during exercise. Subjective fatigue is the fatigue that can be 
produced by unpleasant feeling, such as muscle pain, dyspnoea and an excessive 
heart rate during exercise. Systemic fatigue, which is non-muscular exhaustion, can 
be formed during prolonged exercise, due in part, to dehydration, hyperthermia, 
hypotension, and hypoglycaemia. Asthenia, is the fatigue that mainly has a cerebral 
mediated effect without exhibiting abnormal physiological responses during
exercise. It consists of general exhaustion, weakness, tiredness and the inability to 
perfomi minor physical and mental activities.
Furthermore, fatigue can be sub-divided into i) acute, which is usually self-limited 
fatigue caused by identifiable aetiology, such as physical exertion, and is relieved by 
appropriate rest, and ii) chronic, which lasts more than six months and is not 
associated with exertion (usually with multiple-unlaiown aetiologies) (see Swain, 
2000). During physical activity for example, fatigue is a time-related exercise- 
induced reduction in muscle power capability depending upon the type of exercise 
and environmental conditions and it may have a peripheral or a central origin (e.g. 
Bergstrom and Hultman, 1967; Coyle et a l,  1986; Davis and Bailey, 1997; Meeusen 
and De Meirleir, 1995; Nielsen et al., 1993; Sahlin et a l,  1998; Woledge, 1998). 
However, under some abnormal circumstances such as chronic fatigue syndrome 
(CFS) the aetiology of fatigue cannot be identified easily, probably due to the 
multiple co-existing clinical symptoms that CFS patients may experience (Fukuda et 
a l,  1994). Although a number of studies exclude skeletal muscle dysfunction- 
induced fatigue in CFS suggesting a centrally mediated effect (e.g. Baklieit et a l, 
1992; Bested et a l,  2001; Castell et a l,  1999; Lane et a l, 1998; Lloyd et a l, 1988; 
1991; Sacco et a l, 1999; Sargent et a l,  2002; Sharpe et a l,  1997; Swain, 2000), the 
issue remains controversial and the mechanical origin of fatigue and physical 
activity intolerance in CFS remains unclear.
Some major factors that may influence exercise fatigue development include 
nutrition, pharmacological treatments and environmental temperature. Pre-exercise 
diet, caffeine and creatine (Cr) administration and heat-stress could affect peripheral 
and central mediated factors of exercise fatigue. Their manipulation therefore could 
contribute to probing, elucidating and understanding of the physiological and 
biochemical mechanism(s) of central fatigue development. Although the 
mechanisms of peripheral fatigue have been well characterised and understood the 
mechanism(s) of central fatigue with particular reference on putative brain 
serotonergic and dopamiergic modulators during exercise, have not been extensively 
studied and are not well understood in humans.
1.1 Peripheral fatigue
Peripheral factors contributing to muscle fatigue primarily include intracellular 
metabolic attenuation of the contractile process and excitation contraction-coupling 
failure (Baker et a l, 1993; Gandavia, 1998). Peripheral fatigue during exercise most 
likely depends upon the inability of the energy production systems to produce 
adenosine triphosphate (ATP) (Newsholme and Leech, 1983). This is highly 
associated with the mode, duration and intensity of exercise and pre-exercise 
nutritional status (Burke and Hawley 1999; Coyle, 2000; Horowitz and Klein 2000; 
Lambert et al., 1997; Spriet and Peters, 1998).
During prolonged submaximal exercise for example, in relatively low or 
thermoneutral temperatures fatigue is due to muscle glycogen depletion (Bergstrom 
et a l, 1967; Galloway and Maughan, 1997) and in part, to a reduction in blood 
glucose availability and this is associated with the duration of exercise (Coyle et al.,
1985). These may drive excitation-contmction coupling failure resulting in a slow 
time-course of recovery after this type of exercise (Baker et al., 1993; Edwards et 
a l,  1977). During short-duration high-intensity exercise however, glycogen 
depletion or blood glucose availability do not limit exercise capacity and muscle 
fatigue is developed by the accumulation of intramuscular metabolic end products 
(Newsholme and Leech, 1983). These metabolic end products presumably include: 
i) an increased intramuscular lactic acid, ii) an accumulation in inorganic phosphate 
(Pi), and iii) an accumulation of interstitial potassium (K^). i) The intramuscular 
lactic acid is dissociated into lactate and hydrogen ions (H^) (Fitts and Cellular 
1994). Lactate has a minimal effect in muscle fatigue (Posterino et al., 2001) but H^ 
may enhance muscle acidosis by reducing intramuscular pH (Pate et al., 1995). 
Acidosis, may affect muscle cross bridge or sarcoplasmatic reticulum (SR) function 
(Fitts and Cellular, 1994; Sahlin et al., 1998; Westerblad and Allen, 2002). ii) The 
accumulation in inorganic phosphate (Pi), which is elevated during high intensity 
exercise due to break-down of creatine phosphate (CrP), was found to depress 
contractile function (Baker et al., 1993; Westerblad and Allen, 2002; Westerblad et 
al., 2002). iii) The accumulation of interstitial potassium (K^) was found to reduce 
excitability of active muscle due to increased [K"^]-induced muscle acidification 
(Bangsbo et at., 1996; fuel et al., 2000; Nordsborg et al., 2003).
It is likely however, that the cause of muscle fatigue during intense exercise is due 
to combinations of all the above biochemical reasons without having any direct 
relationship between each mechanism. For example, the concuiTent accumulation of 
intracellular and extracellular which both may reduce pH separately elevating 
muscle acidosis (for review see Fitts and Cellular, 1994; Westerblad et al., 2002). In 
addition, evidence suggests that muscle fatigue may be developed during high- 
intensity exercise due to an elevation in intracellular Ca^^ stores, which may become 
trapped within the SR as a result of precipitation with the elevated levels of 
phosphate, (Allen et al., 2002) and/or to the depletion of intramuscular 
phosphocreatine (PCr) concentration [PCr] (Hultman et al., 1990). These result in a 
reduction in ATP-resynthesis (Soderlimd and Hultman, 1991) and therefore energy 
deficiency (Sahlin et al., 1998). Whatever the situation, it is evident that the 
development of muscle fatigue during exercise is depending on the fine balance 
between hydrolysis (as shown in equation 1.2.1) and re-synthesis of ATP in order 
energy deficiency to be minimised and the intramuscular chemical energy to be 
converted to mechanical power.
ATP’ + H2O -> ADP"'+ Pi^‘ + H" [1.2.1]
However, since the intracellular ATP storage within the skeletal muscle is negligible 
(~ 5mM/kg) (Bergstrom et al., 1967; Coyle et al., 1986; Hultman et al., 1967), ATP 
re-synthesis duiing exercise is provided through the anaerobic alactic, anaerobic 
lactic and aerobic energy production systems (Newsholme and Leech, 1983). The 
anaerobic alactic system involves the breakdown of stored muscle PCr which then 
donates a high-energy phosphate to adenosine diphosphate (ADP) for ATP and Cr 
production, as shown in equation 1.2 .2 :
PCr + ADP + ît< -^C r + ATP [1.2.2]
Glucose + 2P; + 2ADP pyruvate lactate + 2H2O + 2ATP [1.2.3]
The intramuscular PCr that can be stored is at around 15mM-kg"^ dry weight (250- 
400mg in total), and therefore provides an extremely rapid but limited supply of 
ATP (~ 6 s for ‘all ouf exercise) (Hultman et al., 1967; Pernow and Karlson, 1971). 
The anaerobic lactic system produces ATP through the oxidation of carbohydrates
(CHO) by way of glycolysis and lactate and production (Gollnick and 
Heiinansen, 1973). Glycolysis involves a series of chemical reactions which break 
down glucose or glycogen to the end-product pyruvate acid. Pyruvate is then 
converted to lactate as shown by equation 1.2.3. This yields a low ATP in 
comparison to the capacity of the aerobic system, but at a more rapid rate (Alpert, 
1965).
The aerobic system utilises the energy available through the oxidation of CHO, fats 
and to a much lesser degree protein (Newsholme and Leech, 1983). As described 
above, glucose or glycogen is broken dovm through glycolysis resulting in the 
production of pyruvate. Since pyruvate is then converted to acetyl coenzyme A 
(acetyl Co A), it is available for the Krebs cycle within the mitochondria. Fats 
undergo y^-oxidation leading to the production of acetyl Co A. Proteins have a more
complex catabolic steps compared to CHO and fats. Proteins depending on the
specific amino acids enter the energy production system at the level of pyruvate, 
acetyl CoA or directly within the Krebs cycle (for reviews see Haiper et al., 1984; 
Wolfe 2000; Newsholme and Leech, 1983).
Acetyl CoA undergoes further chemical reactions within the Krebs cycle, which 
most importantly lead to the generation of nicotinamide adenine dinucleotide 
(NADH) and, to a lesser degree, flavin adenine dinucleotide (FADH2). These 
reduced substrates are then available to the electron transport system and go through 
a series of redox reactions, with O2 being the final electron acceptor. The energy 
from these electron transfers pumps protons across the mitochondrial membrane and 
the electrical gradient then harnesses the energy required for ATP re-synthesis. The 
O2 taken up per ATP produced is higher for fat than CHO, although the CO2 
production per O2 is less for fat than CHO metabolism as shown by equations 1.2.4 
and 1.2.5, respectively (for more details see Newsholme and Leech 1983).
C16H32O2 + 2 3 O2 <-> I 6CO2 + I 6H2O +130 ATP [1.2.4]
C6H 12O6+ 606 ^  6CO2 + 6H2O + 38 ATP [1.2.5]
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1.1.1 Nutritional considerations and peripheral fatigue
From a historical point of view, the pioneering studies by Ki'Ogh and Lindhard 
(1920) using respiratory exchange ratio (RER) measurement, demonstrated the 
fundamental role of CHO and fat as the major sources of energy production during 
prolonged exercise. In addition, Levine et a l,  (1924), in studies measuiing blood 
glucose concentration ([glucose]) at the end o f a marathon race identified the basic 
role o f hypoglycaemia in developing muscle fatigue.
After this initial work many studies have been conducted to identify ways to delay 
an early onset of fatigue during exercise. Gordon et ah, (1925) suggested that pre­
exercise CHO loading and CHO replacement were able to enhance blood [glucose] 
and to suppress early muscle fatigue during prolonged exercise. Similarly, 
Bergstrom and Hultman (1966; 1967), using the direct needle muscle biopsy 
technique, observed that muscle glycogen was gradually depleted if  the submaximal 
exercise was sustained and it was almost totally depleted after an exhausted 
prolonged exercise bout. Bergstrom and Hultman, designed an outstanding 
experiment in order to produce muscle glycogen depletion in an active leg and to 
compare the muscle glycogen levels between the active and resting quadricep 
muscle the following days after consuming high CHO diet. Interestingly, they found 
lower and normal muscle glycogen levels on the active and resting muscles 
respectively at exhaustion relative to pre-exercise levels. After three days CHO 
loading the muscle glycogen levels o f the active muscle were ahnost a two-fold 
higher compared with the inactive muscle. Consequently, they recommended the 
classic CHO-loading and ‘glycogen supercompensation’ regimen before and after a 
prolonged exercise respectively and stressed out the important role of the enzyme 
glycogen synthase in contributing to glycogen resynthesis.
Thereafter, many studies have supported that CHO loading may enhance endurance 
performance (Coyle et al., 1983; 1986; Coggan and Coyle, 1987; 1991; Burke and 
Hawley, 1999; Febbraio et a l, 2000) by reducing the rate o f glycogen utilization, 
sparing therefore the glycogen in type I muscle fibres (Tsintzas et al., 1995) and by 
suppressing hepatic glucose production and increasing glucose uptake tlnough an 
increased plasma glucose and insulin levels (McConell et al., 1994). However, 
although Febbraio et al., (2000) found an increase in performance after high CHO
ingestion before and during exercise they did not find a difference in the 
contribution of CHO and fat oxidation to skeletal muscle. In a subsequent study 
also, it was found that an additional 3g-kg'^ (from 6g-kg"  ^ to 9g-kg‘^ ) three days 
CHO loading (Hawley et al., 1997), or a pre-exercise high CHO ingestion (Sparks et 
a l, 1998) did not improve endurance perfoi*mance or prevent early glycogen 
depletion during prolonged exercise. This probably occurred because as stated 
eailier the liver and muscle glycogen stores capacity are relatively small, at 
approximately 400g and 90g respectively in a -70kg male athlete (Bergstrom et al., 
1967; Hultman et al., 1967; Coyle, et al., 1986; Maughan, 2002).
On the other hand, it has been shown that pre-exercise CHO loading may result in 
fat sparing rather than in sparing endogenous CHO stores (Bosch et al., 1993) or 
muscle glycogen stores during exercise (Bosch et al., 1994; Coyle et al., 1986). It 
has been also shown that even when large amount of CHO is ingested before or 
during exercise the amount of blood glucose disappearance (Rd) and uptake is 
relatively small (Febbraio et al., 2000). The latter is supported by Bosch et al. 
(1994) and Wagenmakers et al. (1993). These authors suggested that the maximum 
oxidation rate of orally-ingested CHO is not more than 1.1 g.min"^ ; even if CHO 
ingestion rates increases up to 2 g.min'^ during exercise the glucose oxidation rate is 
not more than 1 g.min .^ In addition, high rate of CHO ingestion has been found to 
completely block endogenous glucose production and to attenuate exogenous 
glucose oxidation (Jeukendrup et al., 1999).
Alternative ways for delaying glycogen depletion during exercise have therefore 
been investigated. For example, pre-exercise high fat meal (Hawley et al., 2000; 
Hickson et al., 1977; Okaiio et al., 1996; 1998; Pitsiladis et al., 1999; Whitley et al., 
1998) and medium-chain-triglycerides (MCT) ingestion (Jeukendrup et al., 1996; 
Angus et al., 2000) were found to enhance circulating plasma [FFA] and fat 
oxidation. Hickson et al. (1977) using Wistar rats examined whether an increase in 
circulation of plasma FF A by com oil/heparin infusion could enhance CHO sparing 
by slowing the rate of glycogen use during prolonged exercise. They found an 
increase in circulating plasma levels of FF A, blood glycerol, 3-hydroxybutyrate (3- 
OHB), and improvement in endurance exercise performance in the rats that were 
administrated fat-oil/heparin (5 ml of com oil + 200 U sodium heparin) relative to 
control (5 ml of carboxymethyl cellulose + 0.9% NaCl), results that were attributed
___
to CHO-sparing. Similarly, Pitsiladis et al. (1999) examined the combined effect of 
CHO loading and pre-exercise high fat meal/heparin administration on metabolic 
responses and endurance performance during prolonged exercise to exhaustion at 
10°C. Although no significant differences between trials were obseiwed on major 
cardiovascular and metabolic responses ( Vo^, RER, HR, blood glucose and lactate) 
there were significant differences throughout exercise in plasma [FFA], resting 
blood glycerol and plasma TG levels, which all were higher in the high fat trial. 
Pitsiladis et al. (1999) concluded that such diet manipulation may improve 
endurance performance of well-trained cyclists by increasing circulating FFA levels, 
resulting in an earlier rise in the rate of fat utilisation and sparing CHO. However, 
although other investigators found an increase in fat oxidation and CHO sparing 
(Hawley et al., 2000) or an enliancement in plasma [FFA] (Okano et al., 1996; 
1998), [glycerol] and [3-OHB] (Whitley et al., 1998) following pre-exercise high fat 
meal manipulations they observed no improvement in endurance.
It is possible that the inconsistencies between the above studies regarding 
metabolism and exercise perfonnance, (after artificial elevation in plasma [FFA]), to 
be due to the different experimental protocols used. For example, different i) 
environmental temperatures (see Galloway and Maughan, 1997), ii) fluid 
replacement protocols during the trials (see McConell et al., 1997), iii) pre-exercise 
diet manipulation regimes (see Hawley and Burke, 1997; Tamopolsky et al., 1995), 
iv) exercise intensities, prolonged exercise to fatigue for example, between 50% to 
80% of V o2 max and/or time-trials (see Angus et al,, 2000 ), and v) inadequate 
recovery after each experimental trial by some studies (i.e. only 24 hours recovery) 
(e.g. Whitley et al., 1998) but not by others (more than 48 hours recovery) (see 
Goforth et al., 1997). According to Goforth et al, (1997), after prolonged exercise, at 
least 48 hours are required under resting supercompensated condition in order to 
achieve a complete hepatic-glycogen store recovery.
However, some other important central neural-factors may play a role in modifying 
exercise performance after pre-exercise high fat meal manipulation. For example, 
the artificial elevation in plasma [FFA], although it may increase fat oxidation and 
enhance CHO-sparing in some cases (Hawley et al., 2000; Hickson et al., 1977; 
Pitsiladis et al., 1999) it may reverse this metabolic benefit in some others by 
enliancing brain serotonin (5-HT) turnover and increasing effort perception (Young,
caffeine is co-ingested with the high fat meal. However, the exact mechanism in 
reducing effort perception after caffeine ingestion and/or whether effort perception 
is associated with the brain 5-HT and DA functions in humans during exercise is 
still unknown.
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1986). Plasma FFA may displace tryptophan (Trp) (the brain 5-HT precursor) from
■plasma albumin and therefore elevate brain Trp uptake and 5-HT turnover (Curzon 
et al., 1973) (see sections 1.2.1 and 1.2.5 for more details). Pitsiladis et al., (1999) 
for example, observed that after a pre-exercise high fat meal/heparin administration 
there was an earlier rise in perceived exertion and 5 out to 6 subjects ranked the fat 
trial as the most difficult.
Some studies linked brain 5-HT metabolic up-regulation with elevation in effort
perception during exercise (Blomstiand et ah, 1995; 1997; Davis et ah, 1993). Davis
and Bailey (1997) have proposed that a high brain 5-HT:DA ratio may favour
central fatigue, while a low 5-HT:DA ratio may favour increased arousal and
motivation. Consuming a high fat meal prior to exercise has the potential, therefore,
to increase brain 5-HT turnover elevating perception of effort. On the other hand, a i
recent study, has shown an enhancement in exercise perfonnance when the brain 5-
HT:DA ratio was reduced after intracerebral caffeine injection (Davis et al., 2003).
Some others have also demonstrated that caffeine reduced effort perception during
exercise resulting in enlianced exercise performance (Cole et al., 1996; Bridge et ah,
2000). Perception of effort during exercise may therefore be the outcome of a fine
balance between the 5-HT and DA fimctions, with changes in effort perception
_resulting from a disturbance of this balance. Consequently, it could be hypothesised 
that if  the increased effort perception after a high fat meal (Pitsiladis et al., 1999) 
imitates an increased brain 5-HT function and the reduction in effort perception with 
caffeine (Bridge et ah, 2000; Cole et ah, 1996; Jacobson et ah, 2001) reflects a 
reduction in brain 5-HT:DA ratio (Davis et ah, 2003) this effect might be reversed if
I
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1.2 Central fatigue
Various approaches have been used to establish a definition for central fatigue, to 
distinguish its functional development and mechanical origin and to discriminate it 
from peripheral fatigue. Central fatigue can be defined as the voluntary or 
involuntary inliibition of motor units resulting in a reduction in motor unit firing 
fi'equency due to malfiinction o f neuronal-drive centres (Edwards, 1981). These 
CNS dysfunctions, which reduce the ability to fully activate the muscle, cannot be 
explained by a dysfunction within the skeletal muscle cell (Davis and Bailey, 1997).
Central fatigue is characterised by a progressive decline in discharge rate of moto- 
neurones and therefore a progi'essive reduction in muscle contraction (Gandevia,
1998). CNS fatigue can be distinguished from peripheral fatigue by comparing the 
repeated maximal voluntary force generated with a maximal electrical (tetanic) 
stimulation. It has been suggested for example that when there is a gi*eater fall in 
voluntary force compared to electrical stimulation force, fatigue is partly due to 
central factors. However, when both muscle contractions, voluntary and tetanic 
force decline in synchr ony the fatigue has a muscular mediated effect and not a CNS 
origin (Asmussen, 1979; Bigland-Ritchie, 1981; Bigland-Ritchie et al., 1986).
Aspects that may be implicated in producing central fatigue or central inhibition j
include an attenuation of motor-coifex drive information supply, increase in tremor ]
of the exercising limb and inability of the motor neurons to recruit only the specific 
muscle-group associated with the muscle contraction in order to achieve an |
energetic task (Gandevia, 1998). However, the reduction in motor neurons charge ' |
may be due to mechanoreceptors reflex feedback or associated with skeletal muscle 
activation-end products that may affect group III and IV nerve endings (Bigland- 
Ritchie et al., 1992). Therefore, it is reasonable to consider that central fatigue 
during exercise is perhaps associated with muscle metabolic end products. No 
strong body of studies has to date simultaneously examined the interaction between 
central components of fatigue and muscle metabolic responses during exercise.
The various tecliniques of comparing voluntary and involuntary muscle contraction 
(Twitch Interpolation Technique) to examine peripheral and central fatigue, 
however, preclude the examination of central physiological and biochemical 
parameters, which may play a role in fatigue process when many muscles groups are
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involved during exercise (for review see Enoka and Stuart, 1992). Furthermore, 
although the exact mechanisin(s) in driving to moto-neuronal failure is not clear, 
brain serotonergic pathway dysfunction may play a role. It was recently reported 
that the primary functions of brain 5-HT system is to facilitate the motor output and 
to concurrently restrain sensory infomiation processing (Jacobs and Fornal, 1993;
1999). For example, it has been suggested that during metabolic up-regulation of 
brain 5-HT synthesis, more than the normal amount of this neurotransmitter can be 
released into the synaptic cleft diuing neuronal firing charge resulting in a higher 
postsynaptic stimulation in 5-HT neurons which may enhance central fatigue and 
lethargy (Newsholme et al., 1987). However, the metabolic regulation of brain 5-HT 
is mainly dependent on the availability of plasma amino acids precursors, free and 
total Trp. Brain 5-HT does not contain an enzymatic step that is rate limiting for its 
own bio-synthesis and formation (Anderson, 1981; Curzon et al., 1973; Sama et al., 
1985).
1.2.1 Tryptophan: structure, synthesis and metabolism
Interest in the amino acid Tip (Figure 1.1) centres on its role as a precursor to brain 
5-HT (Figure 1.2.), which acts as a neurotransmitter allowing neurons to transfer 
electrical impulses to other neurons and cells (Femstrom, 2000) and regulating 
significant physiological functions such as mood, sleep, thermoregulation, pain, 
appetite and fatigue (Young, 1986).
Figure 1.1 Chemical stincture of the essential amino acid tryptophan ■]|
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Figure 1.2 Conversion of tryptophan to brain 5-hydrohytryptamine (5-HT)
.Trp is an essential amino acid which is similar to phenylalanine and tyrosine in 
structure with aromatic amino-acids groups (Young, 1986). Its concentration in 
human cells is dependent upon dietary intake and the peripheral protein synthesis
,
(Reilly et ah, 1997). Rich dietary sources of Trp include poultry meats, milk, dairy, 
eggs, nuts, wheat germ and mainly grains and legumes such as beans (Newsholme 
and Leech, 1991). The daily requirement amount of Trp in an adult is around 0.25 g 
and dietary deficiency, which can induce a negative niti'ogen balance, is rare imder 
noitnal circumstances (for review see Newsholme and Leech, 1991). Nevertheless, it 
has been reported that the average daily Trp intake is at around 1-1.5 g and during 
clinical therapeutic prescription is at approximately 4 g (Reilly et al., 1997).
Although little is known about chronic or excessive Trp ingestion, the majority of 
psychophannacological and nutritional studies suggest that acute Trp depletion or 
loading significantly affects human behaviour by reducing or elevating brain 5-HT 
synthesis (for reviews see Yoimg, 1986; Reilly et al., 1997; Femstrom, 2000). In 
short, studies carried out by Young and colleagues (1985; 1988) showed that Trp- 
deficient drinlc caused a marked plasma Trp depletion promoting depression and 
reducing perfonnance on a proof-reading task, hi addition, more recent evidence 
suggests that rapid dietary Trp depletion increases subjective and behavioural 
aggression in subjects with high-trait aggression (Cleare and Bond, 1995), and 
anxiety and fear in subjects with panic disorders (Miller et al., 1995). Furthermore, 
acute Trp depletion increased impulsiveness and reduced stimulus-discriminating 
ability of normal individuals (Walderhaug et al., 2002). In contrast, a high Trp diet >'ï■ '7;
. . I#
increased the plasma [Trp]:[LNAA] ratio, improved mood and reduced depression 
during acute stress in vulnerable subjects by elevating brain 5-HT synthesis 
indicated by measuring plasma prolactin (Prl) levels (a brain 5-HT marker) (Markus 
et al., 2000).
After digestive processing of dietary proteins (to amino acids and di- or tripeptides) 
and proteolysis in the lumen of the intestine, Tip is released to the circulation and 
then is mainly absorbed and metabolised by the liver where is oxidised by 
tryptophan oxidase (Newsholme and Leech, 1991). Thereafter, Trp may be 
metabolised by tluee major metabolic pathways in mammals, i) In the periphery Trp 
is metabolised to fomiyl-kynurenine by the enzymes tryptophan-2,3-dioxygenase 
and indoleamine-2 ,3-dioxygenase and then to kynurenine by the enzyme kynurenine 
fonnylase (Lapin, 1980; Stone and Comiick, 1985; Moroni, 1999). ii) In the brain 
Tip is metabolised to 5-HT via hydroxylation of Trp and decarboxylation of 5- 
hydroxytryptophan and the rate-limiting enzyme of this reaction is tiyptophan 
hydroxylase (Newsholme et al., 1987). In the brain Tip, can also be metabolised to 
kynurenine by the enzyme indoleamine-2 ,3-dioxygenase, under some abnonnal 
circumstances such as inflammation (Saito et al., 1993). Metabolism of Trp to 
kynurenine in the brain is believed to account for 45% of its metabolism to 5-HT 
(Gal and Sheiman, 1980). iii) Lastly about 3% of Trp is metabolised to tryptamine 
in the brain (Lapin, 1981) and tryptamine is further converted to kyniuamines (Stone 
and Darlington, 2002).
It was reported that more than 95% of dietary Trp (that is not used in protein 
synthesis) is metabolised to kynurenine (Stone, 1993; Stone and Darlington, 2002). 
It was of a great interest to note that one of the significant reactions after the 
conversion of Trp to kynurenine in the liver is that kynurenine can be easily earned 
to cerebrospinal fluid (Heyes and Quearry, 1990) or directly passed to various brain 
regions by the LNAA-carrier (Fukui et al., 1991). Therefore, its concentration may 
be elevated in the brain. It was previously found for example that at around 60% of 
the brain [kynurenine] has a peripheral origin (Gal and Sherman, 1980). In the brain 
after the conversion of Trp to kynurenine the later can further be metabolised to 
kynurenic acid by the kynurenine aminotransferases, to quinolinate acid by 3- 
hydroxyatliralinic acid oxidase (Stone and Darlighton, 2002) or to anthamilic acid 
by kynureninease (Amirkhani et al., 2002). Kynurenic acid was found to be
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neuroprotective but quinolinate acid highly neurotoxic and it may cause 
mitochondrial dysfunction, increase free-radical generation and produce neuronal 
damage in vivo (Stone and Darlighton, 2002). Although the normal concentration of 
quinolinate acid in the brain is around and seldom surpasses 1 //M, in some abnormal 
circumstances such as in response to bacterial endotoxin it can be increased to the 
levels of 246/M  and 66 /M  in the brain and extracellular space respectively, 
producing toxicity within a few hours (for review see Stone and Darlington, 2002). 
Consequently, quantifying plasma [kynurenine] and its metabolites during exercise- 
stress may give a better understanding of the role of plasma Trp uptake by the brain 
and also examine whether kynurenine metabolites play a role in central fatigue 
during exercise.
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Figure 1.3 Chemical structures of the large neutral amino acids; tyrosine, phenylalanine, 
leucine, isoleucine, and valine
One of the main distinguishing characteristics of Trp from the other amino acids is 
that it is loosely boimd to plasma albumin (McMenamy and Oncley, 1958) and 
shares, with the other LNAA including the aromatic amino acids, the same plasma 
transport (L-system) carrier (Femstrom and Wurtman, 1972). The L-system earner 
includes leucine, isoleucine, valine, phenylalanine, methionine, tyrosine and 
tryptophan (Kilberg et a l, 1980). The LNAA include tyrosine, phenylalanine.
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leucine, isoleucine, valine; the branched chain amino acids (BCAA) include valine, 
leucine, and isoleucine; the aromatic amino acids include phenylalanine and tyrosine 
(Figm*e 1.3).
One of the main questions regarding Trp regulation, metabolism and its role on 5- 
HT synthesis is whether it is the free, albumin-bound Trp or both that contribute in 
brain 5-HT synthesis (Bloxam et al., 1980; Chaouloff et al., 1986; Yuwiler et al., 
1977). It has been previously observed that the bound Trp molecules have the ability 
to be released rapidly from albumin molecules in the blood enabling all bound Trp 
molecules to be taken up from brain and entrance 5-HT synthesis (Pardridge and 
Fierer, 1990; Femstrom and Femstrom, 1993). However, this action may be 
dependent on the experimental conditions. For instance, starvation was reported to 
elevate brain Trp levels by increasing availability of free Trp due to an enhancement 
in lipolysis and plasma [FFA], which may displace Trp from albumin (Chaouloff, 
1993; Curzon et al. 1973).
Some physiological parameters may affect the delivery of Trp to the brain-regions 
and therefore the brain 5-HT synthesis. These include i) the plasma Trp binding to 
albumin (Bloxam et al., 1980; Sama et at., 1985; Yamamoto et al., 1997); ii) The 
plasma LNAA that competes with Trp to cross the BBB (Femstrom and Wurtman,
1972); iii) The plasma [FFA], which may displace Trp from albumin (Curzon et al.,
1973); iv) The degree that total Trp is freed from albumin when the blood passes 
through the brain regions (Pardridge, 1979); v) Disturbances of the L-system 
transporters (Yamamoto and Newsholme, 2000); vi) Alteration in peripheral or brain 
kynurenine pathways of Trp metabolism that may affect plasma and brain [Trp] and 
therefore diminish Trp metabolism to brain 5-HT (Tiihonen et al., 2001); vii) In
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It was reported that 90% of Trp is loosely bounded to plasma albumin and the 
remaining 10% is imbound (Cangiano et al., 1999). Consequently, plasma [Trp] can 
change proportionally to the plasma [LNAA] and easily cross the blood brain barrier 
(BBB) (Femstrom and Wurtman, 1971; Pardridge, 1977). This may enliance brain 
5-HT synthesis although controversy does exist. A few studies for example, 
suggested that brain 5-HT synthesis may increase irrespective of the plasma [Trp] 
and brain Trp uptake (Elks et al., 1979) or Trp levels do not modify brain 
serotonergic neurons functional activity (Tmlson, 1985). a;
vitro studies also showed that an increase in plasma kynurenine levels may enhance 
plasma free-[Trp] by reducing the binding Trp to albumin since kynurenine 
competes with Trp for binding to plasma albumin (Cangiano et al., 1999).
1.2.2 Brain serotonergic system and behaviour
5-HT was initially discovered in the serum by Rapport and colleagues (1948) who 
suggested that 5-HT has the ability to elevate blood vessel tone (cited by Dinan, 
1996). However, the discovery of 5-HT in the brain regions was only reported in the 
mid fifties by Twarog and Page (1953) and further established in the early sixties by 
Dahlstrom and colleagues (1965 cited by Dinan, 1996). Its significant role in 
regulating various neurochemical reactions in human and, more specifically, in 
hypothalamic and neuroendocrine regulation, was discovered only over the last two 
decades (for review see Dinan, 1996).
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Figure 1.4 Schematic illustrations of the brain parts that accommodate the brain 5-HT 
synthesis and actions.
Brain 5-HT is a member of indolamines, which included with catecholamines 
(dopamine, epinephrine and norepinephrine) in biogenic amines. The cell bodies of 
serotonergic neurones are present in the mesencephalon, pons and medulla 
oblongata which are all mainly located in or near the brain stem raphe nuclei with 
projection to the hypothalamus (Jacobs and Fomal, 1999) and possibly to all areas in
17
(Chaouloff efn/., 1999).
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CNS (Figure 1.4). For example, efferent fibres of 5-HT-containing neurons may 
innervate the hippocampus, cortex, nucleus caudatus and accumbens, putamen, the 
substantia nigra, various thalamic centres, medulla and ventral horn of the spinal 
cord (Meeusen and De Meirleir, 1995). As stated above, all brain 5-HT is 
synthesised in the brain because the rate limiting enzyme, tryptophan hydroxylase, 
of brain 5-HT biosynthesis is not saturated under physiological conditions 
(Femstrom and Wurtman, 1972; Reilly et al., 1997).
Brain 5-HT is charged at physiological pH without being able to cross the BBB or to 
be diffiised into cells firom the extracellular space (Diksic and Young, 2001). The 
rate at which 5-HT is released from neurons in the brain has been demonstrated to 
influence the rate of 5-HT timiover and synthesis (Schaechter and Wurtman, 1990).
The specific brain-regions that are implicated to accommodate the 5-HT synthesis 
are mainly hypothalamus (Bailey et al., 1993b) midbrain, hippocampus, striatum 
(Chaouloff et al., 1989), and frontal cortex (Meeusen et al., 1996) (Fig. 1.4). Brain 
5-HT is believed to play an important role in various neui'oendocrine, physiological 
and subjective behavioural functions. These include regulation of the activation of 
the hypothalamic-pituitary-adrenal (HPA) axis, anterior pituitary and the adrenal 
cortex, appetite, locomotion, thermoregulation, sleep, arousal, pain sensation, effort 
perception and exercise fatigue (Acworth et al., 1986; Ben-Jonathan et al., 1989;
Dinan 1996; Newsholme et al., 1987; Wilckens et al., 1992; Young 1986). There is 
now considerable evidence to support the concept that the presence of 5-HT nerve 
terminals and/or receptors in different brain regions are associated with different 
responses to various behavioural and neuroendrocrinological stressors. For example, 
hippocampus, hypothalamus, brainstem and medulla are key stress-related 
neuroendocrine regulators regions and amygdala, striatiun, part of liippocampus, 
cortex and periaqueductal grey are key stress-related behavioural responses regions 
(Chaouloff et ah, 1999). Consequently, the neuroendrocrinological responses 
intended to provide physiological adjustments, via the sympathetic nervous system 
and corticotropic axis, which pennit suitable behavioural responses to stimulus
■i'SA
■ii',:The significant role o f brain 5-HT on human behaviour is due to its action as a 
neurotransmitter. Like dopamine (DA) (see below) and nor-epineplirine, 5-HT is 
known to act as chemical messenger transmitting signals from one neuron to another
including chemicals by which efferent neurons communicate with effector cells 
(Meeusen and De Meirleir, 1995). Changes therefore, in the synthesis and 
concentration of one neurotransmitter may influence the activity of the other 
reflecting modifications in neuroendocrine, physiological and psychological 
conditions (Dishman, 1997; Newsholme et ah, 1987). For these reasons many 
studies examined the metabolic effect of brain 5-HT on various clinical diseases. 
However, the actual role of this neurotransmitter and its effect in modifying the 
functional status of human behaviour in health and disease during exercise remains 
to be deteiinined. This probably occurs because the serotonergic neurons interact 
with the other monoaminergic neurons (dopaminergic, noradrenergic) (Davis and 
Bailey, 1997; Meeusen et al., 2001) and/or act independently to modify brain 
function and motor output (Gu, 2002). Previously, there has been discussion about 
the actual role of each of the monoaminergic systems linking dopaminergic neurons 
mainly with motor activity and norandrenergic system primarily with autonomic 
function (Meeusen and De Meirleir, 1995). However, recent evidence suggests that 
serotonergic neurons play a vital role not only in regulating smooth and cardiac 
muscle activation but also in altering neuroendocrine function, facilitating skeletal- 
muscle motor activity (Jacobs and Fomal, 1999) and coordinating sympathetic nerve 
activity (Bago et al., 2002).
1.2.3 Brain dopaminergic system and behaviour
The role of tire neurotransmitter DA or 3,4 dihydroxypheiiylethylamine in human 
behaviour was first reported only five decades ago (see Baumester and Francis,
2002). Thereafter, several clinical studies support the significant effect of brain DA 
metabolism on affective behaviour (Moore and Lookingland, 2000) and 
neurological diseases such as Parkinsonism, Alzheimer (Prat et al., 2000; Smith and 
Zigmond, 2003; Sutoo and Akiyama, 2003) and schizophrenia (Baumeister and 
Francis 2002). hr addition, brain DA system has been reported to affect mood state 
and cognitive behaviour (i.e. Di receptors) (Goldman-Rakic et al., 2000). Although 
DA was the first nem'otransmitter that has been reported to potentially determine 
motor activity (Freed and Yamamoto, 1985) and CNS fatigue (Bliss and Ailion, 
1971) in rat, only few studies have examined the role of putative modulators of brain 
DA flinction in central fatigue during exercise in humairs (e.g. Bridge et al., 2003).
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Dopaminergic cells group are foimd in the mesencephalon, the diencephalon and the 
telencephalon and most of the DA neurons, in the higher vertebrates, are located in 
the midbrain within the substantia nigra and the ventral tegmental area (for review 
see Goridis and Rohrer, 2002). The substantia nigra and ventral tegmental DA- 
neurons innervate the striatum (or limbic system) and neocortex respectively (Hynes 
and Rosenthal, 1999). The loss of substantia nigra DA-neurons result in the motor 
disorders such as Parkinsonism whereas overstimulation of ventral tegmental DA 
neurons has been associated with mental illnesses such as schizophrenia and drug 
addiction (see Hynes and Rosenthal, 1999).
DA is synthesised from the amino acid Tyr that is initially hydroxylated to 3,4- 
dihydroxyphenylalanine (DOPA) by Tyi* hydroxylase, the rate-limiting enzyme for 
brain DA biosynthesis (for DA structure, synthesis and metabolism see Fig. 1.5).
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Figure 1.5: Dopamine structure, enzymatic pathways of DA synthesis and DA metabolism. 
Adapted from Moore and Lookingland, (2000).
The majority o f this enzyme is located within the catecholamine nerve terminals. 
DOPA then, is decarboxylated to DA by the enzyme dopa-decarboxylase. DA, 
under normal physiological conditions is metabolised to 3,4-dihydroxyphenelinic 
acid (DOPAC) by monoamine oxidase and aldehyde oxidase. Thereafter, DOPAC is 
metabolised into homovallinic acid by catecho-o-methyltranslerase (for reviews of
2 0
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DA metabolism see Goridis and Rolirer, 2002; Femstrom and Femstrom 1994; 
Moore and Lookingland, 2000). However, although changes in plasma [Tyr] via 
nutritional effects may modify brain DA metabolism (Femstrom and Femstrom 
1994; 1995), some studies have recently demonstrated a direct metabolic up- 
regulation of brain DA synthesis, through predominantly adenosine receptors- 
inhibition effects (e.g. Davis et ah, 2003; Fredholm et ah, 1999), irrespective of 
levels of peripheral [Tyr] and brain Tyr uptake (for more details see section 1.2.5.3). 
In addition, it has been suggested that daily exercise may increase Ca^ "^  levels and 
semm Ca '^  ^ is transported to the brain where it activates Tyr hydroxylase which 
stimulates DA synthesis tlnough a calcium/calmodium-dependent system (for 
review see Sutoo and Akiyama, 2003).
Some studies, using rats support but not entirely explain the role of brain 
dopaminergic function in modifying exercise performance and central fatigue 
(Bailey et ah, 1993a; Chaouloff et ah, 1986a; Davis et ah, 2003; For more extensive 
discussion associated with these studies see sections 1.2.5.2 and 1.2.6.4). 
Consequently, more studies are required to examine the role of brain dopaminergic 
modulators and function in central fatigue in humans.
1.2.4 Methods for detecting brain 5-HT and DA metabolism
Various invasive and non-invasive methods have been applied to examine brain 5- 
HT and DA metabolism. The most extensively used methods include i) whole brain 
microdialysis techniques (see Benveniste and Huttemier, 1990), ii) cerebrospinal 
fluid (CSF) collection for inspecting 5-hydroxyindole-3-acetic acid (5-HI A A) and 
3,4-dixydroxyphenylacetic acid, the brain 5-HT and DA metabolites respectively 
(e.g. Chaouloff et al., 1986a; Bertilsson, 1987), iii) Positron Emission Tomography 
(PET) (see Diksic and Young, 2001) for detecting small structures such as brain 
stem and brain metabolic responses (Tirelli et ah, 1998), iv) a-methyl-L-tryptophan 
method employed alone (Diksic and Grdisa, 1995) or in combination with auto­
radiography or PET techniques (see Diksic and Young, 2001), v) measurement of 
plasma [Prl] (Ben-Jonathan et ah, 1989; De Meirleir et ah, 1985b).
Microdialysis, may be predominantly used in small animals during free movement 
with limited amount of brain trauma tissue in order to assess alterations in
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neurotransmitters metabolisms in brain extracellular space (Benveniste and 
Huttemier, 1990). Autoradiography measurement is for visualising small animals’ 
brain 5-HT synthesis under specific stressors (see Nagahiro et ah, 1990). a-methyl- 
L-tryptophan method permits the imaging of the brain trapping of labelled a- 
methyl-L-tryptophan, which is analogous of Trp, enabling the calculation of the 
brain 5-HT synthesis (see Diksic and Young, 2001).
Some methods employed however, to examine brain neurotransmission are not in 
general applicable when humans are tested. These include methods where a 5-HT 
agonist or antagonist diiigs are administrated and brain microdialysis or 
autoradiography techniques are used for direct quantification of 5-HT metabolism, 
hr addition, apart from not being generally applicable in humans the validity o f a- 
methyl-L-tryptophan method has recently been extensively criticised. a-methyl-L- 
tryptophan for example, is a substrate for Trp hydroxylase but not for protein 
synthesis and its final metabolite product, which is a-methyl-5-hydroxytryptamine, 
accumulates in brain tissue as it is not a substrate for monoamine oxidases. 
Consequently the calculation of 5-HT synthesis using this method is inaccurate (see 
Gharib et a l, 1999; Shoaf et a l, 2000). The PET method however, although it has 
many advantages is economically limited (Tirelli et al., 1998). Furthermore, 
although the CSF collection-method has been previously found useful in animal 
studies (Chaouloff et al., 1986a), some limitations should be noted. For example, 
there are not matching responses between changes in brain neurotransmission (e.g. 
5-HT and DA) synthesis and CSF metabolites (e.g. 5-HIAA and DOPAC) (for 
review see Diksic and Young, 2001). Indeed, in a study conducted by Chaouloff et 
al., (1986a) there was an increase in brain DA synthesis and its metabolite, DOPAC, 
during rumring but there were no changes in CSF-DOPAC levels. In addition, the 
pain and discomfort of a lumbar puncture is imethical for human volunteers. For 
these reasons and for practical perspectives it is obviously difficult to collect 
multiple CSF samples for examining the rate responses of 5-HT synthesis during 
exercise. Consequently, probably the most economical and practically applicable 
method would be with human subjects undergoing examination and multiple blood 
samples collected, in order to investigate brain 5-HT and DA metabolism is the 
plasma [Prl] method with a simultaneous examination of the putative brain 5-HT 
(plasma Trp, LNAA, FFA) and DA (plasma Tyr) modulators.
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1.2.4.1 Prolactin: brain 5-HT and DA metabolic interaction marker
Prl, which in human is composed of 199 amino acids, is a single-chain protein 
hormone secreted by the adenohypophysis (pituitary gland) (Sinha, 1995). This is an 
endocrine gland in the small, bony cavity at the base of the brain with projection to 
hypothalamus (Ben-Jonathan et a l, 1989). The majority of human studies are 
currently limited to examining the association between peripheral indices (markers) 
of central fatigue and exercise performance due to difficulty in directly assessing 
brain 5-HT and DA levels.
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Figure 1.6 Schematic illustration of the control of hypothalamic (anterior pituitary gland) 
prolactin (PRL) release, 1. Augmentation of plasma FFA increases free-TRP displacement 
from albumin, 2. Plasma free-TRP, BCAA, and TYR compete for transport to the brain over 
the L-carrier at the BBB. 3. The brain free-TRP is converted to brain 5-HT at serotonergic 
nerve terminals. 4. The TYR is converted to dopamine at dopaminergic terminals. 5. The 
newly synthesised 5-HT and DA are released in the outer layer of the median eminence. 
Then they enter the portal circulation, where they may directly act on the mamotrophs of the 
anterior pituitary. 6 . 5-HT which is bounded to 5-HTi receptors has a stimulatory effect on 
PRL release. 7. DA, which is bounded to DA2 receptors, has an inhibitory effect on PRL 
release. Adapted by Struder et al. (1998) and re-modified based on Struder et al. (1998), 
Bed-Jonathan et al. (1989), Nagy et al. (1992).
However, evidence suggests that Prl release is mainly under the control of the 
central serotonergic system (De Meirleir et a/., 1985a; b) and/or under the 
hypothalamic 5-HT and DA metabolic interaction (for review see Ben-Jonathan et 
ah, 1989; Freeman et ah, 2000). For example, DA has been suggested to be the 
major Prl-secretion inhibitor factor (Nagy et ah, 1992) and 5-HT injection or its
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agonist precursors and re-uptake inliibitors have been found to increase 
hypothalamic Prl release (e.g. Somoza et al., 1983; Van de Kar et al., 1996) (Figure 
1.6). Confirming the regulatory control of brain serotonergic system on Prl 
secretion, recent clinical studies using a 5-HTiA-receptors agonist drug, buspirone, 
observed an elevation in plasma [Prl] suggesting a metabolic up-regulation of these 
receptors resulting in enhancing Prl secretion (Bakheit et al., 1992; Meltzer and 
Maes, 1994; Sharpe et a l,  1996).
It should be noted that some studies do not support that changes in peripheral 
modulators of brain 5-HT influence Prl secretion and/or brain 5-HT and DA 
metabolic interaction. For example, Struder et al. (1995) found an elevation in 
plasma ffee-[Ti*p] and ifee-[Trp]:[BCAA] ratio during temiis but there was no effect 
on plasma [Prl]. They suggested a dissociation between plasma ffee-[Trp]:[BCAA] 
ratio and [Prl] during exercise. However, although inconsistency does exist, strong 
body of evidence suggests that plasma [Prl] represents brain 5-HT metabolism 
and/or 5-HT and DA metabolic interaction (e.g. Ben-Jonathan et al., 1989; De 
Meirleir et al., 1985a; b; Fischer et al., 1991; Lamberts and MacLeod, 1978; Nagy et 
al., 1992; Somoza et al., 1983; Struder et al., 1997; Van de Kar et al., 1996).
1.2.5 Brain 5-HT and DA metabolism and ‘central fatigue’
The first studies to report a metabolic up-regulation of brain 5-HT synthesis during 
exercise were published in the early sixties and mid-seventies by Barchas and 
Freedman (1963) and Romanowski and Grabiec (1974). They used animal models 
and obseiwed a significant elevation in the whole brain [5-HT] after prolonged 
swimming and running respectively. Thereafter, and based on the role of brain 
dopaminergic system in controlling human movement (Freed and Yamamoto, 1985), 
DA has been implicated in fatigue process during exercise. Heyes et al., (1985; 
1988) for example, suggested that manipulation of brain dopaminergic system was 
able to modify exercise performance. However, they did not indicate to what extent 
and under which mechanisms DA influence exercise perfonnance. Subsequently, in 
a pioneering series of studies by Chaouloff and colleagues (1985; 1986a; b; 1987) it 
was demonstrated the association between i) plasma ffee-Trp:BCAA ratio and brain 
5-HT synthesis, ii) CSF and 5-HIAA levels and iii) brain 5-HT/DA metabolic
24
interaction and motor activity during exercise. Chaouloff et aL, (1985) for example, 
use rats to examine the effect of prolonged submaximal running (1 h and 2 h) on 
lipolysis, [Trp] in plasma, liver and brain and on whole brain 5-HT and 5-HIAA. 
They found that prolonged iimning significantly increased plasma [FFA], which 
displaced Trp from albumin and therefore elevated brain fi'ee Trp uptake leading to 
accelerating brain 5-HT synthesis. It is noted that these responses to running were 
more potent after 2h than after Ih  of activity and also they were more effective to 
pre-exercise fasting than non-fasting condition (Chaouloff et al., 1985).
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Figure 1.7 The primaiy components of ‘central fatigue’ hypothesis at rest and during 
prolonged exercise (see text for details). BCAA: branched-chain amino acids; FA: Fatty 
acids; f-TRP: free TRP; 5-HT: 5-hydroxytryptamine (serotonin); TRP: tryptophan. Adapted 
fr om Davis et al., (2000).
Newsholme et ah, (1987) proposed the ‘central fatigue’ hypothesis to explain the 
relationship between plasma [Trp]:[LNAA] ratio and brain 5-HT turnover in light of 
the information on the effects of brain 5-HT on motivation, effort perception, 
sleepiness, lethargy, and fatigue (Figure 1.7). According to this hypothesis, during 
prolonged exercise, when the glycogen stores become progressively reduced there is 
an increase in BCAA catabolism and in adipose tissue lipolysis, in order both 
nutrients to contribute to muscle energy production (ATP). The increase in BCAA 
muscle uptake reduces plasma [BCAA] and increases plasma [Trp]:[BCAA] ratio. 
On the other hand, an increase in adipose tissue lipolysis and plasma [FFA] may 
additionally increase plasma [Trp] because plasma [FFA] may displace Trp from 
albumin and potentially increase [Trp]:[LNAA] ratio (Curzon et al., 1973; Spector 
1975). Since Trp competes with the other LNAA for transport across the BBB 
(Padridge et al., 1977; 1986; Femstrom, 1994) (Figure 1.7), the previous reactions 
may increase brain Trp uptake and 5-HT turnover, which may contribute in central 
fatigue (Newsholme et al., 1987).
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Testing the ‘central fatigue’ hypothesis two early studies conducted by Blomstrand, 
Newsholme and colleagues (1988; 1989) suggest that prolonged exercise increases 
plasma [Trp], [Trp];[BCAA] ratio and therefore brain 5-HT synthesis supporting 
this hypothesis. Thereafter, investigators have used nutritional supplementations and 
5-HT and DA agonist and antagonist dmgs to test the validity of this hypothesis in 
experimental settings as well as the effect of nutritional supplements and drags on 
central fatigue during exercise.
1.2.5.1 Central fatigue and nutritional considerations
Blomstrand and colleagues (1991a; 1991b) have supported that prolonged exercise 
may induce elevation in plasma [Trp]:[BCAA] ratio, which in turn may enhance 
brain 5-HT synthesis leading to central fatigue and this effect can be ameliorated 
during exercise by BCAA supplementation. However, although Blomstrand et al. 
(1991a; b) have shown a reduction in plasma [Trp]:[BCAA] ratio and an 
improvement in exercise and mental performance during a marathon race, a 30km 
rumiing trial and soccer game, some methodological limitations should be pointed 
out from these reports. For example, Blomstrand et al. did not initially obseiwe 
differences in marathon performance time between BCAA and placebo gi'oups but 
only after subdivision of faster and slower athletes (according to their performance­
time in the race). Since there was no a clear rational of subdividing the athletes into 
two groups without justifying the cut-off criteria in this selection there is a 
possibility for statistical bias, hi addition, apart from this bias some other factors that 
may affect brain 5-HT synthesis and exercise performance should be considered 
during uncontrolled field studies. For example, the pre-race diet and caffeine 
consumption that both affect neurotransmission and brain 5-HT and DA modulators 
were not controlled (Chaouloff, 1993; Davis et al., 1992; 2000; 2003; Fredholm et 
al., 1985; 1999). Environmental temperature also and fluid replacement during the 
race both of which can modify muscle metabolism (Febbraio et al., 1996) and CNS 
function and therefore exercise performance was impossible to control (Galloway 
and Maughan, 1997; Nielsen et al., 1993; Nybo and Nielsen 2001a, b, c; Nybo et a l,
2003). Consequently, due to these methodological limitations the studies by 
Blomstrand et a l, (1991a, b) do not provide strong support of the central fatigue 
hypothesis as proposed by Newsholme et al., (1987) but do not preclude the 
involvement of brain 5-HT system in central fatigue during exercise.
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Several other laboratory studies have however, demonstrated an attenuation in 
central fatigue development during exercise when there is a reduction in plasma 
[Trp]:[LNAA] ratio through CHO supplementations. Davis et al. (1992) examined 
the effect of 6% and 12% of CHO drinks on peripheral modulators and indices of 
brain 5-HT function during prolonged exercise. They observed a reversion of 
plasma ffee-[Trp]:[BCAA] ratio and an enliancement in endurance perfoimance 
without observing any peripheral metabolic benefit following CHO feeding. They 
attributed their findings to the action of CHO supplementation in delaying an early 
elevation in FF A mobilisation and plasma [FFA] which displaces Trp from albumin 
increasing [Trp]:[LNAA] ratio, brain Trp uptake and 5-HT turnover. However, 
Davis et al. (1992) may have overestimated their perfbraiance results because 
several of the subjects in the CHO trials were stopped, prior to volitional fatigue. 
Consequently, it was not possible to determine the actual cause o f fatigue between 
6% and 12% CHO-treatments and whether this could be associated with the plasma 
regulators of Trp transport to the brain.
Contradictory results concerning the effect of CHO feeding on plasma 
[Trp]:[BCAA] ratio but without precluding the implication of brain 5-HT metabolic 
up-regulation during exercise, were obtained by Farris et al. (1998). Using racing 
horses, they found that Trp infusion has diminished time to fatigue and elevated 
plasma [Prl] relative to placebo and glucose infusions trials. They suggested a 
metabolic up-regulation of brain 5-HT synthesis, without obseiwing muscle 
glycogen depletion. However, there was no effect of glucose infusion on plasma 
[FFA], free-[Trp] and free-[Trp]:[BCAA] ratio results that dispute the metabolic 
theory of central fatigue during prolonged exercise as proposed by Newsholme et 
al., (1987). Moreover, these results do not preclude a central fatigue development 
since Prl secretion was elevated and endui'ance performance diminished after Trp 
infusion (Farris et al., 1998). These results, regarding the role Trp in brain 5-HT 
synthesis and central fatigue, are consistent with those obtained by Soares et al. 
(2003) who suggested that intracerobroventricular Trp injection reduced mechanical 
efficiency and time to fatigue in rats. Gomez-Marino et al. (2001). Using brain 
micro dialysis teclinique they observed that the direct brain administration of the 
amino acids L-valine attenuated the extracellular elevation in hippocampus 5-HT
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release and thus central fatigue development during exercise by reducing brain Trp 
uptake.
In contrast, van Hall et aL (1995) found a reduction (8-12%) and an elevation (7- to 
20 fold) in brain Trp uptake after a BCAA supplementation and Trp ingestion 
respectively but no performance improvement in well-trained endurance athletes. In 
addition, Madsen et al. (1996) supported van Hall et al. (1995) results but in 
disagreement with Davis et al. (1992) and Farris et al. (1998), who both did not 
observe any improvement in endurance performance of well-trained athletes after 
BCAA or glucose supplements. Although ffee-[Trp]:[BCAA] ratio was significantly 
lower with BCAA relative to glucose or placebo. Finally, Verger et al. (1994) found 
that BCAA supplementation even reduced exercise performance relative to glucose 
or placebo supplements adding more confusion to this debate.
According to Davis et al. (2000) one possible reason for the discrepancies among 
studies used BCAA supplementations is the amoimt of BCAA given and that large 
dose may be required in order to produce attenuation in brain 5-HT synthesis during 
exercise. However, when large doses of BCAA were administrated, although there 
was a reduction in brain Trp uptake, there was an elevation in ammonia production 
due to metabolic deamination of amino acids during exercise (Wagenmakers, 1992). 
It is noted for example, that in the studies by van Hall et al. (1995) and Madsen et 
al. (1996) the ammonia production was significantly higher during exercise after 
BCAA relative to glucose and placebo treatments.
Ammonia was found to be noxious to the muscles and brain and to reduce 
performance by attenuating motor control and motor coordination (Banister and 
Cameron, 1990; MacLean and Graham, 1993; Wagenmakers et al., 1989). hi 
addition, ammonia production was found to be more pronounced when the prior to 
exercise glycogen levels were low causing a net rate of protein uptake and oxidation 
from muscles (Blomstrand and Saltin, 1999; Lemon and Mullin, 1980). Therefore, 
considering that many studies have examined the effect of pre-exercise BCAA 
supplementation on exercise performance and central fatigue after an overnight fast 
it was possible this manipulation would negatively affect performance. It was also 
found that even when muscle glycogen levels are normal before exercise ammonia
28
#7
production was higher after BCAA supplementation trial compared with placebo 
gi'oup (MacLean and Graham, 1993).
Summary and interpretation
It is difficult to explain the contradictory findings regarding the effect of nutritional 
supplements (BCAA, CHO, Trp) on ‘central fatigue’. It is possible that changes in 
peripheral modulators of brain 5-HT function via BCAA, CHO and Trp 
inteiwentions do not always reflect changes in brain 5-HT synthesis. Alternatively, 
Trp infusion per se may directly enhance brain 5-HT synthesis without significantly 
influencing putative plasma modulators of 5-HT synthesis and this is more 
prominent in animals models relative to human subjects. Although, after BCAA 
supplementation, ammonia production seems to be a reason for reducing exercise 
perfonnance due to its toxicity in muscle and brain (e.g., Banister and Cameron, 
1990), several other studies do not support an elevation in ammonia production after 
BCAA supplementation (e.g. Blomstrand et ah, 1997). Others have reported that 
even when ammonia production is elevated this did not diminish exercise 
performance (e.g., Calders et ah, 1997; 1999). It is also possible that BCAA and 
CHO supplements enhance muscle metabolism and therefore diminish peripheral 
fatigue during exercise rather than attenuating plasma [Trp]:[BCAA] ratio, brain 5- 
HT synthesis and central fatigue. Blomstrand et ah (1996) for example, using 
muscle biopsy technique found that BCAA supplementation contributed in 
maintaining muscle glycogen levels during prolonged exercise relative to placebo 
trial suggesting an increased supply of BCAA prevents muscle glycogen 
degradation during exercise.
Some major factors therefore that may contribute in discrepancies among the above 
studies are i) different experimental protocols, ii) the fitness level of the subjects 
used and iii) the environmental temperature during the experiments. In Blomstrand 
et ah (1991a; b) studies for example, the BCAA supplementation improved the 
physical and mental performance of the slower-ninners who were considered to be 
less-trained than the faster-runners. On the other hand, in subsequent control 
laboratory studies where well-trained endurance athletes were examined after 
BCAA supplementation, exercise performance was not improved (Blomstrand et ah, 
1997; van Hall et ah, 1995). Acworth et ah (1986) for example, demonstrated that 
brain Trp uptake and therefore 5-HT turnover increased significantly during
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prolonged submaximal exercise only in untrained rats. In addition, recent results 
indicate that well-trained individuals have different responses to Trp and cortisol 
regulation and 5-HT2a and j-HTzc receptors during exercise than non-fit individuals 
(Brooks et ah, 2001; Dwyer and Browning, 2000; Weicker and Struder, 2001). It is 
possible that the chronic endurance training (> 6 weeks) (Dwyer and Flynn, 2002; 
Jakeman et ah, 1994) increases the sensitivity of 5-HT post-synaptic receptors 
resulting in metabolic down-regulation in brain 5-HT synthesis and therefore 
attenuation in central fatigue (Newsholme and Blomstrand, 1996). In addition, it has 
been shown that differences in environmental temperature (from 11 °C to 2(fC  or 
20'^C to 30°C) can significantly influence thermoregulatory responses, substrate 
oxidation and fatigue development during prolonged exercise (Galloway and 
Maughan, 1997). Consequently, since enviromnental temperature camiot be 
controlled during field studies and the ambient temperature used from many 
previous laboratory studies could affect exercise fatigue for reasons other than 
glycogen depletion (e.g. thennophysiological stress), so that the implication o f brain 
serotonergic system in the fatigue process cannot be easily interpreted.
Based on these studies it could be suggested that BCAA and CHO supplements and 
Trp infusion may not be efficient nutritional manipulation methods to study central 
fatigue during exercise. Considering that 8 to 16-fold elevations of [Tip]:[LNAA] 
ratio are needed through diet manipulation to produce changes in brain 5-HT 
turnover (Leathwood and Femstrom, 1990) other strategies should be used in order 
to elicit changes in brain 5-HT synthesis and therefore study central fatigue 
development. Since plasma FFA may displace Trp from albumin (e.g. Curzon et al.,
1973) an artificial elevation in circulating plasma [FFA] should be an alternative 
physiological strategy in order to elicit changes in brain 5-HT metabolism.
1.2.5.2 Central fatigue and pharmacological considerations
The association between brain 5-HT metabolism and central fatigue was further 
examined by pharmacological-intervention studies. Wilson and Maughan (1992) 
examined the effect of Paroxetine (20 mg), a selective serotonin reuptake inliibitor 
(SSRI) drug, on exercise performance in humans. SSRI drugs block the re-entry of 
5-HT in the pre-synaptic nerve ending increasing extracellular [5-HT] (Meeusen et 
aL, 2001). Wilson and Maughan, found that SSRI diminished endurance exercise 
performance without affecting peripheral metabolic and physiological responses,
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results that were attributed to the increased synaptosomal [5-HT] and therefore 
central fatigue. However, Wilson and Maughan did not measure several important 
blood metabolite variables of the brain 5-HT and DA function, such as peripheral 
indices (e.g. plasma Prl) and modulators (plasma Trp, LNAA, Tyr and FFA). It is 
therefore, not clear whether the inliibition in exercise performance observed after a 
SSRI drug is accoimted for by an up-regulation of brain 5-HT synthesis and if so, 
what mechanism is responsible for this inhibition in exercise performance.
More controlled studies, however, suggested that up-regulation of brain 5-HT 
synthesis or a down-regulation of brain DA metabolism may develop central fatigue 
during exercise. Bailey et aL (1993a and b), using rats found that exercise 
perfonnance deteriorated or improved after administration of brain 5-HT agonist 
(quipazine dimaleate or m-chlorophenyl piperazine) and antagonist (LY 53,857) 
drags respectively. Interestingly, the results obtained by Bailey et aL (1993b), which 
are consistent with the results obtained by Chaouloff et aL (1986), demonstrated a 
strong association between brain 5-HT and DA metabolic interaction and central 
fatigue during exercise. Bailey et aL (1993b) suggested that it is not only the 
elevation in brain 5-HT synthesis that plays a role in central fatigue development but 
the reduction in brain [DA] or elevation in brain [5-HT]:[DA] ratio is important. 
However, although animal models studying the effect of drugs on brain 5-HT 
metabolism seems to be relative consistent, there is not the same consistency when 
humans are examined.
Davis et aL (1993) using Fluoxetine (SSRI drug) suggested that endurance 
perfoimance deteriorated and effort perception elevated without observing 
significant differences on various metabolic and cardiovascular responses in 
humans. In addition, Struder et aL (1998) examined the effect of Paroxetine (20 
mg), BCAA, tyrosine and placebo interventions on brain monoamines and central 
fatigue during prolonged exercise in humans. They found that Paroxetine diminished 
endurance performance relative to placebo, BCAA and Tyr trials. However, plasma 
[Prl] was not influenced by the SSRI drag but it was significantly higher after 20 g 
Tyr administration relative to the three other trials, hi addition, although BCAA 
treatment reduced plasma free-[Trp]:[BCAA] ratio, ffee-[Tip] was not different 
between the trials and endurance performance was not improved relative to placebo 
and Tyr trials. These results suggest that if  plasma or brain [Trp] is not acutely
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elevated after diet or SSRI manipulation, changes in brain 5-HT synthesis and 
endurance performance should not be expected.
Other human studies, however, have failed to observe influences on exercise 
performance and brain monoaminergic system after pharmacological manipulation 
(e.g. Meeusen et aL, 1997; 2001). Meeusen et al. (2001) administrated capsules 
containing 20 mg-Fluoxetine or placeho in eight well-trained cyclists and they found 
no differences on exercise performance, various blood metabolites and effort 
perception. However, they found an increase in plasma [Prl] and ^-endorphins levels 
after placebo relative to SSRI treatment suggesting no increase in hypothalamic 5- 
HT ftmction with SSRI drug. In a subsequent study Meeusen et al. (1997) using a 5- 
HT antagonist drug, Ritanserin, and a DA agonist, L-DOPA, examined the brain 5- 
HT and DA metabolic interaction and central fatigue during prolonged submaximal 
exercise. They demonstrated that neither the DA agonist nor the 5-HT antagonist 
drugs when given in two single doses, influenced exercise performance.
Summary and interpretation
The inconsistencies among pharmacological studies examining central fatigue 
during exercise in humans may be due to various factors: i) the dosages of the drugs 
used relative to the fitness levels and body weight of the subjects. For example, 
Wilson and Maughan (1992), Struder et aL (1998) and Meeusen et aL (1997; 2001) 
used recreationally active, moderate fit and very well-trained endurance groups 
respectively but the same dose (20 mg) of the drugs, although the mean body weight 
varies between the studies; ii) the different drugs used. Fluoxetine or Paroxetine. 
Although, both drugs have SRRI action, the effectiveness of the drugs to influence 
brain 5-HT receptors is not the same, with Fluoxetine being relatively more potent 
SSRI (5-HT3 receptors) than Paroxetine. Probably because Fluoxetine does not 
interfere with the re-uptake of DA and nor-epineplrrine (Bowsher et aL, 1988); iii) 
the different exercise protocols in association with the fitness levels o f the subjects. 
After giving the same drug for example, Wilson and Maughan (1992) found an 
increased exercise performance in moderately fit subjects and Meeusen et al. (1997; 
2001) found no difference in endurance performance in well-trained subjects; iv) the 
inability of some subjects within the study groups to tolerate the drugs causing 
individual variation in response and therefore interferes with the mean results 
(Bridge et aL, 2001); v) the inability of the SSRI drugs to influence 5-HT receptors
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due to single or double doses given prior to the experiments. Some studies for 
example, observed a delayed increase in some aspect of brain 5-HT synthesis after 
single administration of SSRI drugs (e.g. Rigdon and Wang, 1991). This occurs 
because a single or double dose of SSRI drug may initially decrease 5-HT cells 
firing since the subjects are not desensitised to the drugs action (Chaouloff, 1993; 
Rigdon and Wang, 1991). Recent neuroendocrine-challenge studies for example, 
have failed to observe changes in brain 5-HT receptors after single doses of agonist 
or antagonist to 5-HT drugs (Montgomery et aL, 2001; Bhagwagar et aL, 2003); and 
finally; vi) the genetically determined differences on the behavioural, physiological 
and biochemical responses to monoamine agonist and antagonist drugs and to 
exercise-stress between the rat species (Martin et aL, 2000a; b; Pollier et aL, 2000). 
For example, SSRI response was found to differ among spontaneously-hypextensive, 
Lewis and Wistar-Kyoto rats after administration of the same amount of a 5-HT 
metabolic inliibitor drug: citalopram. (Pollier et aL, 2000).
In addition, most of the above-referred studies did not concurrently examine aspects 
affecting both peripheral and central components affecting fatigue and effort 
perception during exercise. It is difficult therefore to interpret the actual mechanism 
in diminishing or enhancing exercise performance after nutritional and 
pharmacological interventions. These factors make the existing results imcleai* and 
more studies using alternative strategies are warranted to examine central fatigue in 
humans.
1.2.6 Caffeine and exercise fatigue: focused on central effect
Caffeine is probably the most widely consumed ‘drug’ in modem societies all over 
the world (Fredholm et aL, 1999). Dietary sources of caffeine come from foods and 
beverages such as chocolate bars, cacao products and soft drinks but especially from 
coffee and tea (Fredholm et aL, 1999). It has been generally agreed that caffeine has 
the potential to impi'ove mood-state and cognitive performance and stimulate CNS 
resulting in attenuating tiredness and sleepiness (Hofer and Battig, 1994; Hogervorst 
et aL, 1999; Kamimori et aL, 2000). Medically, caffeine has been suggested to be 
useful as a cardiac stimulant, mild diuretic and a headache inliibitor (George, 2000). 
Although caffeine has extensively been investigated, the question of what is the 
actual mechanism(s) by which it affects human tissues, especially CNS, is still
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remained unanswered. Pharmacological studies into caffeine have proposed many 
theories, most of them however inconclusive, none entirely accepted or well 
characterised and understood. The problem arises from the multiple and 
simultaneous actions of caffeine on several tissues such as neuroendocrine, 
cardiovascular, respiratory, renal, and central and peripheral nervous systems 
(Fredholm et aL, 1985; Zhang and Wells, 1990).
Although, evidence suggests that caffeine may be a potential drug of abuse 
(Holtzman et aL, 1990) there are no strong side effects after caffeine consumption or 
any important negative consequences on human health. There are no strict medical 
restrictions on the amount of caffeine consumed by humans (see Fredliolm et aL,
1999). However, excessive and acute caffeine intake (e.g. 40 cups of coffee which 
may achieve more than 0.5 mM plasma [caffeine]) has been shown to be a toxic 
dose and it can negatively affect physiological function and psychological state 
(Fredholm, 1980). In addition, some reports suggest that caffeine should not be 
ignored as a possible addictive drug because it has a similar mechanistic action such 
as other psychoactive CNS-stimulant drugs including amphetamines, cocaine and 
heroin (Holtzman et aL, 1990). It should be noted however, that caffeine has a much 
milder effects than amphetamines, cocaine and heroin (see George, 2000). Caffeine 
does not have any nutritional value hut the last three decades it was commonly and 
extensively used by sports competitors as a nutritional ergogenic aid (Dodd et aL, 
1993; Graham, 2000a; b). For this reason the international Olympic Committee 
(IOC) were concerned about research relating to the ergogenic effect of caffeine and 
defined levels of more than 12 mg/1 of caffeine in urine as illegal doping, adding it 
to the list of band substances (Spriet, 1995).
1.2.6.1 Biochemistry of caffeine
Caffeine (C8H 10N4O2) or 1,3,7-trimethylxanthine, is a member o f a group of purine 
alkaloids (organic compound found in plants whose name derives from its chemical 
basis) known medically as the xanthines or methyl-xanthines (Figure 1.8a). Other 
chemical members of this group are theophylline, theobromine, and paraxanthine 
(Figure 1.8b) (Arnaud, 1987). Theophylline and theobromine are predominantly 
found in tea (0.3% by mass) and cacao beans (1.5% by mass) respectively as well as 
in human metabolites of caffeine. Around 75% of paraxantine is derived from 
caffeine metabolism (Amaud, 1993).
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Figure 1.8a Chemical structure of caffeine (1,3,7-trimethylxanthine) and adenosine
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Figure 1.8b Chemical structure of caffeine’s primary metabolic breakdown products, the 
dimethylxanthines: paraxanthine (1,7-dimethylxanthine), theobromine (3,7-
dimethylxanthine), and theophylline (1,3-dimethylxanthine) adapted from Hawke et aL, 
(2000).
1.2.6.2 Metabolism of Caffeine
After caffeine ingestion, caffeine can be spread rapidly to almost all cells of the 
human body by passing tlirough the cell membranes, including BBS due to its 
hydrophobic properties compounds (Fredholm et aL, 1999). The blood-to-plasma 
ratio of caffeine is close to unity indicating limited plasma protein binding and free 
passage into blood cells (McCall et aL, 1982). Absorption of caffeine from tea and 
coffee is much faster than from soft drinks; for hot drinks the caffeine levels are 
highest about one hour after consumption (Morgan et aL, 1982; Ai*naud and Welsch, 
1982). Generally, caffeine absorption from gastiointestinal tract is rapid reaching at 
around 99% in both animal and humans about 45 min after intake (Bonati et aL, 
1982). However, evidence suggests that caffeine absorption is not complete when 
the compound is taken orally from coffee (Arnaud, 1993; Morgan et aL, 1982).
After circulating the body, most caffeine molecules will eventually be taken up by 
the liver, where they are metabolised. The principal mechanism is the déméthylation 
and/or C-8 oxidation of caffeine, a trimethylxanthine, into dimethylxanthines and
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monomethylxanthines (Amaud, 1993). This produces dimethylxanthines and as we 
saw before the primary caffeine metabolites: paraxanthine, theophylline and 
theobromine, hi addition, in the liver, takes place the biotransformation of caffeine 
by oxidisation and conversion to uric acids and water-soluble caffeine can be 
directly lost in urine. There is no accumulation of caffeine in body fat or specific 
organs and the same permeability that enables caffeine to enter into the cells, also 
facilitates its rapid exertion from the cells (Fredholm et ai,, 1999).
For physiological doses (less than 10 mg-kg'^), caffeine half-life (the time taken for 
the body to eliminate one half of a given amount of a compound), ranges between 
2.5 to 4,5 hours in healthy human-adults and it is relatively similar with monkeys’ 
ranging fiom 3 to 5 hours (Bonati et aL, 1984-5). However, it is not the same in 
small animals such as rat and mouse (0.7 to 1.2 hours) (Amaud, 1987). The primary 
metabolic difference between small animal and humans is that in small animals 
around 40% of caffeine is metabolised to trimethyl (3-metyl) derivatives as opposed 
to 6% in humans (Amaud, 1993). In addition, caffeine metabolism in human leads 
to paraxantine (~ 75% of caffeine intake) but in animals this leads to theophylline 
formation (Fredholm et aL, 1999). However, theophylline is a more potent 
inhibitory factor of brain adenosine receptors than caffeine itself or paraxanthine 
(Benowitz et aL, 1995). It is noted that several studies suggested that women could 
metabolise caffeine at around a 25% faster rate than men (see Fredholm et aL,
1999). Consequently, this in association with the different caffeine half-lives 
between animals and human may be a reason of the inconsistencies between studies 
into the actions of caffeine.
1,2.6.3 Actions of caffeine
Caffeine has been suggested to have four particular actions in vitro, although the 
relationship between these actions and the drug effects in vivo are not well 
established. These actions include: i) adenosine A2A and A% receptors blockade, ii) 
inhibition of the enzyme phosphodiesterase resulting in attenuation of cyclic 
nucleotide breakdown, iii) enhancement in Ca^^ release and action in periphery, and 
iv) GABAa receptors blockade (Fredholm, 1980). However, the actions of caffeine 
on human physiological tissues are depended upon its’ dose. For example, in order 
to achieve an inhibition of the enzyme phosphodiesterase, to block GABAa 
receptors and to enhance Ca^^ release at around 20, 40, and 100 cups of coffee (~
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0.5 to 4 inM of plasma [caffeine]) respectively are required (Fredliolm, 1985). 
However, these doses of caffeine intake were found to produce severe toxicity with 
sometimes fatal consequences in humans; therefore these excessive caffeine intake 
levels should be avoided (Fredholm et aL, 1999). Only adenosine receptor inhibition 
can be achieved in human with physiological caffeine doses (less than 10 mg-kg'\ 
equivalent to 1-6 cups of coffee) antagonising almost all the actions of adenosine in 
human tissues, especially in CNS (see Fredholm, 1999). This probably occurs 
because caffeine has a distinctive molecular structure, which is biochemically 
similar to that of adenosine (Figure 1.8a) (Holtzman et aL, 1991). For this reason, 
caffeine molecules have the advantage of binding to adenosine receptors sites and 
deactivating and/or antagonising adenosine hinctions (Zhang and Wells, 1990).
Adenosine is created by the human body (mainly by brain tissue) and adenosine 
molecules are attached to their receptors sites (A%, A2A, A%B A3) (Latini and Pedata, 
2001). These are located at various tissues through-out the body including brain, 
cardiac and smooth muscles, adrenal gland and adipose tissue (Van Soeren and 
Graham, 1998). Adenosine plays an important role in biochemical processes, such as 
energy transfer - as adenosine triphosphate (ATP) and adenosine diphosphate (ADP) 
- and in signal transduction as cyclic adenosine monophosphate (cAMP) (Latini and 
Pedata, 2001). At cellular level adenosine receptors may inhibit (Ai) or stimulate 
(A2A) adenylate cyclase respectively which catalyses the formation of cAMP from 
ATP (Olah and Stiles, 2000).
Adenosine is probably the most important neuromodulator in the central and 
peripheral neiwous system meaning that its molecules can be diffused easily tlirough 
the synaptic cleft and control neiwe impulsiveness (Latini and Pedata, 2001). 
Consequently, adenosine has the potential to decrease the rate of spontaneous nerve 
cell firing and inhibits the release of several neurotransmitters, including DA, which 
controls the neuronal excitability. When adenosine molecules bind the adenosine 
receptors (mainly to Ai, A2A receptors) in the brain contribute i) to dilating blood 
vessels enabling more oxygen to be up taken by the CNS and sometimes causing 
vascular headaches (Latini and Pedata, 2001), and ii) to enhancing the release of 
neurochemical signals implicated to contribute in body relaxation and promote 
mood-depressing, drowsiness and lethargy (Fredholm et aL, 1995). For this reason 
some headache medications involve caffeine in order to counterbalance adenosine
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activation (Fredholm et a l, 1985; 1999). hi humans, for example, the Ai and A2A 
receptors are blocked with caffeine with a Kd of less than 50 pM (Fredholm et aL,
1999). Consequently, even after small caffeine doses (1-2 cups of coffee), caffeine 
may antagonise this drowsiness effect of adenosine enabling human cells to function 
slightly faster than normal and facilitating brain alertness; even when adenosine 
levels are high in the body (Fredholm et aL, 1999; Garrett and Griffiths, 1997).
Additionally, due to the increase in cell function and to the alertness effects of 
caffeine on CNS, there is a stimulation of the pituitary gland which enliances 
epinephrine production that it may further antagonise the drowsiness (Graham, 
2000a) and also increase adipose tissue lipolysis, fat oxidation and muscle blood 
flow (Costill et aL, 1978; Essig et aL, 1980; Ivy et aL, 1979, see section 1.2.4.6 for 
more details). However, the most significant action of caffeine as an adenosine 
receptors’ inhibitor is likely to be the promotion of brain dopaminergic activation, 
which has been found to regulate several basic neurological functions including 
integi'ative control of muscle movement, motor coordination and balance (Davis and 
Bailey, 1997; Meeusen and De Meirleir, 1995), body temperature (Hasegawa et aL,
2000), and hormonal secretion (Ben-Jonathan et aL, 1989). Apart from these effects, 
dopaminergic system has the potential to stimulate the ‘pleasure centre’ in the CNS 
(Fene et aL, 1992; Fredholm et aL, 1995), and reduce perception of exertion and/or 
physical and mental fatigue sensation (Davis and Bailey, 1997). Consequently, 
antagonism of adenosine activation in the CNS through physiological amount of 
caffeine ingestion may have the potential to attenuate central fatigue during exercise 
by enhancing brain DA:5-HT ratio.
Even though the primary action of caffeine may be to block adenosine receptors 
leading to inliibition of brain DA release this leads to some secondary effects on the 
CNS, autonomic NS and cardiovascular system (Fredholm et aL, 1999). Caffeine for 
example, has been shown to increase spontaneous electrical activity, enhance 
convulsant activity, stimulate locomotor activity and augment operant response rates 
in CNS (Daly, 1993). Caffeine also has been shown to relax bronchial smooth 
muscle (Garrett and Griffiths, 1997) and enliance inspiratory muscle contraction 
(assessed by changes in the power spectral density o f the diaphragm 
electromyogram during loaded breathing) which lead to a reduction in inspiratory 
muscle fatigue (Supinski et aL, 1986). Caffeine may enhance respiration by
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blocking brain adenosine receptors (Kawai et aL, 1995), which act to depress 
ventilation by inhibiting respiratory motor centres (Runold et aL, 1989). However, 
the exact mechanism of the effect of caffeine on respiratory muscles remains 
elusive. It has been shown for example that methylxanthines enliance VE and 
attenuate a CNS-fatigue involvement associated with respiratory muscles, by 
stimulating the respiratory motomeurones in medulla (Eldridge et aL, 1983). It was 
also found that caffeine (lOmg-kg"^) increases the amplitude of the neuromuscular 
inspiratory output (Mazzarelli et aL, 1986). An alternative mechanism indicates that 
caffeine (lOmg-kg"^) stimulates carotid sinus nerve discharge through an alteration 
of carotid chomoreceptor blood flow linked with the change in blood pressure 
(Bairam et aL, 1997). It has been previously demonstrated that methylxantines are 
effective bronchodilators useful in the treatment of astlima (Fredholm, 1985).
Furthermore, as it stated above, many studies have observed changes in plasma 
[catecholamines] after caffeine ingestion suggesting an enhancement in sympathetic 
nervous system activation (e.g. Van-Soeren and Grahaml 1998; Graham et aL,
2000). It has been suggested that caffeine influences heart muscle function by 
causing positive inotropic/chronotropic effects (Garrett and Griffiths, 1997). Others 
measuring the heart-rate variability in himians following caffeine ingestion observed 
an enhancement in the activity of both parasympathetic and sympathetic nervous 
systems at rest (Hibino et aL, 1997) and during exercise (Nishijima et aL, 2002). In 
addition, it has been suggested that high coffee intake may cause tachycardia, 
palpitations and a rapid rise in blood pressure via an elevation in norepinephrine 
release (Fredholm et aL, 1999). The release of norepinephrine from sympathetic 
nerves could be regulated by methylxanthines by a presynaptic mechanism at the 
sympathetic nerve terminal and this depends on the antagonism of adenosine acting 
at Ai receptors (Hedqvist et aL, 1978). Consequently, it is possible that the most 
important mechanism underlying increases in catecholamines release is a rise in the 
sympathetic outflow and that this is a centrally regulated phenomenon. (Fredholm et 
aL, 1999).
1.2.6.4 Caffeine and exercise performance
The effect of caffeine on exercise performance was first examined by Costill et aL 
(1978), Ivy et aL (1979), Essig et aL (1980) based on the early observation that i) 
caffeine may enhance epinephrine release and therefore elevate plasma [FFA] by
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stimulating adipose tissue lipolysis (Bellet et aL, 1968). And ii) elevating circulating 
plasma FFA may enhance fat oxidation and therefore reduce muscle glycogen use 
contributing in CHO sparing during prolonged exercise (Costill et aL, 1977; Rennie 
et aL, 1976). After a series of studies using animal and human models Co still et aL 
(1978), Ivy et aL (1979) and Essig et aL (1980) observed that caffeine enhanced 
epinephrine release and contributed to enhancing adipose tissue lipolysis, increasing 
plasma FFA uptake and fat oxidation and reducing muscle glycogen use. This 
resulted in enhanced CHO sparing and improved endurance performance. 
Thereafter, several reports provided supporting evidence for the ‘metabolic theory’ 
effect of caffeine on exercise performance (e.g. Chesley et aL, 1998; Dodd et aL, 
1993; Spriet et aL, 1992).
However, many studies have recently disputed the metabolic theory effect of 
caffeine on endurance performance (Chesley et aL, 1995; Cox et aL, 2002; Graham 
et aL, 2000; Graham and Spriet 1991; Graham and Spriet 1995; Greer et al., 2000; 
Laurent et aL, 2000; Mohr et aL, 1998; Roy et aL, 2001; Van Soeren et aL, 1996;
1998). In addition, improved high intensity exercise performance has also been 
demonstrated following caffeine ingestion (e.g. McNaughton, 1986; Flinn et aL, 
1990; Jackman et aL, 1996), where muscle glycogen depletion is clearly not the 
primary cause of fatigue. It is likely that caffeine may enhance endurance 
perfoimance, not by sparing muscle glycogen but through other, possibly CNS 
effects. Caffeine for example, has been reported to i) reduce effort perception (e.g. 
Cole et aL, 1996), ii) attenuate brain 5-HT turnover, tlirough an inliibition of the 
enzyme tryptophan hydroxylase (Lim et aL, 2001), and iii) inhibit central adenosine 
receptor activation, thereby attenuating ‘central fatigue’ by increasing DA:5-HT 
ratio in the brain (Davis et aL, 2003). However, the exact mechanism of these 
possible CNS actions of caffeine on exercise performance is still under discussion 
and no studies have examined the effect of caffeine on putative modulators of brain 
5-HT and DA function during exercise in humans.
1.2.7 Heat stress and exercise: focused on central impairment
It has been well established that exercise capacity is impaired in the heat relative to 
thermoneutral or mildly-cold environments (e.g. Bruck and Olschewski, 1987; 
Febbraio et aL, 1994; Galloway and Maughan, 1997; Nielsen et aL, 1993) but the
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precise mechanisms remain to be determined. Classic studies attributed the 
decrement in exercise capacity in the heat to reductions in muscle blood flow and a 
fall in blood and plasma volume (Nadel et aL, 1979; 1980; Rowell et aL, 1966) and 
to dehydration (Buskirk et aL, 1958; Cadaiette et aL, 1984). Hyperthermia can also 
limit exercise performance by increasing muscle lactate production and accelerating 
the rate of muscle glycogen depletion (Fink et aL, 1975) even during prolonged 
exercise in thermoneutral enviromnent (20°C) (Kozlowski et aL, 1985).
On the other hand, other studies have recently attributed the decline in exercise 
perfoimance in the heat to dehydration induced reduction in blood supply to 
exercising muscle by lowering perfusion pressure and systemic blood flow (e.g. 
Gonzalez-Alonso et aL, 1998). In a subsequent study Gonzalez-Alonso et aL (1999) 
examined whether reduction in muscle blood flow with heat stress-induced 
dehydration would decrease substrate delivery and metabolism and heat removal to 
and fr om exercising muscle during prolonged exercise. They found that there was no 
impairment of substiate metabolite or lactate removal but heat and dehydration 
elevated CHO oxidation and lactate production. They also found that most of the 
metabolic heat produced was released out of the active muscle to the surrounding 
areas suggesting that hypertheimia per se rather than a dehydration-induced 
alteration in muscle metabolism contributes in an early fatigue during exercise in the 
heat. In addition, although glycogen depletion was found to limit exercise capacity 
during prolonged exercise in 11°C (relative to exercise in 4°C, 21°C, or 31°C) in the 
heat some other factors probably CNS in origin should be considered to limit 
endurance capacity (Galloway and Maughan 1997).
Nielsen and colleagues (1993; 1997) have extensively investigated the role of core 
and brain temperature on exercise performance impairment in the heat. They 
initially proposed that when core temperature increases, at approximately 39.6°C, is 
a critical factor to inhibit exercise performance by reducing central motivation to 
exercise. In subsequent studies changes in electroencephalogram of the brain’s 
frontal area have been observed during exercise with hyperthermia suggesting that 
fatigue may occur at a critical brain temperature (Nielsen et aL, 2001); which may 
cause a cerebral blood flow dysfunction (Nybo et aL, 2002) or brain glucose uptake 
abnoiinality (Nybo et aL, 2003). However, the exact mechanism(s) of this 
dysfunction and/or whether increased core and brain temperatures may have
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secondary affect brain monoamines, especially increased 5-HT metabolism or 
reduced brain DA function, during prolonged exercise in the heat is not known yet 
(Nielsen and Nybo, 2003).
1.2.7.1 Exercise in the heat and brain 5-HT metabolism
Several studies link exercise in the heat with a metabolic up-regulation of brain 5- 
HT synthesis, which was found to contribute in elevating body-heat storage (e.g. 
Feldberg and Myers, 1964; Lin et aL, 1998; Sugimoto et aL, 2000; Mills and 
Robertshaw, 1981; Laatikainen et aL, 1988). Feldberg and Myers, (1964) for 
example, using animal models and continuous recording examined core body 
temperature regulation after intraventricular injection of 5-HT and catecholamines. 
They obseiwed that rectal temperature rose significantly, above the baseline levels 
after the injection of 5-HT but fall to normal levels after the injection of 
catecholamines. They suggested that high levels of injected 5-HT cause an increase 
in core body temperature and high levels of catecholamines have an antagonistic 
effect. The hypothesis of increased brain [5-HT] elevates core temperature is later 
supported by Sugimoto et aL (2000) and Lin et al. (1998). For example, when 
hypothalamic [5-HT] was increased in the rat by administration of Fluoxetine (i.e. 5- 
HT reuptake inhibitor) and 5-hydoxytryptophan (i.e. a 5-HT precursor), there was an 
increase in metabolic heat production with a concomitant reduction in heat loss (Lin 
et al. 1998). This is also supported by Sugimoto et al. (2000) who found that after 
administration of 5-HT agonist (p-Chloroamphetamine) the mice body temperature 
was increased, while it was decreased after administration of 5-HT2a antagonist.
On the other hand, Brisson et aL (1986) observed a positive correlation between 
increased core temperature and plasma [Prl]. In a subsequent study Brisson et al. 
(1991) compared plasma [Prl] during prolonged exercise (67% ofVo^max) in 41°C 
or lO^C. They found that during exercise in the heat either exogenous or endogenous 
heat loading increased blood [Prl] while no changes in [Prl] were observed during 
exercise in the cold condition. They concluded that changes in plasma [Prl] are 
highly regulated by exogenous or endogenous thermal-stress. Pitsiladis et al. (2002) 
also examined the effect of environmental temperatui'e on peripheral markers of 
brain serotonergic function and their association with exercise performance during 
prolonged exercise in the heat and in the cold after low and high CHO diets. They
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found that serum [Prl] was significantly higher and exercise performance lower 
during the two trials at 30°C (low and high CHO trials) relative to the two trials at 
10°C. They concluded that exercise in the heat, inducing thermal stress may up- 
regulate brain 5-HT metabolism independently of pre-exercise diet manipulation and 
peripheral modulators of brain 5-HT synthesis (plasma total and free [Trp] and free 
[Trp]:[BCAA] ratio). Consequently, based on the above results the central fatigue 
development during exercise in the heat is evident but the mechanisms are still 
unknown.
Some strategies, such as face/head cooling (e.g. Brisson et ah, 1989) or pre-exercise 
whole body cooling (e.g. Kay et al., 1999) were employed in an attempt to reduce 
thermal-stress and/or attenuate the elevation in Prl secretion. Gonzalea-Alonse et al.
(1999) for example, examined whether fatigue development during exercise in the
heat in trained athletes occurs at the same critical levels of core and muscle
temperature, despite differences in starting core temperatures and its rate of rise.
They designed an experiment where core, muscle (vastus lateralis) and skin
temperatures were manipulated prior to exercise by immersing the subjects in water
at 17 °C (pre-cooling trial), 36 °C (control trial) and 40 °C (pre-heating trial)
respectively. They foimd that in all three trials, fatigue during moderate exercise at
40 °C occuiTed at the same high levels of internal body (oesophageal temperature ~
40.1 °C) and muscle ( -  40.7 °C) temperatures when the initial value or the rate of
increased body temperature were altered. Despite the same core and muscle
temperatures observed at fatigue in all trials the shortest time to fatigue was found
on the pre-heating trial relative to pre-cooling and control trials. These results may
suggest that the initial core temperature plays an important role in the fatigue
.process during exercise in the heat and in the increase in the rate in body heat 
storage which contribute to the development of exercise fatigue.
However, although whole body pre-cooling may be beneficial during short-tei*m 
intense exercise (i.e. 1000 m time-trial) (Maresh and Sleivert, 1999), the
k « ■effectiveness of pre-cooling strategies in attenuating brain temperature (e.g.
Brengelmann, 1993), body heat storage and enhancing exercise perfonnance in the 
heat is insignificant when exercise lasts longer than 20-30 min (e.g. Drust et al.,
2000). Consequently, alternative approaches for reducing body heat storage and 
thermal stress during exercise in the heat (in an attempt to restrain a possibly brain
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5-HT synthesis and ‘central fatigue’) are required. It is possible that this can be 
achieved by Cr supplementation thi'ough its putative water-retention effect or via its 
positive effect on brain DA function (see Chapter 5). However, to date no studies 
have examined this particular hypothesis in humans.
1.2.7.2 Creatine supplementation and exercise in the heat
Creatine (Cr) or as chemically known, a-methylguanidino-acetic acid was first 
discovered by Chevreul, a French scientist, in 1832 from a meat extract. Its name is 
derived from the Greek word Kreas, which means flesh or meat from skeletal 
muscles. It was not until 1847 however, that Lieberg confimied its appearance as a 
regular constituent of flesh extracted from mammals (see Demant and Rliodes, 
1999). A significant observation by Lieberg was that the flesh of wild foxes 
involved ten-fold as much Cr as that of captive creatures suggesting a strong 
association between Cr accumulation and muscular exercise (Demant and Rhodes, 
1999). Thereafter, the studies by Denis (1912) and Folin (1914) (cited by Demant 
and Rhodes, 1999) demonstrated a 70% elevation in muscle [Cr] after Cr ingestion, 
and the studies by Fiske and Subbarow (1927, 1929) (cited by Demant and Rhodes,
1999) reported the presence of labile phosphorus in resting muscle and its reduction 
in electrically active cat skeletal muscle which was called phosphorcreatine (FCr). 
hi addition, these early experiments from Fiske and Subbarow, using electrical 
stimulation on skeletal muscle, demonstrated the role of Cr and PCr in skeletal 
muscle metabolism. However, it was only within the last two decades that 
systematic research into the effects of Cr supplementation on muscle metabolism 
and exercise performance has been undertaken (Kreider, 2003).
1.2.7.2.1 Biochemistry and actions of creatine
Cr (a-methylguanidino-acetic acid) is a naturally occurring compound synthesised 
predominantly in the liver, kidney and pancreas fi'om three amino acids: arginine, 
glycine and methionine and it is converted to creatinine before removal by the 
kidneys (see Lemon, 2002). The transamidination process starts with the transfer of 
an amidine group from arginine to glycine, which leads to the foimation of 
guanidinoacetate and ornithine, and is a reversible reaction catalysed by the enzyme 
glycine-amidine-transamidinase in kidney (Devlin, 1992) (Figure 1.9). Cr is then 
formed by the addition of a methyl group from (S)-adenosylmethionine
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(transmethylation), which requires the enzyme methytransferase for the iiTeversible 
chemical reaction in liver. Thereafter, Cr is converted to Cr phosphate (CrP) by the 
enzyme creatine phosphokinase and then under a non-enzymatic process, CrP is 
metabolised to creatinine (Devlin, 1992) (Figure 1.9).
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Figure 1.9 Chemical structure of creatine, the transamidination procedure of Cr in kidney 
and biosynthesis process of Cr in liver. Adapted from King (1998).
The normal plasma [Cr] ranges from 50 to 100 /anol/L (Harris et aL, 1992) and the 
vast majority of the body Cr/PCr pool, proportionally, is located in the muscle and 
neural tissues (Guimbal and Kilimami, 1993). Approximately 95% of the total 
body’s [Cr] is found in skeletal muscle; the remaining 5% found mostly in the brain, 
heart and testes (Demant and Rliodes, 1999). Since the main site of Cr utilisation is 
skeletal muscle, Cr must be transported from its site of synthesis to skeletal muscle 
via the blood-stream (Demant and Rhodes, 1999). After arriving at the skeletal 
muscle, uptake of Cr occurs against a concentration gradient and it enters a number 
o f cell types via a Na"^  dependent neurotransmitter transporter family associated to 
taurine and the members of the of y-aminobutyric acid/betaine transporters (Guimbal 
and Kilimami, 1993). It has been also found that the presence of insulin and 
deficiency of vitamin E appears to enhance and reduce the Cr uptake respectively 
(Gerber et aL, 1965; Haugland and Chang, 1975).
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Ill muscle and neural tissue, most of the Cr is phosphorylated to PCr in a reaction 
that is catalysed by the enzyme creatine kinase (CK) (Wallimann et aL, 1992). CK 
has four main isoforms (isoenzymes); i) Cytosolic or CK-MM, which is the skeletal 
muscle isofoim, ii) CK-BB which is the brain isoform, iii) CK-MB which is the 
isoform found in cardiac muscle, and iv) Mt-CK, the specific mitochondrial iso form 
(Brdiczka et aL, 1994; O’ Gorman et aL, 1996; Wallimami et aL, 1992). CK is a key 
enzyme involved in cellular energy homeostasis and it reversibly catalyses the 
transfer of the high-energy phosphate bond in PCr to ADP to form ATP, and it 
catalyses the hansfer of the high-energy phosphate bond in ATP to Cr to form PCr.
1.2.7.2.2 Creatine and exercise performance
As stated above, during high-intensity exercise (~10 sec) the availability of PCr is 
the limiting factor of skeletal muscle perfonnance. Consequently, Cr 
supplementation may enhance maximal-intensity exercise performance by 
increasing intramuscular Cr and PCr levels (Hands et aL, 1992; Kreider et aL, 1998) 
and accelerate the resynthesis rate of PCr (Greenhaff et aL, 1994). Thus, increased 
intracellular [PCr] contributes in transporting high-energy phosphates from 
mitochondria to cytosol and supplying high-energy phosphate into adenosine ATP 
preventing ATP depletion (Guerrero-Ontiveros and Wallimann, 1998). However, 
there are inconsistencies in whether Cr enhances muscle contraction and therefore 
high-intensity exercise performance (see Lemon, 2002).
Only few studies however, have examined Cr supplementation during prolonged 
exercise with some positive (Kern et aL, 2001; Volek et aL, 2001) or not significant 
(Vogel et aL, 2000) results on exercise performance, metabolic and 
theimoregulatory responses. However, none of the above studies has examined 
endurance perfoimance using a prolonged time trial exercise protocol to fatigue. 
Vogel et aL (2000) for example, examined power output ( 5 x 5  sec maximal 
cycling) before and after 75 min prolonged exercise at 32°C. In the study by Kem et 
aL (2001) although thermal-stress was attenuated tlirough water retention effect of 
Cr, the endurance performance was not evaluated because subjects were examined 
only for a fixed time period (60 min). In the study by Volek et aL (2001), although 
exercise performance (35 min prolonged exercise followed by 5 x 5 sec repeated- 
sprints) in the heat was improved, the cardiovascular, thermoregulatory and 
hoimonal responses were unaltered. However, in this study there were no available
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blood, cardiovascular, and perceptual responses to Cr supplementation data for more 
than 35 min of submaximal exercise and there was no examination of endurance 
perfonnance. Consequently, whether Cr supplementation improved exercise 
performance tlirough an enhancement in muscle contraction, body water 
maintenance or via any central effect is not known.
Studies have observed that Cr supplementation may enhance total body water 
(TBW) (e.g. Hultman et aL, 1996; Ziegenfuss et aL, 1998). This effect of Cr could 
prevent dehydration and body heat storage during prolonged exercise in the heat 
(Kern et aL, 2001). Dehydration and exercise in the heat were found to modify brain 
thermoregulatory centres, control evaporative heat loss (Turlejska and Lyszczart, 
1982), elevate hypothalamic 5-HT synthesis (Scacchi et aL, 1989; Mahapaita et aL, 
1991; Bridge et aL, 2003), increase effort perception and diminish exercise 
performance (Armstrong et aL, 1985; Nybo and Nielsen 2001c; Bridge et aL, 2000). 
The exact mechanism(s) however of the potential effect of Cr supplementation to 
attenuate body heat storage remains to be determined.
1.2.7.2.3 Creatine supplementation and brain effects
Studies on cerebral metabolism following oral Cr supplementation have been carried 
out in brain slices and animal models in order to assess the putative neuroprotective 
potential ascribed to the excess availability of Cr. Cr may exert neuroprotection by 
increasing or at least maintenance ATP/ADP and PCr/Cr levels in brain tissue and 
thereby providing extra energy for ion homeostasis and for the functional and 
structural integrity of mitochondria which lead to a protection against MPTP- 
induced dopamine depletion (Klivenyi et aL, 2004). Oral Cr supplementation for 
example, was found to increase brain [PCr] and to improve neuronal sui"vival in rats 
administered malonate or 3-nitropropionic acid to deplete succinate dehydrogenase 
and mimic the pathophysiology o f Huntington’s disease (Matthews et aL, 1998). In 
addition, oral Cr supplementation increased brain DA synthesis in the substantia 
nigra of Parkinsonian mice, produced by n-methyl-4-phenyl-1,2,3,6- 
tetrahydropyridine (MPTP) exposure, by increasing the number of suiwiving 
tyi'osine hydroxylasa(TH)-positive neurons (Klivenyi et al., 2004) and by enhancing 
tyrosine hydroxylase activation (the rate-limiting enzyme o f brain DA biosynthesis) 
(Klivenyi et ah, 1999; Matthews et al., 1999). The exact mechanisms however of the 
potential effect of Cr to enhance TH-positive neurons remain elusive.
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1.2.8 Clu'onic fatigue syndrome
A general fatigue sensation or even exhaustion with unknown aetiology characterise 
most of the neurological diseases such as Parkinson, multiple sclerosis, post-polio 
fatigue, fibromyalgia, neurasthenia, depression and chronic fatigue syndrome (CFS) 
(Chaudhuri and Behan, 2000; Lloyd 1998). hi CFS, several studies imply both 
peripheral (Lane et aL, 1994; 1995) but predominantly central abnormalities 
responsible for the development and persistence of the general drowsiness 
characterising the illness (e.g. Bakheit et aL, 1992; Cleare et aL, 1995; Demitrack et 
al., 1991; Swain, 2000). However, the precise cause of the pathogenesis of the 
disease remains to be determined.
CFS has become relatively prominent and recognisable disorder only in the 1980s 
(e.g. Barnes, 1986; Holmes et aL, 1988). Although some outbreaks of the disease 
have been reported in the late 1930s by the US Public Health organisation (Lee, 
1998) and in late 1950s by some medical reports, leading to the term ‘epidemic 
neuromyasthenia’ (Henderson and Shelokov, 1958; Poskanzer et aL, 1957). The 
prevalence of CFS has been recorded at 75-200 per 100,000 in preliminary 
community surveys, using criteria that excluded those with prior depression (Jason 
et aL, 1995). However, when major depression criteria have been included 740 cases 
per 100,000 has been recorded (Wessely et aL, 1997). Generally, CFS incidence, in 
primary care, is now estimated at 5 in 1000 individuals (Wessely et aL, 1995) and 
the prevalence of the illness was found to be significantly higher among women 
(373 per 100,000 persons) than men (83 per 100,000 persons) (Reyes et aL, 2003).
It is noted also that although a previous approach considered CFS to present more 
commonly in young adults, between 20 and 40 years (Levine, 1998), recent 
demogiaphic and psychiatric based surveys reported CFS incidence in 5-15 years 
old children (e.g. Jordan et aL, 1998; Chalder et aL, 2003). hi a community survey 
in USA for example, 2% of 4000 children were found to have CFS-like disease 
(Jordan et aL, 2000). In a recent clinical study, the incidences in CFS in children 
were found to be related to an abnormal brain function involving higher blood flow 
in the left basal ganglia and thalamus (Tomoda et aL, 2000).
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1.2.8.1 Diagnosis of CFS
The clinical diagnosis o f CFS is not simple because o f the absence o f the specific 
biochemical markers o f the disease (Lange et aL, 1998). In addition, because several 
major symptoms o f this illness are common and co-exist with the symptoms o f other 
clinical diseases such as fibromyalgia, irritable-bowel syndrome, thyroid disease, 
anaemia but especially major depression (Chaudhuri and Behan, 2000) definitive 
diagnosis is difficult. For this reason, regularly CFS patients are diagnosed and 
treated as depressed patients (Layzer, 1998).
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Figure 1.10 Immune mediators, neurotransmitters implicated and neuroendocrine factors 
(triangle) may modify neurological responses and enhance the risk factors (left square) and 
CNS symptoms (right square) associated with the pathogenesis of CFS. The 
neuroendorcrine pathway (F ‘ reversed arrow from left) associated with hypothalamic- 
pituitary-adrenal axis, immune system and gastrointestinal tract dysregulation. The 
sympathetic NS pathway (2"*^  reversed arrow from left) associated with heart and blood 
vessels, immune system and gastrointestinal tract dysfunction. The immune pathway (S"* 
reversed arrow from left) related with the immune system, lymphoid organs responses. The 
sensory pathway (F ‘ reversed arrow from right) associated with the possible 
musculoskeletal system dysregulation in CFS. Adapted from Royal Australasian College of  
Physicians (2002).
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The primary diagnosis of CFS is depended upon which symptoms are the most 
dominant but usually the diagnosis of CFS is accompanied with concurrent 
depression diagnosis which most of the CFS patients experienced (Royal 
Australasian College o f  Physicians, 2002). Due to the multiple clinical and 
neurological symptoms that characterise CFS (see Figure 1.10), it has been 
suggested that CFS cannot be simply defined as a specific disease and the term 
illness or asthenia are used (Layzer, 1998). The diagnosis of CFS is based on eight 
clinical symptoms. These include 1) impaired memory or concentration, 2) sore 
tluoat, 3) tender cervical or axillary lymph nodes, 4) muscle pain, 5) multi-joint pain 
without arthritis, 6) headaches of a new type, pattern, or severity, 7) unrefreshing 
sleep, and 8) post-exertional malaise lasting more than 24 h (Fukuda et ah, 1994; 
Lee, 1998; Lloyd, 1998). If four or more (> 4) of these symptoms, which are 
completely unrelated to physical exertion, are consistent and concurrently appear for 
more that six months CFS should be considered (Fukuda et aL, 1994).
1.2.8.2 Chronic Fatigue Syndrome and central nenral mechanism
The first report that demonstrated an implication of CNS dysfunction in chronic 
fatigue diseases conducted by Poteliakhoff (1981) who showed a significant lower 
baseline cortisol levels in chronic fatigue patients relative to control. However, this 
novel study by Poteliakhoff did not specifically include CFS patients since the 
disease was not recognisable until late 1980s. Subsequently, two reports by Lloyd et 
aL (1988; 1991) precluded muscle contractile failure to be associated with the 
pathogenesis of the disease implying a central mediated effect. Similarly, a study 
measuring cortisol and glucocorticoid levels between CFS patient and control group 
implicated the hypothalamic-pituitary-adrenal (HPA) axis dysfunction being 
responsible for the development of the disease precluding therefore the primary 
immune system disturbances in the pathogenesis of the CFS (Demitrack et aL, 
1991). Thereafter, several studies focused on the role of CNS in the pathogenesis 
and pathophysiology of CFS. Nemo-imaging studies for example, have shown that 
CFS patients had significant hypo-metabolic responses in right medio-frontal cortex 
and brainstem in comparison with the healthy control gi'oup (e.g. Tirelli et aL, 1998; 
Lange et aL, 1998). In addition, the serotonergic system has received considerable 
attention, because of its association with ‘central fatigue’ (e.g. Newsholme et aL,
50
— 1 _ ; . . .
1987) and its involvement in the control of HP A axis function (Chaouloff, 1993; 
Komaroff and Bucliward, 1998).
Central serotonergic function in CFS patients has been assessed using 
neuroendocrine challenge tests and measuring circulating levels of 5-HT modulators, 
such as plasma [Trp] (e.g. Castell et al., 1998) and other indices like Prl secretion and 
cortisol response (Bakheit et ah, 1992; Cleaie et ah, 2000; Sharpe et ah, 1997). 
However, a recent neuroendocrine challenge and physical stress study suggested an 
insignificant effect of the potential lower cortisol secretion on the pathogenesis of CFS 
(Gaab et ah, 2002). Additionally, some other studies measured GH responses to 
neuroendocrine challenge since GH deficiency or HPA dysfunction-induced GH 
release attenuation may deteriorate muscle contraction (Parker et ah, 2001). However, 
a recent, large and well-designed study that examined GH responses to 
neuroendocrine challenge (hydrocortisone treatment) in CFS did not support GH 
deficiency in CFS (Cleare et ah, 2000). Consequently, the lack of significant 
implication of GH and cortisol observed by neuroendocrine challenge studies may 
enable brain serotonergic system dysfunction as an important factor in the 
development of CFS.
Up-regulation of hypothalamic 5-HT ia post-synaptic receptors, indicated by measuring 
hypothalamic Prl secretion, in CFS patients has been reported at rest after a 5-HT 
agonist ding, buspirone (Bakheit et ah, 1992; Sharpe et ah, 1996). Enhanced 5-HT 
activity has been shown following administration of the selective 5-HT releasing drug, 
ri-fenfluramine (Cleare et ah, 1995; Sharpe et ah, 1997). As with peripheral indices, 
however, reports of an association between abnormal 5-HT function and CFS have not 
been witliout controversy. Two studies recorded enhanced 5-HT mediated responses to 
ri-fenfluramine in patients with CFS (i.e., as reflected in raised levels of cortisol and 
Prl) (Cleare et ah, 1995; Shaipe et ah, 1997) while another investigation found no 
differences between CFS patients and healthy controls in these indices of serotonergic 
function (Beam et ah, 1995). However, buspirone and ri-fenfluramine were found not 
only to enhance 5-HT activation but also to bind to DA-D2 receptors and affect 
catecholamines respectively (Sharpe et ah, 1996). Their action therefore in enhancing 
hypothalamic Prl secretion may be due to its ability in blocking D% receptors’ 
activation. This is tire primary Prl secretion inhibitor factor (Parker et ah, 2001).
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Consequently, the extent to which the inconsistencies might reflect heterogeneity of 
patient responses or to neuroendocrine challenge tests limitations is presently unclear.
1.2.8.3 Chronic Fatigue Syndrome and exercise tolerance
It has been well established that CFS is a disorder associated with persistent, often 
debilitating, physical and mental fatigue, that can be exacerbated by even mild 
degree of physical activity (Komaroff and Buchwald, 1998; Fukuda et a l,  1994). A 
number of studies have therefore examined whether the pathogenesis of the disease 
is associated with skeletal muscle dysfunction and/or cardiovascular system 
abnormalities. The results however, obtained from those studies are conflicting. 
Early reports for example indicated abnonnalities of muscle metabolism (Wong et 
aL, 1992) and/or histology in CFS (Behan et aL, 1992). Wong et al. (1992) for 
example, using magnetic resonance spectroscopy (MRS) examined metabolic 
responses of the gastronemius muscles during graded exercise to exhaustion and at 
recovery. They found a higher acceleration rate in muscle glycolysis during exercise 
and a lower intracellular ATP concentration at exhaustion in CFS patients relative to 
sedentary control group. They concluded that a deficiency in oxidative metabolism 
with a secondary acceleration of glycolysis in the skeletal muscle causes a reduction 
in physical endurance during exercise in CFS. In addition, Behan et al. (1991) using 
muscle biopsy examined muscle characteristics in postviral fatigue syndrome 
patients and they found mild to severe atrophy of type II fibres and mitochondrial 
abnonnalities in 39 out of 50 patients.
De Becker et al, (2000) also examined cardiovascular responses in CFS female 
patients at rest and after graded exercise to maximum. They found that CFS patient 
had lower maximum oxidative capacity and achieved lower maximum work-load. 
CFS patients also had higher resting HR but lower HR at maximum relative to 
control. De Becker et al. suggested that autonomic nervous system disturbances 
associated with peripheral incapability being responsible for the pathogenesis of 
CFS. Fulle et al. (2000) also, examined whether the pathogenesis of CFS is 
explained by oxidative damage to DNA and lipids in skeletal muscle sample 
comparing CFS patients with matched sedentary control. Consistent with Behan et 
al., (1991), Fulle et al. (2000) suggested that mitochondrial dysfunction and 
oxidative damage may be important factors in the pathogenesis of CFS. Similarly, in 
a subsequent study Fulle et al. (2003) investigated whether excitation-contraction-
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coupling abnonnalities could be involved in the development and sustaining nature 
of CFS. They suggested that CFS patients had significant abnormalities in Na’^ /K’^ 
pump function, sarcoplasmatic reticulum network and Ca^^ transporters to muscle 
dysfunction relative to control. However, it is noted that the studies by Fulle et al. 
(2000; 2003) are characterised by a small-unpaired sample size, only six subjects in 
each gi'oup, and therefore the generalisation of the results should be considered with 
caution.
Inconsistencies however, in the literature suggest that other mechanisms may be 
involved. For example, initial indications of premature blood lactate accumulation 
during exercise in CFS patients (Lane et al., 1994) were followed by subsequent 
studies showing considerable variation in the blood lactate response to exercise 
(Lane et a l,  1995). In addition, Lloyd et al., (1988 and 1991) examined whether 
peripheral and subjective fatigue are responsible for the pathogenesis of CFS. They 
found that peripheral responses to physical activity such as muscle strength and 
fatigability were normal in CFS when compared with healthy control group but the 
results concerning effort perception between the two studies were inconsistent. They 
suggested that muscle contractile failure and poor motivation are not important 
factors in the pathogenesis of CFS. More-recent studies also suggested that lactate 
metabolism and Vo^max were normal in CFS (Sargent et al., 2002). hi a subsequent 
study, it was found that although tliere was a partial restriction in muscle blood flow 
in CFS patients, oxygen delivery, (measured with near infrared spectroscopy) and 
oxidative muscle metabolism, (measured with MRS) there were no differences 
between CFS and sedentary control groups during exercise and recovery (McCully 
et al., 2004). Consequently, these results may suggest no muscle metabolic or 
histological abnormalities nor cardiovascular incapability in CFS patients indicating 
possible a central mediated effect.
It is possible that some peripheral abnormalities and the characteristic exercise 
intolerance of CFS, observed from some studies, are due to deconditioning (e.g 
Fulcher and White, 2000; Montague et al., 1989). Deconditioning may be of 
primary importance in the pathogenesis of the disease (Riley et al., 1990) and 
contributes in exacerbating the symptoms and maintenance of the physical disability 
in CFS (Gaab et al., 2002). Alternatively, some other studies support the hypothesis 
that CFS is a heterogeneous disorder with some patients influenced by peripheral
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abnonnalities but some others not susceptable (Barnes et al., 1993; Lane et al., 
1998). Barnes et al. (1993) for example, measured muscle bioenergetic and 
intracellular pH in CFS patients using phosphorus MRS. Although, they found 
abnonnal muscle metabolic responses in 12 out of 46 patients, overall there were no 
significant abnormalities in glycolysis, mitochondrial metabolism and pH regulation 
in CFS patient when compared with sedentary control. However, although several 
lines of evidence exist to suggest an abnormal hypothalamic response (e.g. 
Demitrack et al., 1991), particularly central neirrotransmitter dysfunctions in CFS 
(e.g. Bekheit et al., 1992; Cleare et al., 1995), the modulators of brain serotonergic 
and dopaminergic functions in association with perceptual and metabolic responses 
have yet to be studied in this patient population during exercise.
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1.3 Objectives
The primary pmpose of the present research is i) to clarify and improve the current 
understanding of the role of putative brain 5-HT and DA modulators (free and total 
Trp, Tyr, LNAA) and therefore of the brain serotonergic and dopaminergic function 
in exercise fatigue ii) to elucidate the relationship with the brain 5-HT and DA 
modulators and perceptual and metabolic responses in health and exercise intolerant 
patients and iii) to differentiate the mechanism between peripheral and central 
fatigue development in health and disease during exercise. The four separate 
experiments (Chapters 3 and 4: experiments 1 and 2, Chapter 5: experiment 3 and 
Chapter 6: experiment 4) share these common objectives, although the specific aim 
of each separate experimental chapter is summarised below:
A. Experiments 1 and 2. To simultaneously examine physiological and 
biochemical aspects affecting central and peripheral fatigue in well trained 
humans, using caffeine co-ingested with a pre-exercise high fat meal. This 
examination was intended i) to elucidate the relationship between putative 
modulators of brain 5-HT and DA function and perceptual and exercise 
fatigue development and ii) to clarify whether the actions of caffeine are 
associated with brain 5-HT and DA activation or with putative altered 
substrate utilisation effects dynamic exercise in well-trained humans.
B. Experiment 3. To examine the effects of oral Cr supplementation induced 
hyperhydration on putative modulators and indices of brain serotonergic and 
dopaminergic function, perceptual and thermoregulatory responses during 
exercise in the heat in well-trained humans.
C. Experiment 4. To investigate the role of putative plasma modulators of brain 
5-HT and DA function (Trp, Tyi*, LNAA) in possible central fatigue 
development in CFS patients at rest and dining gi'aded exercise-stress and to 
evaluate the association between these modulators and perceptual, metabolic 
and cardiovascular responses in CFS patients.
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Chapter two
General Methods
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2. General Methods
This chapter describes the general methodology used throughout this thesis. The 
thesis presents four main experiments. Specific methods to each particular 
experiment are described in the relevant chapters.
2.1 Subjects and study approval
All experiments (EXPs) described in the present thesis involved human volunteers. 
The subjects for experiments 1 (n = 8), 2, (n = 1 0 ) and 3 (n = 21) were all well- 
trained male athletes. For EXP 4, subjects were chronic fatigue syndrome (CFS) 
patients (male: n = 2 , female: n = 10) and healthy inactive sedentary control (male: n 
= 2 and female: n = 9).
Prior to each EXP, all subjects were informed of the nature and the purpose of the 
EXP and they made fully aware o f the known risks associated with each 
experimental trial. Subjects in EXPs 1 ,2 ,3  and 4 (sedentary control) underwent a 
general medical assessment including completion of a questioimaire relating to 
subjects individual and family medical history and physical activity profile 
(Appendix A). All patients who took part in EXP 4 fulfilled the Centres for Disease 
Control Criteria for CFS (Fukuda et aL, 1994) and were clinically examined in order 
to exclude any other medical condition. Primarily office based workers were 
recruited as control subjects and individually matched to CFS patients for physical 
activity. All subjects provided written informed consent prior to their participation 
in an EXP (Appendix B). It was emphasised that subjects should only take part in 
the EXP if they agreed to fiilfil all requirements and were fully committed. All EXPs 
were approved by the University of Glasgow Research Ethics Committee.
2.2 Determination o f Vo^max, lactate threshold and exercise work-rate
Prior to EXPs 1, 2 and 3, all subjects underwent a Vo^max test using a ramp
incremental protocol (15-20 W-min^) to the limit of tolerance (Figure 2.1) on an 
electrically braked cycle ergometer (EXP 1 ; Excalibur Sport, Lode, The 
Netherlands; EXPs 2 and 3: Bosch Erg-551 Forckenbecksti, Berlin, Geimany). The 
two different cycle-ergometers were methodologically demanded since the
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Excalibur Sport ergometer used in EXP 1 could not be used in EXPs 2 and 3 as in 
these EXPs the 10°C and 30 ambient temperature respectively with 70% relative 
humidity employed (during the familiarisations and main trails) could damage the 
Excalibur Sport ergometer. The primary criteria for indicating Vo^max were the 
reaching plateau o f Vo^ with an increasing work-load (i.e. EXP 1) in conjunction
with achieving near maximum heart rate (HR) (220 beats-niin'^ -  years of age) (i.e. 
EXPs 2 and 3) (Astrand and Rodalh, 1977; Lamb, 1984).
0 Fatigue (t^m)
aI
Vo 2 max
-3 -1
Time (hours)
15 to 20 Watts -min"^
unloaded
-5
Pulmonaiy gas exchange 
measurments & HR
/ r20
Time (min)
Figure 2.1 Schematic of the protocol used during incremental cycle tests to the 
limit of tolerance (tum) for experiments 1-3.
o 4.0
3.0
e 2 . 0
0.0 1.0 2.0 3.0 4.0
V O 2 ( L / m i n  -  STPD)
Figure 2.2 Non-invasive estimation of LT (or AT) using V-slope technique. Best-fit lines 
(SI & S2) are plotted though the sub- and supra-LT data respectively, LT determined as the 
point of intersection of the two lines. Adapted from Beaver et aL, (1986).
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Lactate threshold (LT) or anaerobic tlrreshold (AT) was estimated non-invasively as 
the Vo 2 at wliich: (a) the break-point in the relationship between CO2 output ( VcOj ) 
and VO2 ("V-slope" technique, (Beaver et aL, 1986)} occurred and (b) the ventilatory 
equivalent for O2 (VE/VOj) started to increase systematically without a concomitant 
increase in the ventilatory equivalent for CO2 (VE/VcOg) (Whipp et aL, 1986) 
(Figui'e 2.2). The purpose of measuring the LT was to deliberately normalise 
exercise intensity across the individuals, not only relative to VOjmax, but also the 
LT. This allows a more valid standardisation of exercise intensity during the main 
exercise trials in EXPs 1, 2, and 3 since not everyone's LT will occur at the same 
percentage of VO2 max. Therefore, the term A (see method sections chapters 3, 4 and 
5) can describe exercise intensity more accurately, as initially proposed by Rausch et 
aL (1991).
2.3 Gas exchange measurements: Vo2 max and constant-load protocols
In EXPs 1 and 4, gas exchange variables were detennined breath-by-breath using 
previously derived algorithms (Beaver et aL, 1973). Respired volumes were 
measured using a bi-directional turbine volume transducer (VMM, Alpha 
Technologies, Laguna Niguel, USA), calibrated using a high precision three litre 
syringe (Hans Rudolph, Kansas City, MO, USA). Respired gas concentrations were 
measured every 20 ms by a quadrupole mass spectrometer (QP9000, Morgan 
Medical, Gillingham, Kent, UK), which was calibrated against two precision- 
analysed gas mixtures. In EXPs 2 and 3 expired gas collections were made into 
Douglas bags at rest for 5 min, during unloaded pedalling for 2 min, and every 
minute during the incremental test. Expired gases were analysed for [O2] (Servomex 
570A, East Sussex, UK) and [CO2] (Servomex 1400 B4, East Sussex, UK), volume 
(dry gas meter, Harvard Apparatus Ltd., Hertfordshire, UK) and temperature (C6600 
10-Channel Microprocessor, Comark, Hertfordshire, UK). All gas vohunes were 
corrected to STPD. The gas analysers were calibrated before each test using a two- 
point calibration with precision gases (CO2 7.5%, O2 16%, N2 balance, certified 
standard gas). Barometric pressure for all EXPs (1-4) was measured using a standard 
mercury barometer. The results from the incremental tests were used to define the 
relevant work-rates for each EXPs (see individual Chapters).
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The breath-by-breath gas exchange analysis of the response to exercise is typically 
associated with ‘noise’, which has been extensively characterised (Lamarra et aL, 
1987; Rossiter et aL, 2000; Puente-Maestu et aL, 2001). These authors demonstrated 
the noise as an uncorrelated Gaussian distribution and that this confounding noise 
can prevent accurate characterisation of the underlying physiological response if  not 
considered. In EXPs 1 and 4, the breathing pattern was monitored carefully for 
in'egularities such as mis-triggered breaths, which can be caused by swallowing, 
sighing or coughing. Such breaths, which are clearly not indicative of the underlying 
physiological response, were identified by examining the chart tracing of the volume 
and gas concentration raw signals as well as the on-line individual breath 
characteristics, such as tidal volume, the dur ation of inspiration and expiration, and 
end-tidal gas concentrations. Individual breaths were compared with preceding and 
following breaths to determine whether the breath generated by the software was 
indeed a ‘real physiological’ breath. Breaths which were clearly not part of the 
underlying physiological response were excluded from subsequent data analysis, 
although dubious breaths were not removed. In tests where the response could be 
justifiably mathematically modelled, as linear the exclusion of such breaths was 
carried out by removing breaths which lie ± 4 s.d. outside the mean response as 
previously described by Lamarra et aL (1987).
The raw breath-by-breath data during the constant-load phase in EXP 1 was initially 
examined for outliers (‘noise’). After removal of outliers (i.e., ± 4 s.d.), 2 min 
averages for VO^, VCO^, RER, Ve were calculated for the following time points: 
8-10, 18-20 and 28-30 min. In EXP 2 and EXP 3 expired gases were collected into 
Douglas bags at rest for 5 min and thereafter for 1 min every 15 min in EXP 2 and 
every 5 min thi'Oughout exercise in EXP 3. V o^, VCO^, VE and RER were 
subsequently used to determine energy expenditure (EXP 1-3) (Ravussin et aL, 
1985) and the rates of CHO and fat utilisation (Jansson and Kaijser, 1982) (EXP 1- 
2). Energy expenditure (EE) was calculated for each time-point using the following
equation: EE(kcal-m in') = [4.686 + (RER- 0,707/0.293) 0.361] V o^.
fil
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2.4. Heart rate and Ratings o f Perceived Exertion
In EXPs 1-3 HR was recorded continuously using Polar Sport Tester (Polar Electro 
Oy, Finland) and in EXP 4 using online electrodes. In EXPs 1, 2, and 3, subjective 
ratings of perceived leg tiredness and breathlessness (RPE) were recorded at rest, 
regularly during the constant-load exercise phase (every 10 min, 15 min, and 5 min 
in EXPs 1, 2, and 3 respectively) and at exhaustion using the Borg category scale 
(Borg 1982). In EXP 4, RPE was obtained at rest (sitting on the bicycle ergometer), 
during unloading pedalling, every 3 min during the ramp phase and at exhaustion 
using a visual-analogue scale where "0 " represented ‘nothing at all’ and ‘100 ’ 
represented ‘maximum’.
2.5 Experimental designs
All performance trials and treatments and dietary interventions carried out following 
a Latin-square block design, hi EXPs 1 and 2, where the same group of subject have 
been examined under performing all the different treatments, considerable care was 
given in order to ensure that there was no order effect on performance by involving 
a series of familiarisation trials in the experimental design. The primary scope of 
these trials was to familiaiise the subjects with the main exercise trials and 
experimental procedures. In EXPs 3 and 4, two different groups of subjects 
performed the different treatments. In EXP 3, a full familiarisation scale was 
performed in order to familiarise the subjects with exercise in the heat and humid 
environment.
2.6 Blood sampling and analytical procedures
Arterialised-venous blood samples (Foster et aL, 1972) were obtained in all EXPs 
by introducing either an 18 G or a 21 G camiula into a superficial vein on the dorsal 
surface of the subjects' heated hand. In some subjects where blood sampling from 
the hand proved difficult, a superficial vein in the fore-arm was used. Subjects were 
comfortably seated with their forearm immersed in water at 42-44 °C for at least 10 
min before a resting blood sample was obtained. The cannula was kept patent by a 
slow (ca. 0.5 ml-min'^) infusion of isotonic saline between samples. Artérialisation
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of the venous blood was maintained throughout exercise by heating the hand via an 
infrared heating lamp (EXPs 1, 2, 4). In all EXPs room temperature during resting 
blood sampling was maintained between 20-22  °C.
Blood (10 ml) was drawn into dry syringes and dispensed (8 ml) into tubes 
containing K3EDTA (all EXPs) and the remaining into tubes containing no 
anticoagulant for prolactin (Prl) analysis (see below). Blood metabolites were 
analysed by a spectrophotometric adaptation based of the methods of Maughan 
(1982). Duplicate aliquots (400 pi) of whole blood from the K3EDTA tubes were
rapidly deproteinised in 800 pi of ice-cold 0.3 mol-1"^  perchloric acid (PCA); 
following centrifugation the supernatant was used for the measurement of glucose, 
lactate (all EXPs), pyruvate (EXPs 2 and 4) and glycerol (EXPs 1, 2, 4) (ABX Mira 
Plus Spectrophotometer; ABX Diagnostics, UK), hi order to validate the blood 
analysis methods were tested on a) samples with 1:3 dilution (400 pi, 800 pi 0.3M 
PC A); b) 1:6 dilution (200 pi, 800 pi 0.3M PCA) and c) 1:10 dilution (400 pi, 800 
pi 1.2 M PCA as described by Maughan, 1982) and found no statistically significant 
differences in blood metabolites. A further aliquot of blood (3 ml) was centrifuged 
and the plasma obtained was separated and immediately placed into liquid nitrogen. 
The plasma was then used for the measurements o f FF A (colorimetric method, 
Roche Diagnostics GmbEl, Germany) (all EXPs) and amino acids including free 
tryptophan (free-Trp). For enzymatic methods regarding blood glucose, lactate and 
pyi'uvate and plasma glycerol and FF A analyses see Appendices D l, D2, D3, D4, 
and D5 respectively.
The analysis of plasma amino acids including free-Trp have been performed by 
High Performance Liquid Chromatography (HPLC) using fluorescence detection 
and pre-cohmm derivatisation with 18 o-phthalaldehyde (Hypersel Amino acid 
method, ThermoHypersil-Keystone, Runcorn, UK). In summary, thawed plasma 
samples were spun for 10 min at 3000g at 4 °C and 80pl dispensed into eppendorf- 
tubes containing 20pi of internal standard (1.375mM- L-Methionine Sulfme) and 
lOpl of PCA (3.3M). Samples were vortexed for Imin then spun at 3000g at 4°C for 
an additional lOmin. The supernatant was removed and placed into HPLC-tubes for 
reverse-phase HPLC analysis using a Gilson Gradient HPLC system (Gilson, 
Middleton, USA). A volume of 20pl was typically auto-injected (234 Gilson
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inverting-re-iiiveii:ing samples for 5 min) through 10,000 NMWL, nominal 
molecular weight limit, cellulose filters (Ultrfree-MC filters, Millipore Coiporation,
in haemoglobin and PCV relative to initial resting values (Dill and Costill, 1974).
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Autoinjector, Gilson, Middleton, USA) onto an amino-acids column (250 x 4.6mm 
Ï.D., particle size 5pm, ThennoHypersil-Keystone, Runcorn, UK) at 30°C. The 
mobile phase pumped at a flow rate o f 2.5ml*min 1. Amino acids were determined 
by UV detection (Gilson 121 Fluorometer, Gilson, Middleton, USA) using 250mn 
excitation and 450mn emission. For the analytical preparation of the HPLC buffers
(A and B) and mixed-reagent (C) used as well as calibration standard and mixed 
reagent preparations see Appendix C. For the analysis of free-Trp, Trp was
'separated from protein-bound Trp by filtering plasma (250pl after manually
USA) during centrifugation at 5000g for 60min at 4°C. Filters were filled with a
.95% O2 -  5% CO2 mixture during centrifugation in order to stabilise pH.
Some of the uncoagulated blood was also used for the measurements of 
haemoglobin (cyanmethemoglobin method. Sigma Chemical Company Ltd., Dorset, 
UK) and packed cell volume (PCV) (conventional micro-haematocrit method) in all 
EXPs. Haematocrit was determined in triplicate from aliquots of EDTA blood 
dispensed into micro-haematocrit tubes (Hawskley and Sons Ltd, Lancing, UK), 
centrifuged for 12 min, and determined using a micro haematocrit reader (Hawskley 
and Sons Ltd, Lancing, UK). Plasma volume changes were calculated from changes Ï
The blood in tubes without anticoagulant was allowed to clot and then centrifuged; 
the sermn collected was used for the measurement of Prl (EXPs 1-3). Prl was 
measured on the Bayer AD VIA Centaur immmioassay analyser (Technicon 
Immuno-1 System, Bayer pic, Bayer House, Newbury, UK). The assay is a two-site 
sandwich immunoassay using direct chemiluminometric technology. The first 
antibody is a polyclonal anti-prolactin antibody labeled with acridinium ester. The 
second antibody is a monoclonal mouse anti-prolactin antibody which is covalently 
bound to paramagnetic particles. The assay is standardised against the World Health 
Organization 3^  ^ IRP 84/500 reference material and measures prolactin in 25ul of 
serum. The whole procedure is automated and the within batch and between batch
precision (CV) are < 3 and < 6% over the concentration range for the samples in the 
current study.
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2.7 Statistical analysis
Data from all experiments are expressed as the mean ± s.d. or median (inter-quartile 
range: IQR) as appropriate following a test for the normality of distribution (Shapiro 
statistical normality test). In EXPs 1 and 2 since all subjects completed the Control 
trial first and were subsequently assigned to the two fat trials in randomised order, 
statistical analysis was carried out on the two fat trials. However, the results for all 
trials are shown in all particular figures and tables.
Statistical analysis of the data from EXPs 1 and 2 was carried out using a two-factor 
ANOVA (Treatment x Time) for repeated measures followed by a Student's ^-test 
when a significant main treatment, interaction or time effect was observed. Time to 
exhaustion (in EXP 2) was not normally distributed and was therefore analysed 
using Wilcoxon signed-ranks test. In EXP 3, statistical analysis was carried out 
using a mixed 3-way ANOVA (Group x Pre- and Post- supplementation x Time) 
with repeated measures on the last two factors. A subsequent 2-way ANOVA with 
repeated measures was performed when there was a main effect on Group, Pre-Post 
supplementation, or interaction. Two-sample ^-test (between treatment effect, i.e., 
magnitude of change (A) in the Cr gioup vs. A in the placebo group) and Student t- 
test (within treatment effect, i.e., Pre- vs. Post-supplementation) were perfoimed if  a 
main treatment or interaction effect was observed. For non-parametric data (all 
plasma amino acids, FFA and Prl results), Friedman two-way ANOVA (followed by 
Wilcoxon test) and Mann-Whitney tests were used for paired and unpaired data, 
respectively. Statistical analysis regarding plasma amino acids variables for EXP 3, 
includes eighteen subjects due to the lack of collecting appropriate amount of blood 
fr'om tlrree subjects for either pre- or post supplementation trials. In EXP 4 statistical 
analysis was carried out using independent Student's frtests and Mann-Whitney tests 
for parametric and non-parametric data to assess differences for the measured 
variables between the two groups for each time point, as appropriate.
hi all EXPs, Pearson's product moment r and Spearman’s rho correlation analyses, 
for parametric and non-parametric data respectively were used to assess the 
relationship between selected variables. Correlation analyses perfoimed for each 
time point separately. Statistical significance for all experiments was declared when 
P < 0 .05 .
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Coefficient of Variation (C.V.): C.V. is the s.d. expressed as a proportion or 
percentage of the mean (Bolton, 1997). Consequently, the intra-assay C.V. was 
calculated (see equation 2 . 1. below) from the s.d. of the difference between double 
measurements of the sample expressed as a percentage of the total mean sample 
(Table 2.1). When the cost of the duplicate analysis exceeded £1 per sample, the 
C.V. was determined from at least 10 aliquots of the same sample (Table 2.1).
C.V.% = (s.d./mean) % 100 Equation 2.1.
Table 2.1: Coefficient of Variation of blood and plasma assays
Assay Method n C.V.
Blood glucose Maughan 1982 50 4.3
Blood lactate Maughan 1982 50 1.9
Blood pyruvate Maughan 1982 50 3.9
Blood Hb Cyanmethemoglobin method 50 0.3
PCV Micro-haematocrit method 50 13.1
Plasma glycerol Boobis and Maughan 1983 12 3.5
Plasma FFA Colorimetric method, Roche Diagnostics 10 3.4
Plasma Valine Hypersel Amino acid method (HPLC) 10 5.7
Plasma Isoleucine Hypersel Amino acid method (HPLC) 10 4.5
Plasma Leucine Hypersel Amino acid method (HPLC) 10 5.2
Plasma Tyrosine Hypersel Amino acid method (HPLC) 10 2.5
Plasma Phenylalanine Hypersel Amino acid method (HPLC) 10 5.9
Plasma Tryptophan Hypersel Amino acid method (HPLC) 10 4.1
Plasma free-Tryptophan Hypersel Amino acid method (HPLC) 15 4.5
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Chapter three 
(Experiments 1 and 2)
A differentiation attempt between central and peripheral components 
affecting fatigue; the effect o f  caffeine co-ingested with a high fat meal
6 6
3.1 Introduction
Previous attempts to investigate central fatigue during exercise have not 
concunently examined physiological and biochemical variables that may play a role 
in both peripheral and central fatigue development. Consequently, when ‘central 
fatigue’ has previously been studied in humans (e.g. Blomstrand, 1988; 1989; 
1991b) and animals (e.g. Bailey et aL, 1993a) there was not always an inclusive 
assessment of whether metabolic, cardiovascular and perceptual responses had 
played a role in the fatigue process.
Caffeine has been reported to increase exercise performance by enliancing fat 
oxidation and, therefore, sparing glycogen (e.g. Costill et aL, 1978), paiticularly 
during the early stages of prolonged high intensity exercise (Spriet et aL, 1992) (see 
Chapter 1, section 1.2.6.4). A number of mechanisms have been proposed to explain 
this caffeine-induced sparing of muscle glycogen: i) caffeine may reduce muscle 
glycogenolytic rate by inhibiting glycogen phosphorylase a (Phos a) activity (the 
flux-generating step for muscle glycogenolysis) by decreasing the sensitivity of 
Phos a kinetics with respect to Pi which may play a major role in the control of 
skeletal muscle glycogenolysis in vivo (Rush and Spriet, 2001); ii) caffeine can 
entrance free fatty acid (FFA) mobilisation by stimulating the release of epinephrine 
and, hence, increase the potential for fat oxidation (Spriet et aL, 1992); and iii) 
caffeine may indirectly promote fat oxidation and carbohydrate (CHO) sparing by 
inhibiting adenosine receptors in adipose tissue, which otherwise inhibit FFA 
mobilisation from adipocytes (Spriet 1995).
Recently however, several studies observed an increase in endurance performance 
without supporting the ‘metabolic theory’ effect of caffeine and others found an 
improvement in high intensity exercise performance, following caffeine ingestion, 
where muscle glycogen depletion is clearly not the primary cause of fatigue (see 
Chapter 1, section 1.2.6.4). Consequently, caffeine may enliance endurance 
performance, not by sparing muscle glycogen as often suggested, but tlii'ough other 
effect(s). For example, caffeine has been reported to i) reduce effort perception 
(RPE) (e.g. Cole et aL, 1996), ii) attenuate ‘central fatigue’ by reducing brain 
serotonin turnover, through an inhibition of tryptophan hydroxylase expression (Lim 
et aL, 2001), and iii) inhibit central adenosine receptors activation, thereby 
attenuating ‘central fatigue’ by increasing the DA:5-HT ratio in the brain (Davis et
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a l, 2003). Alternatively, caffeine or one of its by-products could directly affect 
skeletal muscle and/or influence the propagation of neural signals in regions 
between the brain and neuromuscular junction (see Spriet, 1995 for review). The 
contradictions reported in the literatm*e may be due to the multiple sites of action of 
caffeine, within both the central neivous system (CNS) and peripheral tissues (e.g. 
Fredholm et aL, 1999). Based on the above information it could be hypothesised that 
caffeine may have at least two significant actions, a peripheral (metabolic) action 
and/or a CNS effect. Consequently, an alternative approach, which attempts to 
distinguish primary from secondary effects of caffeine is required before its effect 
on brain neurotransmission during exercise is considered.
An acute increase in plasma [FFA] similar to that reported following caffeine 
ingestion can be induced by giving subjects a high fat meal with or without 
intralipid-heparin infusion (Romijn et aL, 1995; Okano et aL, 1996; 1998; Whitley 
et aL, 1998), with consequent increases in the rate of fat utilisation (Rennie et aL, 
1976; Costill et aL, 1977; Dyck et aL, 1993; Vukovich et aL, 1993; Hawley et aL, 
2000) and, therefore, improvement in exercise performance (Hickson et aL, 1977; 
Pitsiladis et aL, 1999). Consequently, the aim of the first two experiments (EXPs) 
was to differentiate between central and peripheral aspects affecting fatigue and to 
examine perceptual and metabolic responses during constant-load submaximal 
exercise, and on incremental and endurance exercise perfonnance after caffeine co- 
ingested with a high fat meal. The high fat meal was employed in an attempt to 
increase plasma [FFA] and fat metabolism (Pitsiladis et aL, 1999) so that any action 
of caffeine on adipose tissue lipolysis would be insignificant. Caffeine co-ingested 
with a high fat meal regimen was employed in order the mechanism(s) associated 
with central and peripheral fatigue could be evaluated. It was hypothesised that co­
ingestion of caffeine with a high fat meal could differentiate between putative 
substrate utilisation (metabolic) effects and CNS actions of caffeine.
3.2 Methods 
Subjects
Eight male endurance-trained subjects (mean ± s.d.) (age 27 + 4 years; height 178 ± 
6 cm; body mass 73.7 ± 7.8 kg; maximal oxygen uptake ( Vo^max) 57 + 5 ml kg'
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'•min'^), and ten endurance-trained male cyclists (age 25 ± 6 years; height 182 + 7 
cm; body mass 74.3 ± 8.6 kg; Vo^max 62 + 5 ml-kg'^-min'^) volunteered to 
participate in EXP 1 and EXP 2, respectively. For more information regarding 
subjects medical screening and study approval see Chapter 2.
Experimental design
The deteimination of Vo^max, LT and test workloads are described in chapter 2. The 
schematic illustrations of the experimental designs for both EXP 1 and 2 are 
presented in Figure 3.1 and 3.2 respectively.
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Figure 3.1 Schematic illustration of the experimental design in experiment 1
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third exercise tests, subjects consumed a standardised high fat meal (1 g fat kg-1
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In both EXPs subjects perfoimed three experimental trials, the first one after a high
CHO meal (Control tiial) and the remaining two after a pre-exercise high fat meal
with (EC trial) and without (F trial) caffeine ingestion, hi EXP 1, subjects cycled at a
,work-rate equivalent to 63 % of each subject's peak power output [i.e., 73 ± 5 
% V o 2 max or 46 ± 4 % A, which is the difference between the VOg at the LT and 
V o 2 max, as proposed by Rausch et aL, 1991], which was immediately followed by a
15 W-min“^ ramp to the limit of tolerance. In EXP 1, each consecutive test was 
separated by at least one week h'om the previous one. In EXP 2, subjects cycled to 
exhaustion at a similar work-rate [i.e., 74 ± 5 % VOgmax or 42 ± 3 % A].
Subjects undei*went at least two familiaiisation trials prior to the tliree exercise tests, 
in order to become familiarised with the exercise protocol and experimental 
procedures and to adjust the desired exercise intensity. In EXP 2, During the 
familiarisation period (i.e., 3 days prior to the second familiarisation trial), each 
subject's normal energy intake and diet composition were determined from weighed 
dietary intake data, using a computerised version of the food composition tables of 
McCance and Widdowson (revised by Holland et aL, 1991). Based on this 
information, subjects were prescribed a 70 % CHO diet throughout the study period, 
intended to increase and maintain muscle and liver glycogen content (Bergstrom et 
aL, 1967) before each of the main exercise trials. The 70 % CHO diet was 
isoenergetic with each subject's normal daily energy intake, and food items 
prescribed were based predominantly on each subject’s normal diet. In EXP 1, 
subjects were provided with a dietary record book and weight scale and they were 
advised to record and keep their nonnal daily energy intake throughout the 
experimental period and to try to consume items that involve mostly CHO 
nutritional contents. A particular nutritional list was given to each subject. The 
subjects were advised to consume the same items with a similar weighted amount 
for thr ee days prior to each experimental trial.
Four hrs prior to the first exercise test in both EXP 1 and EXP 2, subjects consumed 
a standardised high CHO meal (90 % of energy intake in the form of CHO; Control 
trial). Since the Control trial was always performed first, it was not included into the
,:v
randomisation hence into the statistical analysis. Four hrs prior to the second and
I,:3|
body mass; 90 % of energy intake in the form of fat). The standardised high fat meal 
was consistent with a commercial double fresh cream (Fat: 96.1 %; CHO: 2.2 %; 
Proteins: 1.6 %) mixed with lOOg fresh strawbenies (9 kcal; Fat 0.17g; CHO 2g; 
Proteins O.lg) in order to improve the palatability of the meal (Pitsiladis et aL,
1999). The composition and nutrition values of the fresh double-cream consistent: 
Per lOOg: energy 445 kcal (or 1813KJ), Fat 47.5g (saturated 32.21g; unsaturated 
13.8g; polysatui-ated 1.49g) or 427.5 kcal, CHO 2.5g or 10 kcal, Protein 1.79g or 
7.16 kcal, Fibre Og, Sodium trace salt O.lg. All experimental meals were 
isoenergetic and prepared by the same investigator. One hr prior to exercise 
following the high fat meals, subjects ingested, in a cross-over double blind manner,
capsules containing caffeine (EXP 1: 7 mg-kg'^ body mass, EXP 2: 7.5 mg-kg"^ body 
mass; FC trial) or an equivalent amount of placebo (calcium carbonate; F trial). 
Caffeine was ingested one hr prior to exercise in an attempt to elicit peak plasma 
[caffeine] (Burg, 1975; Robertson et aL, 1978). Subjects were advised to avoid 
consuming items that contained caffeine or alcohol for at least 48 hours prior to each 
experiment or to ingest any vitamins supplements or any medication throughout the 
experimental period. Subjects required to avoid any strenuous activity for at least 72 
hours prior to each exercise trial.
Procedures
All exercise tests were canied out between 16:00-21:00 hrs following a 4 hr fast, 
where water was allowed ad libitum. Subjects reported to the laboratory 1.5 lirs prior 
to the staif of exercise, and on the two fat trials consumed capsules containing 
caffeine or placebo, 3 hrs after consuming the fat meal. Body mass was measured 
and, subsequently, subjects were seated comfortably with their right hand and 
forearm immersed for 15 min in warm water. For caimulation, blood sampling at 
rest and during exercise, HR and RPE recording see Chapter 2.
Briefly, in both experiments initial blood samples were obtained at rest. For EXP 1, 
further blood samples were obtained at 10 min intervals during the constant-load 
phase, at the end of the ramp, and at 5 and 10 min post-exercise and for EXP 2, at 15 
min intervals throughout exercise until the 90 min time-point and at exhaustion, hi 
EXP 1 ambient temperatuie during the trials was 20 ”C. hi EXP 2, the subjects were 
transfeiTed to the climatic chamber (ambient temperature of 10.2 ± 0.2 ”C, relative
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,humidity 69.8 ± 1.0% and air velocity of approximately 3.6 m sec ) and began 
exercise within 1 min of entering the chamber room. The exercise intensity and 
ambient temperature in EXP 2 were chosen to induce fatigue that would be most 
likely of muscle glycogen depletion, rather than the result of some failure in the 
thermoregulatory system (Galloway and Maughan, 1997). In EXP 2, subjects 
ingested 7.14 g-kg“^ and 2.14 g-kg"  ^ body weight of water at rest and every 15 min 
throughout exercise, respectively in order to minimise dehydration (McConell et aL,
1997). The subjects were asked to maintain a pedal cadence of 60-80 ipm 
throughout the test; exhaustion was defined as the point at which the subject could 
no longer maintain the pedal cadence above 60 rpm.
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Following exercise in EXP 2, subjects were weighed and loss of body mass was 
calculated, after correcting for water consumed during exercise and the pre and post­
exercise differences in body mass were calculated. Time to exhaustion was 
recorded, but withheld fi'om the subject until all trials had been completed and the 
subject had answered the post-intervention questioimaire. Subjects were asked to 
predict the order of treatments received during the study, and to nominate the 
treatment they perceived produced their best performance. The experimental 
protocol for the removal, treatments and analyses of blood and plasma as well as gas 
exchange measurements and statistical methods used are described in chapter 2 .
3.3 Results 
Dietary analysis
Analysis of the subjects’ normal diet and average daily energy intake, in addition to 
diet composition during the experimental period (including the three meals for EXP 
2) are shown in Table 3.1. There were no differences in energy intake or diet 
composition during the three days prior to each exercise test. No change in body 
mass occurred during the entire study-period in both experiments; body mass prior 
to the Control, F and FC trials was 74.2 ± 9.7 kg, 74.4 + 9.5 kg, and 74.4 ± 9.3 kg in 
EXP 1 (P = 0.9) and 74.1 ± 7.8 kg, 74.1 ± 7.7 kg, and 73.9 ± 7.6 kg in EXP 2 (P  = 
0.4), respectively.
---------- Li--------- ---- ---- :
Table 3.1: Average energy intake and diet composition before, and during the 12- 
day weighted intake, and each of the experimental meals in EXP 2. Values are given 
as mean ± s.d. or median (range).
Normal diet CHO diet (day 1-3)
CHO meal 
(day 4)
CHO diet 
(day 5-7)
Fat meal CHO diet 
(day 8) (day 9-11)
Fat meal 
(day 12)
Energy 13.6±4.0 14.Ü3.4 3.2±0.3 14.3±3.3 3.0±0.7 14.4±3.4 3.0±0.7
intake (MJ-day'b (MJ-day ' ’) (MJ) (MJ-day '7 (MJ) (MJ-day'7 (MJ)
CHO (%) 54.5±8.6 72.1 ±3.5 87.0±1.6 73.2±4.3 8.4±0.6 73.1 ±4 8.4±0.6
Fat (%) 30.1±8.5 15.6±3.4 3.2±0.5 14.2±3.7 89.3±0,7 14.1±3.9 89.3±0.7
Protein (%) 14.2±3.3 12.1±2.3 9.8±1.5 12.6±2.1 2.3±0.1 12.7±2,5 2.3±0.1
Alcohol (%) 0(7.18) 0.17 - - 0.1 -
Performance
Time to fatigue during maximal incremental exercise (EXP 1: Control trial: 4.9 ± 
1.8 min; F trial: 5.0 ± 2.2 min; FC trial: 5.0 ± 2.2 min, P  = 0.9) and sub-maximal 
constant-load exercise (EXP 2: Control trial: 116(88-145) min; F trial: 122(96-144) 
min; FC trial: 127(107-176) min, P = 0.2) was similar between the two fat trials 
(Fig. 3.3). In EXP 1, peak power output (Control trial: 346 ± 33 W; F trial: 340 ± 33
W, FC trial: 342 ± 32 W) and VOjpeak (Control trial: 3.74 ± 0.24 L-min'^; F trial: 
3.67 ± 0.24 L-min"^; FC trial: 3.76 ± 0.28 L-min'*) were not different between fat 
trials. Flowever, Vo^max determined during the initial incremental test (4.17 ± 0.32
L-min'^) was significantly higher than Vo^ peak during the tliree experimental trials. 
Perception o f  effort
hi both experiments, ratings of perceived leg exertion were significantly lower 
during constant-load exercise following FC compared to the F trial (EXP 1: F(ij) = 
70.875, P  = 0.0001; EXP 2: Fp,9) = 11.985, P  = 0.007) (Fig. 3.4). Ratings of 
perceived breathlessness were lower during constant-load exercise following FC in 
both experiments, significantly so at 10 min and 30 min time-points in EXP 1 (F(i,7) 
= 15.996, P  = 0.005). In EXP 1, six out of eight subjects ranked the F trial as the 
most difficult trial (the remaining two subjects being unsure) and in EXP 2, six out 
of ten subjects ranked the FC as the easiest trial (one subject was unsure).
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Fig. 3.3. Incremental exercise performance in EXP 1 (top panel), mean (s.d.) and 
Endurance exercise perfonnance in EXP 2 (bottom panel), median (Interquartile range: 
IQR).
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Fig. 3.4. Ratings of perceived exertion, for leg muscular discomfort (top panels) and 
breathlessness (bottom panels) (mean ± s.d.) in EXP 1 (left side) and EXP 2 (right side). *: 
indicates a significant difference between F (O) and FC ( • )  trials. indicates significant 
differences over time in both trials. The dash line indicates the Control trial.
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Cardiopulmonary variables, fuel oxidation
HR increased over time on all trials in both experiments (Fig. 3.5). No difference 
between trials was found in EXP 1 (F(ij)= 1.710; P  = 0.232). In EXP 2, there was a 
significant interaction (treatment x time) on HR being significantly higher 
tlu’oughout exercise on the FC compared with the F trial (F(ijo) = 3.690; P  = 0.001).
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Fig. 3,5. Heart rate responses (mean ± s.d.) in EXP 1 (left side) and EXP 2 (right side). 
indicates a significant difference between F  (O) and FC ( • )  trials. indicates significant 
differences over time in both trials. The dash line indicates the Control trial.
Vo 2 increased over time during constant-load exercise on the FC trial in EXP 1, 
and was higher compared with F trial at the 30 min time point (F(i,2) 4.771; P =
0.026) (Table 3.2). In EXP 2, VOj increased over time on both trials and was 
higher on the FC trial compared with the F trial (F(i,9) -  9.980; P  ^  0.02); statistical 
significance was achieved at the 75 min time point (Table 3.3). VCOj increased 
similarly on the two fat trials in both EXP 1 (Table 3.2) and 2 (Table 3.3) but it was 
not significantly different between the trials (EXP 1: F(i,7) = 2.243; P = 0.178, EXP 
2: F(i,cj) = 0.326; P -  0.582). There was a progressive increase in VE over time on 
both trials in the two experiments. VE tented to be higher, during constant-load 
exercise, on the FC compared with the F trial in EXP 1 (F(ij) = 3.276; P ~ 0.068) 
(Table 3.2). In EXP 2, VE was significantly higher on the FC compared with F trial 
(F(i,9) = 10.917; P  = 0.009); statistical significance was reached at 30, 45, 60 and 75 
min (Table 3.3). There was a reduction in RER over time in both experiments, and 
no differences were found between F and FC trials (Tables 3.2 and 3.3) (EXP 1: 
F(i,7)= 0.334; P  -  0.582, EXP 2: F(i,9)= 3.246; P  = 0.105).
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In both experiments, the rate of CHO (EXP 1 : F(ij) = 0.888; P  = 0.377, EXP 2: F(i,9) 
= 2.089; P -  0.182) and fat oxidation (EXP 1: F(ij) = 0.241; P  = 0.638, EXP 2: F(i,9) 
= 3.372; P  = 0.104) was not different between trials; the rate of fat oxidation 
increased and CFiO oxidation decreased over time (Tables 3.2 and 3.3 respectively). 
Total CHO and fat oxidation during 30 min constant-load exercise (EXP 1) and 
exercise to exhaustion (EXP 2) were not different between fat trials: FC trial: 84 ± 
8g CHO, 14 + 2 g fat; F trial: 78 ± 19 g CHO, 15 ± 6 g fat; Control trial: 90+  18 g 
CHO, 10 + 6  g fat in EXP 1, and FC trial: 371 + 82 g CHO, 77 ± 50 g fat; F trial: 
388 + 90 g CHO, 52 ± 23 g fat; Contiol trial: 367 + 87 g CHO, 39 + 23 g fat in EXP 
2. EE was higher on the FC compared with the F trial and it reached statistical 
significant at 30 min time-point in EXP 1 (Table 3.2) and at 30 min and 75 min 
time-points in EXP 2 (Table 3.3). EE progressively increased over time on both 
trials in EXP 2, and on the FC trial in EXP 1.
Table 3.2: Cardiopulmonary variables for each of the three trials in EXP 1. Values 
are given as mean ± s.d.
Variables Trials 10
Exercise tim e (min) 
20 30 End
V o  2 (L-min'^) Control 3.0±0.2 3.1+0.2 3.1+0.1 3.7+0.2
F 3.0±0,2 3.1+0.2 3.0+0.2 3.7+0.2®
FC 3.1±0.2 3.2+0.2® 3.2+0.2*® 3.8+0.3®
V C Ü 2 (L -m in’) Control 2.9±0.2 2.9+0.2 2.9+0.2 4.0+0.4
F 2.8±0.3 2.8+0.2 2.8+0.2 3.9+0.7®
FC 2.9±0.2 2.9+0.2 2.9+0.2 3.8+0.5®
V E  (L-min"*) Contiol 72±11 79+16 84+17 136+16
F 75±15 80+15 83+18® 136+19®
FC 76±12 83+14® 89+14® 147+17®
RER Control 0.94±0.03 0.94+0.04 0.93+0.03 1.07+0.06
F 0.92±0.04 0.90+0.04® 0.89+0.04® 1.06+0.08®
FC 0.92±0.01 0.91+0.02 0.90+0.01® 1.07+0.06®
Energy Expenditure (kcal-min'*) Control 12.7±0.8 12.8+0.8 12.8+0.6
F 12.6±0.8 12.7+0.7 12.8+0.7 -
FC 12.9+0.9 13.1+0.9® 13.3+0.8*® -
CHO oxidation (g-min"') Control 3.0+0.5 3.0+0.6 2.9+0.6
F 2.8+0.6 2.6+0.6® 2.4+0.7® -
FC 2.9+0.2 2.8+0.3 2.7+0.3 -
Fat oxidation (g-min ') Control 0.3+0.1 0.3+0.1 0.4+0.2
F 0.4+0.2 0.5+0.2® 0.6+0.2® -
FC 0.4+0.1 0.4+0.1 0.5+0.1® -
*: Indicates a significant difference between F and FC trials 
Indicates a significant difference over time compared with the 10 min time-point
76
>n v^ vn
? 5 s s a'd ' VI VO m
rn ro m rn CO m
I u
$
CN m V~lo o o (>■"cqo o o c4 (N CM-H 44 44 44 44 -Hm oo ON VO ONa\ o \ ooo c5 o
V^ o r-- VO“cmo o o O o o
a 4 a a arn m CM o o CO
* CD CD O C" CD CMVO VN VN V~l vn «« * CD o O CM CM CM VN Vo C3N VO CMo CO CD CD o CD 44 44 44 44 44 44 o O o CD CD44 44 44 4 44 44 a vë 44 m cn CD vq m 44 44 a 44 44 ,44vn vq CM m CJ\ On ON VN cn •ncn cn CO cn rn rn !>- oo CD CD CD m rn rn o o CD
V "vi VN
? % S 3 %VN CMcn m cn rn rn rn
V V ) VN 'Cj-CD o o CD o
1a 4 44 44m rn m rn rn cn
VCD CD P o o CD44 44 44 44 44 41CM CM orn rn m rn rn rn
m VN m
4 4 3 3 4 1m o om rn rn rn rn rn
'Cf m r-- '4 m VCD CD o o PCD CD o CD o 044 44 44 44 4' 44rn m cn m cnCD CD o CD CD CD
I o
•I
g
2 °
0 %0044 44 44CJn 00mVO VO r-
CD CD VO44 44 44VO VO CDVO VO e'­
I
en m V0 0 0CD CD CD44 44mCDs ON CTSCD CD CD
V 'Cf V0 0 0CD CD CD44 44 44-4- mON ON CDsCD CD CD
m m 'rnCD CD CDCD CD CD44 44 44VOs Os PCD CD CD
m m ■M"0 CD PCD CD 044 44 44V V mON ON ON<D <D CD
soo ohioo oo oo 
o  o  o
L r
r t
3 3 Mm
os'tb K
' 3 3  a
rn  ro  rn
L r
VO 00 VO C4 P0 CD CD 0 CD CD
P a a 4 # acn rn rn 0 CD CD
oo 00 VO r—1P
1 a 1 1rn rn CM CD CD CD
m VO VN VN CMÇ) CD 0 CD CD 044 44 44 44 44 44cn CM ON cn "C4cn rn CM CD 0 CD
l> P V VO 'V P CM44 44 CD CD CD CD 0 CD
cn VN P a 44 a 4cn rn rn 0 CD 0
■B ,S3
cd cq
77
Blood metabolites
Plasma [FFA] was not different between fat trials in EXP 1 and remained largely 
unchanged during exercise (F(i,7)= 0.139; P  = 0.721) (Fig. 3.6). However, in EXP 2, 
a higher [FFA] was found on the FC trial compared with the F trial at rest, and horn 
15 min to 90 min during exercise (F(i,9)= 10.959; P  = 0.009). [FFA] decreased at the 
15 min time-point, compared to resting levels, in both fat trials. Thereafter, there 
was a progressive increase over time in both trials. Plasma [glycerol] was greater 
dming the FC trial compared with the F trial, in both EXPs 1 (F(u) = 5.928; P  = 
0.045) and 2 (F(i,9) = 25.921; P  = 0.001). In both experiments, plasma [glycerol] 
increased significantly over time in both fat trials compared with the baseline values 
(Fig. 3.6).
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Fig 3. 6 . Plasma FFA (bottom panels) and plasma glycerol (top panels) responses (mean ± 
s.d.) in EXP 1 (left side) and EXP 2 (right side). *: indicates a significant difference 
between F ( 0 )  and FC ( •  ) trials. indicates significant differences over time in both trials. 
The dash line indicates the Control trial.
Higher blood [glucose] was foimd on the FC trial compared with the F trial in both 
EXP 1 (F(i,7)= 16.350; P  = 0.007) and EXP 2 (F(i,9) = 23.329; P  = 0.001). In EXP 1, 
[glucose] was higher after 20  min of constant-load exercise, at the end of the ramp 
phase, and during the 10 min recovery period on the FC trial compared with the F 
trial (Fig. 3.7). [Glucose] increased progressively over time on the FC trial from 20 
min of exercise onwards in comparison with the baseline, whereas on the F trial, an
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increase in [glucose] was obseiwed only at exhaustion and during recovery. 
Similarly, in EXP 2, [glucose] was significantly higher on the FC compared with the 
F trial from the 30 min time point until exhaustion. In the FC trial, [glucose] 
decreased after 90 min of exercise relative to the baseline levels, whereas no such 
reduction was found on the F trial (3.7).
^  12-1 
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Time (min) Time (min)
Fig 3.7. Blood glucose (bottom panels) and blood lactate (top panels) responses (mean ± 
s.d.) in EXP 1 (left side) and EXP 2 (right side). *: indicates a significant difference 
between F ( o ) and FC ( •  ) trials. indicates significant differences over time in both trials. 
The dash line indicates the Control trial.
In both experiments, blood [lactate] was significantly higher on the FC trials 
compared with the F trials (EXP 1: F(iTeatment x time: i,6) = 2.382; P  = 0,049; EXP 2; 
F(i,9) = 13.823; P  = 0.005). In EXP 1, [lactate] was significantly higher after 20 min 
of constant-load exercise, at the end of the ramp phase and during recovery on the 
FC trial compared with the F trial (Fig. 3.7). There was an exercise-induced increase 
in [lactate] at the 10 min time point (both fat trials) and at the 20  min time point 
relative to the 10 min time point (FC trial only). Peak [lactate] was measured at the 
end of the ramp phase on the two fat trials, with no differences between trials. In 
EXP 2, higher [lactate] was found throughout exercise on the FC compared to F 
trial. In this experiment, [lactate] inereased significantly at the 15 min time point in 
both trials relative to baseline. No further increases in [lactate] were found during 
the FC trial, whereas on the F trial, [lactate] decreased significantly at 45, 60, and 75 
min compared to the 15 min time point. Blood [pyruvte] was measured and the
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[lactate]:[pyruvate] (L:P) ratio subsequently determined only in EXP 2. [Pyruvte] 
(from 30-60 min) and the (L:P) ratio (15 min and 75 min) were higher during 
exercise on the FC compared with the F trial (F(i,9) = 35.262; P  = 0.001, and F(i,9) = 
6.173; P = 0.042 respectively) (Fig. 3.8). After an initial elevation in [pyruvte] and 
(L:P) ratio from rest to exercise in both fat trials, both remained fairly constant 
thereafter.
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Fig 3.8. Blood pyruvate (bottom panel) and lactate to pyruvate ratio (top panel) responses 
(mean ± s.d.) in EXP 2. *: indicates a significant difference between F (O) and FC (♦ ) 
trials. indicates significant differences over time in both trials. The dash line indicates the 
Contiol trial.
Reported side effects
Four out of the ten subjects in EXP 2 experienced slight gastrointestinal discomfort; 
three following the high fat meal co-ingested with caffeine and one following the 
high fat meal alone. One subject experienced more severe side effects following the 
high fat meal and caffeine ingestion 30 min following exercise. These effects 
included loss of consciousness, dizziness, abdominal pain, nausea and vomiting. 
These effects disappeared shortly after the experience.
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3.4 Discussion
The present study was designed to differentiate between central and peripheral 
aspects affecting fatigue during exercise and to distinguish between the putative 
metabolic and CNS effects of pre-exercise caffeine ingestion. This was achieved by 
having the subjects exercise after elevating their circulating plasma [FFA] with a 
high fat meal and subsequently co-ingesting caffeine or placebo. The use of fat meal 
was employed in an attempt to produce a similar muscle metabolic adjustment at 
rest and during exercise in both F and FC trials and based on the substrate utilisation 
results which were not different between the trials this attempt has been successful. 
In addition, Although smoking, oral contraceptive, ingestion of cruciferous 
vegetable and physical fitness level all were found to influence the metabolic 
pathway of caffeine by altering the activity of the cytochrome P450 isoform 1a2 
which is the enzyme that regulates eaffeine metabolism (Van Soeren and Graham,
1998) there is no evidence to show any effect of high fat meal on the absorption, 
distribution, metabolism, or exertion of caffeine. Differences therefore in exercise 
perfonnance, perceptual, metabolic and cardiovascular responses could be 
accounted by the ingestion of caffeine. Thus, caffeine could differentiate between 
peripheral and central aspects affecting exercise fatigue development enabling 
central components o f fatigue examination.
Assuming therefore, that perception of effort reflects, in part at least, CNS responses 
(Hampson et al., 2001; Utter et a l, 2004), die present results indicate a 
differentiation between the putative metabolic effects and the CNS actions of 
caffeine during constant-load exercise, as effort perception was reduced after 
caffeine ingestion (despite an elevation in cardiopulmonary and metabolic 
responses), but tbere were no differences in substrate utilisation and no 
improvements in exercise performance. Confirming the perception of effort results 
obtained from the present EXPs (n -  18), 12 out of 18 subjects ranked the FC trial as 
the easiest trial. This ranking response to the order of diffieulty of the trials was 
irrespective of performance time since some subjects who ranked the FC trial as the 
easiest one did not have a better exercise performance in the same trial. These 
results demonstrate a dissociation between effort perception, metabolic responses 
and exercise performance.
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It is difficult however, to explain why the subjects in the present experiments 
perceived it easier to exercise with caffeine than without, particularly when one 
considers the accompanying elevation in blood [lactate], Vo^,  VE (EXP 2) and 
heart rate that typically would be expected to augment, rather than attenuate 
perception of effort (Noble et a l,  1983). It is possible that these effects on 
perception of effort are the result of caffeine directly stimulating the CNS; the exact 
mechanism, however, remains unclear. Caffeine may reduce perception of effort by 
inhibiting brain adenosine receptors (Ai and A2) (Davis et ah, 2003), which 
otherwise suppress synaptic transmission within the motor cortex (Phillis and Wu, 
1981), and/or by reducing the excitation threshold of motor-neurones facilitating 
motor unit recmitment (Waldeck, 1975). Alternatively, caffeine may attenuate 
perception of effort by enliancing the secretion of endorphins (Spindel et ah, 1984; 
Laurent et al., 2000), which is well known to reduce pain perception and promote 
euphoria (e.g. Harber and Sutton, 1984). Furthermore, the significant increased VE, 
observed during exercise on the FC trial (EXP 2) might be expected to increase 
dyspnoea (breathlessness) (e.g. Cullen and Kodak, 2002). In contrast, a mismatch 
between VE and perception of breathlessness was found after caffeine ingestion 
with a higher VE and lower rating of breathlessness reported during constant-load 
exercise. The exact mechanism, however, behind this dissociation during exercise is 
also unclear. Caffeine has previously been shown to reduee fatigue and effort 
sensation associated with inspiratory muscle contraction (Supinski et al., 1986). 
Caffeine may also enhance respiration by blocking central adenosine receptors 
(Kawai et al., 1995), which act to depress ventilation by inhibiting respiratory motor 
centres (Runold et al., 1989).
Several studies utilising non-glycogen depletion exercise report an enhancement in 
high-intensity/incremental exercise performance after caffeine ingestion 
(McNaughton, 1986; Flinn et al., 1990; Jackman et al., 1996) and suggest CNS 
involvement in the fatigue process. In EXP 1 therefore, a non-glycogen depletion 
protocol (i.e. 30 min of constant-load exercise followed by incremental exercise to 
fatigue) was employed in an attempt to examine a possible metabolic effect of 
caffeine during the early stages of exercise and to further differentiate between a 
putative metabolic and CNS effect of caffeine during high-intensity exercise. The 
failure of caffeine to improve incremental exercise performance in EXP 1 is not
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consistent with several previous reports (McNaughton, 1986; Flinn et al., 1990). 
This may be due to the effect of caffeine in elevating Vo^ and energy expenditure 
and therefore metabolic rate. Thus, the increased metabolic rate and therefore higher 
ATP demand (Engels et a l, 1999) during the 30 min constant-load exercise phase 
after caffeine ingestion may have negated any ergogenic effect of caffeine on 
incremental exercise performance.
To our knowledge, the present study (EXP 2) was the first which has examined the 
effects of caffeine on endurance perfonnance during prolonged exercise at 10°C. 
Since caffeine ingestion did not appear to influence substrate utilisation, no 
improvement in exercise performance could be reasonably expected, as it is well 
established that fatigue during prolonged exercise to exhaustion at lO^C is due to 
glycogen depletion (Galloway and Maughan, 1997). Therefore, the improvements in 
enduranee exercise performance observed in previous caffeine studies are unlikely 
to be associated with glycogen depletion, unless caffeine ingestion altered substrate 
utilisation.
Alternatively, it is possible that the pre-exercise high fat meal employed in the 
present experiments negated any increase in fat oxidation previously attributed to 
the effect of caffeine. Typically, the limitation in fat oxidation during the early 
stages of exercise is the inadequate FFA delivery to the active skeletal muscles, 
rather than the inability of the muscle to oxidise FFA (Frayn et al., 1996). hi the 
present experiments, however, the plasma [FFA] was elevated prior to exercise by 
acute fat ingestion. Although increased lipolysis was evident after caffeine ingestion 
(based on the higher plasma [glycerol]), the saturation threshold for FFA uptake, 
and possibly, oxidation by skeletal muscle was probably achieved on both fat trials 
due to the high fat meal. Consequently, any caffeine-induced lipolysis would not 
forther enhance FFA utilisation. The performance results also confirm this. For 
example, if  there was a significant contribution of the plasma [FFA] and [glycerol] 
on fat oxidation, endurance performance would be increased following caffeine 
ingestion.
Based on the present substrate oxidation findings, it is unlikely that the significant 
increase in Vo^ observed during exercise after caffeine ingestion reflects a marked 
shift towards fat oxidation (Sherman and Leenders, 1995). It is possible that caffeine
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increased Vo^ due to its concomitant effect in increasing whole body metabolic rate 
without predominantly elevating the relative rates of CHO or fat utilisation (Engels 
et aL, 1999). In agreement with this is the higher energy expenditure observed at rest 
and during exercise on the FC relative to F trial. This elevation in energy 
expenditure observed in previous studies was ascribed to the thermogenic effect of 
caffeine via increased epinephrine secretion (Astrup et aL, 1990; Greer et aL, 2000). 
Increased epinephrine secretion is known to enhance lipolysis (Graham and Spriet, 
1991) and muscle (e.g. Watt et aL, 2001) and liver (e.g. Graham et aL, 2000) 
glycogenolysis.
The higher blood [glucose] and [lactate] observed following caffeine ingestion in the 
present experiments is consistent with many previous studies (Gaesser and Rich, 
1985; Spriet et aL, 1992; Jackman et aL, 1996; Laurent et aL, 2000; Graham et aL,
2000). The higher blood [glucose] has been suggested to be due to an increased liver 
glycogenolysis, although a reduction in blood-glucose uptake by skeletal muscle 
and/or adipose tissue cannot be excluded (e.g. Crist et aL, 1998; Thong et aL, 2002). 
Similarly, the increase in blood [lactate] may result from the inability of the 
mitochondria to handle the high pyruvate load, consequent to an increase in skeletal 
muscle glycogenolysis, therefore providing more substrate for lactate production 
(Holloszy, 1973). The higher [pyruvate] and L:F ratio observed in EXP 2 after 
caffeine ingestion supports this assertion. The elevation however, in blood [lactate] 
cannot solely be attributed to an increase in muscle lactate production through 
anaerobic metabolism. For example, Graham et aL, (2000) found an increase in 
blood [lactate] after caffeine ingestion, without a concomitant elevation in muscle 
lactate production at rest or during exercise, therefore implying inhibition of lactate 
uptake by non-exercising muscles and other tissues (e.g. liver).
Conclusions
In conclusion, while a number of metabolic responses were increased during 
exercise after caffeine ingestion, perception of effort was reduced; the exact 
mechanism however is still unclear. The reduction in effort perception after caffeine 
ingestion with a simultaneous elevation in a nmnber of metabolic/cardiovascular 
responses and no differences in substrate oxidation would suggest a differentiation 
between putative altered substrate utilisation effects of caffeine and CNS actions.
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Despite a possible CNS action, caffeine did not improve exercise performance, thus 
demonstrating a dissociation between effort perception and time to fatigue during 
incremental and endurance exercise performance. However, although central neural 
components may contribute to reduce effort perception after caffeine ingestion, 
whether this reduction is associated with brain serotonergic and dopaminergic 
modulators during exercise remains to be determined.
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Chapter four 
(Experiments 1 and 2)
Brain 5-HT and DA modulators, perceptual responses and exercise 
performance following caffeine co-ingested w ith a high fat meal in
trained humans
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4.1 Introduction
The results presented in Chapter 3 obtained from the EXPs 1 and 2 associated with 
metabolic, cardiovascular and perceptual responses have shown a strong association 
between effort (fatigue) perception and CNS after caffeine co-ingested with a high 
fat meal. However, whether the CNS implication in the RPE development during 
exercise (especially in relatively thermoneutral and mild-cold temperature that 
precludes thermo-physiological stressors involvement in effort perception 
development) in well-trained humans, is associated with brain 5-HT and DA 
function or any other central neural mechanism is not known yet.
As stated in Chapter 1 (section 1.2.5), an enliancement in circulating plasma [FFA] 
may displace Trp from albumin (Stmder et al., 1996) increasing plasma free 
[Trp]:[LNAA] ratio and possibly brain 5-HT synthesis (Bloxam et a l, 1980; Curzon 
et ah, 1973). The first human study for example, to show an improvement in 
exereise capacity following an acute increase in the circulating [FFA] by a high fat 
meal and heparin infusion, also reported the fat trial to be the more difficult trial and 
was accompanied by an early rise in effort perception (Fitsiladis et aL, 1999). On the 
other hand, caffeine was found to enliance exercise performance not via its classic 
CHO-sparing effect but by increasing central motivation to exercise (i.e. reduction 
in effort perception) (Cole et aL, 1996; Bridge et aL, 2000). Furthermore, although 
an increase plasma [Trp] relative to [LNAA] may enhance brain 5-HT synthesis 
(Bloxam et aL, 1980; Cui'zon et aL, 1973), the elevation in brain 5-HT biosynthesis 
is also depended on the expression of tryptophan hydroxylase (TFH), which 
catalyses the rate-limiting step of 5-HT biosynthesis in serotonergic neinons of the 
raphe nuclei (Lim et aL, 2001). A previous study for example, has shown that an 
increased TFH mRNA (gene) elevated TFH activity and contributed to the 
enhancement in 5-HT metabolism (Chamas et aL, 1999). On the other hand, an 
animal study has shown that prolonged exercise performance was diminished when 
the number of TRH-positive cells in the dorsal and median raphe regions had 
increased due to prolonged exercise but caffeine had the potential to reduce brain 5- 
HT biosynthesis during exercise by inhibiting the expression of tryptophan 
hydroxylase- (TFH) (TFH mRNA) positive cells in the dorsal and median raphe 
nucleus (Lim et aL, 2001). hi addition, a recent study has been shown that caffeine 
reduced brain 5-HT:DA ratio by blocking adenosine receptors within the CNS,
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which otherwise inliibit brain DA release (Davis et aL, 2003). Consequently, in the 
present EXPs the co-ingestion of caffeine with a high fat meal was used as a 
physiological strategy (‘vehicle’) in which the mechanism associated with a possible 
brain 5-HT and DA systems involvement in the perceptual and exercise fatigue 
development could be evaluated.
Assuming the increased effort perception following the high fat meal in the study by 
Fitsiladis et aL (1999) reflected a 5-HT mediated central neural adaptation to the 
high fat meal, this effect might therefore be reversed if  caffeine were to be ingested 
simultaneously since caffeine is known to enhance brain DA metabolism (Davis et 
aL, 2003; Fredholm et aL, 1999; Gaixett and Griffiths, 1997) and reduce effort 
perception (e.g. Cole et aL, 1996). Consequently, the aim of these EXFs was to 
examine the relationship between putative modulators of brain 5-HT and DA 
function, perceptual responses and exercise perfonnance following caffeine co­
ingested with a high fat meal in well-trained humans.
4.2 Methods
For information concerning the subjects’ characteristics, experimental design and 
procedures see Chapter 3. Regarding subjects’ medical screening, for camiulation, 
blood sampling, blood treatment, plasma amino acids and Frl analysis and the 
experimental protocol for the removal and statistical analysis are described in 
Chapter 2.
4.3 Results
Some of the results obtained h'om the present two EXFs relating to perceptual, 
metabolic and cardiovascular responses and exercise performance have been 
reported in the previous Chapter 3. In summary, in both EXFs ratings of perceived 
leg exertion were significantly lower during constant-load exercise following FC 
compared to the F trial (Fig. 3.4). Ratings of perceived breathlessness were lower 
during constant-load exercise following FC in both EXFs, significantly so at 10 min 
and 30 min time-points in EXF 1 (Fig. 3.4). hi addition, Vo^, VE (EXP 2), energy 
expenditure, (Tables 3.2, 3.3) blood [glucose] and [lactate] (Fig. 3.7) and plasma 
[glycerol] (Fig. 3.6) were significantly higher on the FC compared with the F trial in
both EXPs. Blood [pyruvate], the L;P ratio (Fig. 3.8), plasma [FFA] (Fig. 3.6) and 
heart rate (Fig. 3.6) were significantly higher on the FC relative to the F tiial in EXP 
2. Time to fatigue (Fig. 3.3), substrate oxidation (Tables 3.2 and 3.3) and sweat rate 
were not significantly different between tbe trials.
Plasma amino acids and prolactin concentrations
There were no significant differences between F and FC trials for total [Trp], [Tyr], 
[LNAA], total [Trp]:[LNAA] ratio total [Trp]:[Tyr] ratio in both EXP 1 (Table 4.1) 
and EXP 2 (Table 4.2). However, there was a tendency for plasma fiee-[Trp] (F(i,9) 
= 4.438; P -  0.064) and fi:ee-[Trp]:[Tyr] ratio (F(i,9)= 4.366; P ~  0.066) to be higher 
on the FC compared to F trial (Fig. 4.1). Plasma fi'ee-[Trp]:[LNAA] ratio was 
significantly higher, at 90 min and at exhaustion, on the FC relative to F trial (F(i,9) = 
6.700; P  = 0.029) (Fig. 4.1). There was no main treatment effect on plasma [Prl] in 
both EXP 1 and 2 (Fig 4.2). In both EXPs plasma [Prl] was progressively increased 
over time in all trials relative to the resting levels, hr EXP 1, plasma [Prl] has 
reached peak values at 5 min during recovery after the ramp phase; in EXP 2 the 
peak plasma [Prl] value was detected at exhaustion.
Table 4.1: Plasma concentrations of amino acids, serotonergic and dopaminergic 
modulators, in Control, F and FC trials in EXP 1. Values are given as 
meani: s.d..
Variables Trials Rest
Blood collection time (min) 
30min End lOmin-post
Total [Trp] (pmol-r') Contiol 34±4 33±6 34±7 3416
F 38±8 37±8 37±7 3415
FC 36±8 37±7 36±8 3418
[Tyrosine] (pmoM'*) Control 58±7 62±11 73±13 74116
F 61±10 6A±\1 75±9® 69111
FC 60±9 66±12® 69±11 65111
[LNAA] (pmol-r’) Contiol 536±81 573±130 665±171 6611172
F 630±99 628±119 706±97 664196FC 615±118 636±92 662±110 6261110
Total [Tip]:[LNAA] ratio Contiol .064±.009 .058±.009 .053±.008 .0531.010
F .062±.019 .059±.010 .0531.010 .0521.010
FC .059±.013 .059±.014 .0541.011 .0591.019
Total [Trp]:[Tyrosine] ratio Control 0.59±.10 0.54±.10 0.481.08 0.471.09
F 0.64±.16 0.58±.09 0.501.1P 0.501.10^
FC 0.60±.13 0.58±.13® 0.521.1 ri 0.581.18
§: hrdicates a significant difference over time relative to the resting values 
s.d.: Standard Deviation
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Table 4.2: Plasma concentrations of amino acids, serotonergic and dopaminergic 
modulators, in Control, F and FC trials in EXP 2. Values are given as 
m ean± s.d..
Variables Trials Rest
Blood collection time (min) 
30min 90min End
Total [Trp] (pmol-f^) Control 3818 3617 3913 4619
F 3817 3917§ 4316* 4219
FC 3817 3917 4319* 4317*
[Tyi'osine] (pmoM' )^ Control 5418 5317 6117 7118
F 5213 5816* 6517* 6815*
FC 5114 5516* 6418* 6617*
[LNAA] (pmolT’) Control 500150 487135 486151 531160
F 522146 532150 518145 518154
FC 505140 499148 504148 506144
Total [Trp]:[LNAA] ratio Control .0761.013 .0771.012 .0811.009 .0881.016
F .0721.012 .0741.013 .0831.015* .0831.021
FC .0751.012 .0801.013 .0851.013* .0851.015*
Total [Trp]:[Tyrosine] ratio Control 0.721.15 0.691.13 .0641.08 0.661.11
F 0.721.14 0.681.13* 0.671.11 0.631.15*
FC 0.741.17 0.721.14 0.671.14 0.651.10*
§: Indicates a significant difference over time relative to the resting values 
s.d.: Standard Deviation
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Fig. 4.1. Plasma free-[Trp]:[LNAA] ratio (bottom panel), ffee-[Trp]:[Tyr] ratio (middle 
panel) and plasma free-[Trp] (top panel) responses (mean ± s.d.) in EXP 2. *: indicates a 
significant difference between F ( ° )  and FC ( • )  trials. indicates significant differences 
over time relative to resting value in both trials. The dash line indicates the Control trial.
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Fig. 4.2. Plasma prolactin responses (mean ± s.d.) between F ( o ) and PC ( •  ) trials in EXP 
1 (bottom panel) and in EXP 2 (top panel). indicates significant differences over time 
relative to resting value in both trials. The dash line indicates the Control trial.
Correlation analysis
There were no significant correlations between plasma fi-ee~[Trp] and RPE, between 
free-[Trp] and plasma [FFA], and between ffee-[Trp] and [Prl], when examined for 
each time-point separately.
4.4 Discussion
The present study examined the relationship between the putative modulators and 
indices of brain serotonergic and dopaminergic ftmction, effort perception and 
performance during exercise in relatively theiinoneutral (20 °C) and cold (10 °C) 
environments following caffeine co-ingested with a high fat meal in well-trained 
humans, hi contrast to several previous studies that have examined putative 
modulators and indices of brain 5-HT and DA functions during exercise (e.g. 
Blomstrand et a l, 1988; 1989; 1997; Davis et a l, 1992; Bailey et a l, 1993b; van 
Hall et a l, 1995; Struder et a l, 1996) the 10 °C temperature, in association with the 
water replacement provided throughout exercise in EXP 2 has been chosen to
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produce fatigue minimising thenno-pliysiological factors (dehydration, early 
increased core or brain temperatures, effort perception or reduction in cardiovascular 
capacity, systematic circulation and muscle blood flow) (see Febbraio et aL, 1996; 
Galloway and Maughan, 1997; Gonzalez-Alonso et ah, 1998; 1999; 2003; McConell 
et ah, 1997; Nybo et aL, 2001; 2002; Nielsen et aL, 1993; 1997).
The results presented here do not support a significant involvement of the putative 
modulators and indices of brain serotonergic and dopaminergic function in the 
fatigue process during submaximal constant-load exercise and maximal incremental 
exercise at moderate to low ambient temperatures. This lack of involvement of the 
putative modulators and indices of ‘central fatigue’ was observed despite a 
significant reduction in effort perception following caffeine ingestion that is most 
likely attributed to central neural mechanism(s).
Caffeine at the micromolar levels utilised in both studies has been shown to cross 
the blood brain barrier (BBB) with the potential to serve as a competitive antagonist 
of adenosine (Fredholm et aL, 1999). The net effect would be to increase central DA 
release by antagonising the inhibition o f adenosine on DA activity, thus reversing 
the increased effort perception induced by the high fat meal in conjunction with the 
exercise stress (Fitsiladis et aL, 1999). This is consistent with the hypothesis that a 
high 5-HT:DA ratio may favour central fatigue, while a low 5-HT:DA ratio may 
favour increased arousal and motivation (Davis et aL, 1993; Davis and Bailey, 
1997). Studies using rats for example, found a reduction in brain 5-HT synthesis and 
in the 5-HT:DA ratio, and an improvement in exercise perfonnance after direct 
intracerebroventicular caffeine injection (Davis et aL, 2003). Similar results were 
found during exercise after a suppression of the expression of TPH-positive cells 
(which catalyses the rate-limiting step of serotonin biosynthesis in serotonergic 
neurons) in the dorsal and median raphe regions through caffeine administration 
(Lim et aL, 2001). In both studies, caffeine was effective in reducing effort 
perception, but did not enhance incremental or endurance exercise performance in 
relatively theimoneutral and low ambient temperatures respectively.
The failure of caffeine to significantly affect brain serotonergic function during 
exercise at theimoneutral and low temperatures in the present experiments is further 
reflected in the lack o f difference in plasma [Prl] between trials (Fig 3). Previous
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studies have shown that Ketanserin, a 5-HT antagonist drug, reduced Prl release 
during graded exercise to exhaustion (De Meirleir et al., 1985a; b). A further study 
reported that Trp infusion reduced exercise performance and caused an earlier 
elevation in plasma [Prl] relative to placebo or glucose inflision (Farris et al., 1998). 
If caffeine at the dosages used in the present experiments, can directly attenuate 
brain 5-HT biosynthesis (Lim et aL, 2001), Prl levels would be expected to be lower 
during the two exercise trials involving caffeine. The finding of no difference in 
[Prl] between caffeine trials in both experiments may imply that caffeine does not 
directly affect brain 5-HT function in well-trained humans when exercise is carried 
out in relatively thermoneutral and low ambient temperatures. Alternatively, 
circulating Prl levels may not be as sensitive a marker of 5-HT as previously 
proposed (De Meirleir et aL, 1985a; b).
Previous studies have demonstrated that elevation in plasma [FFA] displaces Trp 
from binding to albumin and consequently increases the ffee-Trp:LNAA ratio into 
the plasma (Bloxam et aL, 1980; Chaouloff et aL, 1985; Curzon et aL, 1973; Struder 
et aL, 1996). Since Tip and the other LNAAs share the L-system carrier for crossing 
the BBB, the elevation in plasma free-Trp:LNAA ratio may favour brain Trp uptake 
and potentially increase brain 5-HT synthesis (Pardridge, 1986), and hence central 
fatigue (Newsholme et aL, 1987; Blomstrand et aL, 1988). A recent study using 
analbuminaemic rats has shown an improvement in exercise performance after 
reducing brain Tip uptake by blocking the L-system carrier using 2- 
aminobicyclo[2,2,l]heptane-2-carboxylic acid, a specific inhibitor of the L-system 
transporter (Yamamoto and Newsholme, 2000). Conversely, intracerebroventricular 
Trp injection in the same species was found to increase Vo^ and reduce mechanical 
efficiency and exercise performance in rats (Soares et aL, 2003).
In EXP 2, the ffee-[Trp]:[LNAA] ratio was significantly higher although the 
increased was modest, and there was a tendency for ffee~[Trp] and the fine- 
[Trp]:[Tyr] ratio to be higher following caffeine ingestion. This effect may have 
attributed to the action of caffeine in elevating adipose tissue lipolysis and thus 
plasma [FFA], results that are consistent with several previous reports (e.g. Costill et 
aL, 1978; Spriet et aL, 1992). This effect, in conjunction with a reduced effort 
perception following caffeine ingestion could reflect the two opposing actions of the 
high fat meal and caffeine interventions. The former potentially increasing 5-HT
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function and consequently effort perception, and the latter increasing DA function, 
hence reducing effort perception. In addition, this may have caused the modest 
difference on plasma free-[Tip]:[LNAA] between F and FC trials because the high 
fat meal per se has increased plasma [FFA] to a similar magnitude in both trials. 
Consequently the modest elevation in plasma [FFA] observed in the FC trial was 
insignificant to produce massive differences in plasma precursors of brain 5-HT 
function (e.g. free-[Trp] and ffee-[Trp] : [LNAA] ratio.
Several previous studies found that caffeine attenuated effort perception during 
exercise in humans (Bridge et aL, 2000; Cole et aL, 1996; Jacobson et al. 2000; 
Laurent et al., 2000; Motl et aL, 2003). It is not unreasonable therefore, to imply a 
direct elevation in brain DA function with caffeine which may have contributed to 
reduce effort perception. However, in the present EXFs, although caffeine may have 
effectively reduced effort perception by elevating brain DA ftmction (Davis et aL, 
2003), exercise performance was not enhanced. It should be noted, that in both 
studies, the effectiveness of caffeine to reduce effort perception via a central 
dopaminergic-mediated effect can only be speculated as there is currently no 
suitable available marker of brain dopaminergic function. However, plasma [Prl] is 
an index of hypothalamic 5-HT and DA metabolic interaction only (Ben-Jonathan et 
aL, 1989; Freeman et aL, 2000). It is possible therefore that caffeine reduced 
subjective fatigue by increasing brain DA metabolism in other brain regions than the 
hypothalamus without being able to significantly inhibit hypothalamic Prl release. 
Studies using animal models for example, have demonstrated an up-regulation of 
brain 5-HT synthesis or down-regulation of brain DA metabolism during exercise 
not only into the hypothalamus (Bailey et aL, 1993a) but also in the midbrain, 
hippocampus, striatum and frontal cortex (Bailey et aL, 1993b; Chaouloff et aL, 
1989; Gomez-Marino, 2001; Meeusen and De Meirleir, 1995; Meeusen et aL, 1996). 
Consequently, plasma [Prl] in the present EXPs should not be considered to reflect 
changes of the whole brain 5-HT and DA synthesis.
Total CHO and fat oxidation was not different between both F and FC trials, 
confnming the lack of any ergogenic effect of pre-exercise caffeine ingestion when 
muscle metabolic adjustment is manipulated by a high fat meal prior to exercise and 
supporting the role of glycogen depletion in fatigue development during prolonged 
exercise in relatively theimoneutral environments.
95
Conclusion
In conclusion, both experiments presented demonstrate a dissociation between 
putative brain serotonergic modulators and indices and effort perception during 
exercise and a mismatch between effort perception and exercise perfonnance after 
caffeine co-ingested with a high fat meal. The exact mechanism(s) for the 
attenuation of effort perception with caffeine is unlikely therefore to be brain 5-HT- 
mediated but most likely dopamine-mediated. Nevertheless, neither brain 5-HT nor 
DA systems would appear to be implicated in the fatigue process when exercise is 
performed without significant thermoregulatory stress, thus enabling fatigue 
development during exercise to occur due to cardiovascular and/or peripheral 
limiting factors (i.e. glycogen depletion).
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Chapter five
Experiment 3
M easures o f putative brain 5-HT and DA modulators during exercise in 
the heat following creatine supplementation in trained-humans
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5.1 Introduction
It is well established that exercise performance is markedly impaired in hot 
environments but the precise mechanism(s) of fatigue have yet to be determined (see 
chapter 1, section 1.2.8.1). Although strategies like heat-acclimatization (Armstrong 
and Maresh, 1991), whole body or face pre-cooling (Olschewski and Bruck, 1988; 
Lee and Haymes, 1995; Booth et aL, 2001), fluid replacement (Galloway and 
Maughan, 2000), and plasma volume expansion (Watt et aL, 2000) may all extend 
time to fatigue by enhancing cardiovascular and thermoregulatory capacity, 
circulatory failure is not considered as the primary factor limiting exercise 
performance in the heat (e.g. Nielsen and Nybo, 2003). These observations, in 
conjunction with the maintenance of CHO reserves at exhaustion (Galloway and 
Maughan, 1997) and no impairment in the capacity of skeletal muscle to generate 
force during exercise with hyperthermia (Nybo and Nielsen, 2001b), may preclude 
peripheral factors as the main cause of fatigue during exercise in the heat.
Previously, Nielsen and colleagues (1993; 1997) proposed a core temperature 
increase to approximately 39.6 as a critical factor in the reduction of central 
neural motivation and exercise performance. In another study, Nielsen et aL, (2001) 
obtained electroencephalographic recordings from the frontal cortex during exercise 
in the heat and in the cold, in an attempt to examine alertness and central motivation. 
These authors found that the elevation in core temperature significantly reduced 
electrical activity of the frontal cortex and suggested that this reflected a reduction in 
central drive, a rise in effort perception, and consequently, a reduction in exercise 
performance. In subsequent studies, it was proposed that fatigue during exercise in 
the heat may occur at a critical brain temperature, through a reduction in cerebral 
blood flow (Nybo and Nielsen, 2001a; Nybo et aL, 2002) and brain glucose levels 
(Nielsen and Nybo, 2003; Nybo et aL, 2003). However, the exact mechanism(s) for 
these hyperthermia-induced effects and how thermal stress may affect brain 
neurotransmission during exercise in the heat are presently unknown.
Creatine (Cr) has extensively been shown to improve performance during short 
duration, high-intensity exercise by increasing intramuscular Cr and PCr levels 
(Harris et aL, 1992; Kreider et aL, 1998) and by accelerating the resynthesis rate of 
PCr following intense exercise (Greenliaff et aL, 1994). Cr has also been shown to 
increase total body water (TBW) (Hultman et aL, 1996), enhance body thermal
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tolerance during exercise in the heat (Kem et aL, 2001; Ziegenfuss et aL, 1998) and 
improve performance during 35 min of submaximal exercise followed by 3 x 10 sec 
repeated sprints at an ambient temperature of 37 °C (Volek et aL, 2001). However, 
whether these effects of Cr supplementation on thermoregulation and exercise 
performance were due to an increase in intramuscular Cr and/or PCr levels, better 
maintenance o f TBW or central neural effects, is presently unknown.
Several studies have attributed the changes in body temperature (Hasegawa et aL, 
2000; Lin et aL, 1998), the higher effort perception and impaired exercise tolerance 
during exercise in the heat to events localized within the central nervous system, and 
in particular, the serotonergic and dopaminergic systems (Bridge et aL, 2003; 
Pitsiladis et aL, 2002), For example, when hypothalamic [5-HT] was increased in 
the rat by administration of Fluoxetine (i.e. 5-HT reuptake inhibitor) and 5- 
hydoxytryptophan (i.e. a 5-HT precursor), there was an increase in metabolic heat 
production with a concomitant reduction in heat loss (Lin et aL 1998). However, in 
the same species, moderate exercise induced an increase in DA release in the 
preoptic area of the anterior hypothalamus and this was associated with a reduced 
body heat storage and greater resistance to heat-stress (Hasegawa et aL 2000). hi 
addition, Pitsiladis et aL, (2002) found a significant positive correlation between 
elevated serum [Prl] and rectal temperature and effort perception with a concomitant 
reduction in exercise capacity during exercise in the heat. On the other hand, Bridge 
et aL, (2003), using a combined Buspirone (i.e. 5-HTia agonists/dopamine D2 
antagonist) and Pindolol (5-HTia antagonist) neuroendocrine challenge, found the 
DA-induced Prl response to be significantly correlated both with exercise duration 
(73 % of V o 2 max at 35 °C), rectal temperature and the rate of temperature rise. 
These authors concluded that high activity of the dopaminergic pathways in the 
hypothalamus was a predictor of exercise tolerance in the heat.
Interestingly, clinical studies have shown that oral Cr supplementation increased 
brain DA synthesis in the substantia nigra of mice by enhancing tyrosine 
hydroxylase (TH)-positive neurons and TH activation (the rate-limiting enzyme of 
brain DA biosynthesis) (Klivenyi et aL, 1999; 2004; Matthews et aL, 1999). 
Consequently, since the elevation in hypothalamic 5-HT and DA metabolism was 
fomid to increase (Lin et aL 1998) and reduce (Hasegawa et aL 2000) thermal-stress 
and to be a predictor of exercise tolerance in the heat (Bridge et aL, 2003) and Cr
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supplementation was found to enhance TBW (Hultman et aL, 1996) and thermal 
tolerance (Kem et aL, 2001; Ziegenfuss et aL, 1998) it was not unreasonable to 
imply a possible role of Cr in thermoregulation via brain monoamine system. The 
purpose therefore of the present EXP was to examine the effects of oral Cr 
supplementation on thermal-stress and on putative modulators of brain 5-HT and 
DA function during exercise in the heat.
5.2 Methods 
Subjects
Twenty-one endurance-trained male volunteers (n=18 cyclists; n=3 endurance 
runners) provided written informed consent (for subjects physical characteristics see 
Table 5.1) for the study. For more information regarding the subjects medical 
screening and study approval see Chapter 2. Subjects were not engaged in a 
stmctured weight-training program during the study and all were Cr free for at least 
8 weeks prior to the study. The investigators did not reveal prior to interview that 
subjects would be excluded if they had supplemented with Cr in the 8 weeks 
preceding the study. One subject from the placebo group had previously 
supplemented with Cr. No Cr was detected in the baseline urine samples of any 
subject.
Experimental design
The determination of Vo^ max, ET and test workloads are described in Chapter 2. 
The schematic illustration of the experimental design is presented in Figure 5.1.
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Figure 5.1 Schematic illustration of the experimental design in EXP 3
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Briefly, following the VOjmax test, subjects visited the laboratory on at least two 
occasions (familiarisation to exercise in the heat), in addition, to establishing a 
suitable work rate that would elicit fatigue in the heat no less than 40-60 minutes. 
This was achieved by setting the work rate at 20 % A (i.e., 20 % of the difference 
between the Vo^ at the LT and V o jm a x )  during the initial familiarisation session 
and, where necessary, adjusting the work rate for subsequent trials to achieve the 
desired duration. This intensity of exercise was chosen to avoid fatigue occurring as 
a result of muscle glycogen depletion (Galloway and Maughan 1997). Following the 
familiarisation period, subjects were matched for body mass and were randomised, 
in a double-blind fashion, to receive either Cr or placebo. Subjects performed two 
constant-Ioad exercise tests to volitional exhaustion pre- and post-supplementation. 
The first test was conducted at least 48 hrs after the subject's final familiarisation 
trial. The supplementation period for both groups started on the day after the first 
test and finished the day before the second test.
Cr supplementation consisted o f 22.8 g-d'  ^ Cr HzO (equivalent to 5 g Cr x 4 daily) 
and 35 g of glucose polymer made up in 500 mis of warm to hot water for 7 days 
taken at equal inteiwals thi'oughout the day. This protocol has been shown to 
increase resting muscle PCr levels within 5 days (Harris et al. 1992). The placebo 
gi’oup consumed 160 g-d"^  o f glucose polymer (40 g x 4 daily) for 7 days, prepared 
and administered in an identical fashion to the Cr supplement. Both supplements had 
similar taste, textui'e and appearance and were placed in generic packets to ensure 
double-blind administration. During the Cr supplementation period subjects were 
advised to follow their normal diet and weight all food and drink consumed during 
the supplementation period, using digital weighing scales, readable to 1 g. The diet 
was analysed for energy intake and macronutrient content using commercially 
available software (Holland et al., 1991). Subjects were provided with a dietary 
record book and weight scale and they were advised to record and keep their normal 
daily energy intake throughout the experimental period but to try to consume items 
that involve mostly CHO nutritional contents. A particular nutritional list was given 
to each subject. The subjects were advised to consume the same items with a similar 
weighted amount for three days prior to each experimental trial. Subjects were 
advised to avoid consuming items that involve caffeine and alcohol for at least 48 
hours prior to each experiment or to ingest any vitamins or commercial ergogenic-
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aid supplements or any medication throughout the experimental period and to avoid 
any strenuous activity for at least 72 hours prior to each exercise trial. At the end of 
the study all subjects gave verbal assurance that they had complied with these 
instmctions.
U rinaty A nalysis and m uscle Cr uptake estimation
Urinary [Creatinine] ([Crea]) and [Cr] were detennined for each subject following 
24 hour urinary collection for eight consecutive days (during the supplementation 
period). All urine was collected over a 24 hours period in a 5 L container provided 
by the investigators; subjects began urinary collection the day before 
supplementation in order to obtain baseline results. The volume of urine collected 
for each 24 hour period was measured and mixed thoroughly, with two 
representative 20 ml samples being stored at -20° C for subsequent analysis of [Cr] 
and [Crea] using a spectrophotometric enzymatic Crea Kit (Boelrringer Mannheim 
MPRl - Kit no. 839434) on an ABX Mira Plus Spectrophotometer (ABX 
Diagnostics, UK). The Crea content of the urine was measured by a sequence of 
four enzymatic steps as shown below:
1®^ step: Creatinine + H2O creatininase Cr
2"  ^step: Cr + H2O creatinase Sarcosine + Urea
3“^^  step: Sarcosine + H2O + O2 sarcosine oxidase Glycine 4- HCHO + H2O2
4^  ^ step: H2O2 + Phenol derivative + 4-aminophenazone peroxidase red 
benzoquinoneimine dye
Following the measurement of [Crea], the [Cr] content of the urine was then 
measured which involved the removal of the first step of the above creatininase 
reaction, with the remaining three enzymatic reactions (2nd to 4th steps) being 
completed as described by Oversteegen et al., (1987). Total Cr excretion was 
corrected for any observed increase in Crea following supplementation. Estimated 
Cr uptake was calculated by subtracting the total Cr excreted, corrected for [Crea] 
excretion, from the total amount supplemented per day. Estimated intramuscular 
[Cr] (mmol-kg'^dry weight muscle) was calculated based on an estimated muscle 
mass amounting to 40% of body mass and average muscle water content 
approximating 77% of wet weight (Bergstrom et al., 1971) as previously described 
by Maganaris and Maughan (1998). The criteria for subdividing the subjects into
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‘responders’ and ‘non-responders’ of Cr were based on previous muscle biopsies 
studies which proposed an ergogenic tlnreshold for intramuscular Cr uptake of ~ 20 
mmo'kg"^ dry weight muscle (e.g. Casey et ah, 1996; Greenliaff et aL, 1994) and on 
non-invasive muscle Cr uptake-estimation studies (based of urinary Crea exertion) 
which proposed < 25 mmo-kg'^-dry weight muscle as ‘non-responders’ and > 25 
mmo kg'^'dry weight muscle as ‘responders’ to Cr (Kilduff et aL, 2002; 2003).
Procedures
All exercise tests were carried out between 18:00 and 20:00 lir. Subjects reported to 
the laboratory on the day of testing after a standardised meal. Nude body mass were 
measured and body water compartments were estimated using a Bodystat Multiscan 
5000 Bioimpedance analyzer (Bodystat Ltd., Isle of Man) (Van Loan, 1990). This 
method allows TBW and extra-cellular water (ECW) to be estimated; from these 
measurements ICW can also be deduced. These measurements allowed euliydration 
to be indirectly assessed prior to each experiment. The bioimpedance measurements 
were taken while the subjects lay comfortably in a supine position on a non- 
conductive surface with their arms and legs slightly abducted. Thereafter, flexible 
rectal theimistor was inserted 10 cm past the anal sphincter to measure rectal 
temperature (Tree), an index of core temperature and thermistors (C6600 10-channel 
microprocessor. Comark, Hertfordshire, UK) attached to the chest, upper arm, thigh 
and calf for the determination of weighted mean skin temperature (T sk in ) . Tgkin, [ T s k =  
0.3 (Tchest + Tarm) + 0.2 (Tthigii + Tcaif)] (Ramauthau 1964) was calculated for each 
time point. Then, the subject's left hand and forearm were immersed in warm water. 
For artérialisation of the venous at rest and during exercise, cannulation, blood 
sampling, HR and RPE recording see chapter 2.
The subject was transferred to the climatic chamber (ambient temperature of 30.3 ± 
0.5 °C with a relative humidity of 70 ± 2 % and air velocity of approximately 3.6
m-sec'^) and remained seated on the cycle ergometer for a further 5 min while 
resting HR, Tree, Tgkin and gas collections were obtained. Subjects were then 
instructed to begin 5 min of unloaded cycling before further measurements and 
another blood sample were obtained. After 5 min of unloaded cycling, the work rate 
was increased in a ‘single step’ to the predetemiined WR and subjects maintained a 
pedal cadence of 60-90 rpm throughout the test. Subjects exercised at the same WR 
for both experiments (i.e., 16 ± 11 % A or 63 ± 5 % Vo^ max). Exhaustion was
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defined as the point at which the subject could no longer maintain the pedal cadence 
above 60 rpm. Blood samples and measurements of HR, Tree and Tskin were obtained 
at 5 min intervals throughout exercise and at exhaustion (Figure 5.1). After exercise, 
nude body mass was measured. The difference in body mass before and after 
exercise was calculated and subsequently used to estimate sweat rate and sweat loss, 
after correcting for respiratory water loss and substrate oxidation (Mitchell et aL 
1972). Time to exhaustion was recorded but withheld from the subject until all 
exercise tests had been completed. The experimental protocol for the removal, 
treatments and analyses of blood and plasma as well as gas exchange measurements 
and statistical methods used are described in Chapter 2.
5.3 Results
Table 5.1: Physical characteristics of the two groups of !subjects. Values are
presented as the mean ± s.d.
Placebo Group (11= 10) Creatine Group (n=l 1)
Pre Post Pre Post
Age (yr) 27 ±4 - 27 ±5 -
Height (cm) 181+4 - 178 ±7 -
Weight (kg) 71.0 ±6.0 71.2 ±6.0 72.7 ± 6.6 73.4 ±6.6*
Total body water (L) 40.4 + 3.3 40.5 ± 3.2 41.0±3.1 41.6 ±3.2*
Inti'acellular Water (L) 21.9 + 1.8 21.9± 1.8 22.2 ± 1.8 22.7 ± 1.9*
Extracellular Water (L) 
yOjniax (L-min^)
18.5 ±1.5 18.5 ±1.4 18.8 ± 1.4 18.9 ±1.5
4.3 ±0.4 - 4.5 ± 0.4 -
V02max(ml-kg-mrn^) 60.5 ± 4.7 - 61.4 ± 4.6 -
Max work rate (watts) 350 ±34 - 373 ±31 -
*: Indicates a significant difference from pre-supplementation values
Some of the results obtained from this EXP relating to exercise performance, 
cardiovascular, metabolic and thermal responses have been reported elsewhere 
(Kilduff et aL, 2004). In summary, relative to the placebo (Pic) group, Cr 
supplementation increased ICW, TBW and body mass (Table 5.1) and reduced Tree, 
mean body temperature (Ty) (Fig. 5.3), HR and sweat rate. Cr did not affect Tgkin 
(Fig. 5.3), total sweat loss, changes in plasma volume, blood [glucose] and [lactate], 
VOj,  VCO2/ RER, Ve and metabolic rate (Kilduff et al., 2004). Although 
endurance performance was not different between Cr (as whole, n = 11) and Pic 
groups, Cr effectively enhanced performance in the group of subjects (n = 8) 
considered as ‘responders’ to Cr, based on estimated intramuscular Cr uptake 
(Placebo: 50.4 ± 8.4 min vs. 51.2 ± 8.0 min, P ~  0.119; Cr group: 47.0 ± 4.7 min vs.
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49.7 ± 7.5 min, P  = 0.095; ‘responders’: 47.3 ± 4.9 min vs. 51.7 ± 7.4 min, P  = 
0.031) (Fig. 5.2). No side effects were reported following Cr supplementation.
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Fig. 5.2. Time to exhaustion (mean ± s.d.) in the Cr, ‘responders’ and placebo 
supplemented groups. *: indicates a significant difference between pre- and post­
supplementation .
40,0-1
p 39,0 -
37 ,0-
3 6 ,0 -J
R UL 10 15 20 25 30 35 40 
Time (min)
40.0 n
P 39 .0 -
36.0 J
Ex
fp  Pre-
O Post-
R UL 10 15 20 25 30 35 
Time (min)
40 Ex
40,0-140,0-1
^ 3 8 ,0 -
2  36 ,0-36 ,0 -
34.0-34.0-
§3.0.
s  30.0
32.0-
2  30,0 - f ExR UL 10 15 20 25 30 35 40ExR UL 10 15 20 25 30 35 40
Time (min) #  Pre- 
O Post-
Time (mill)
39 ,0 -
36.0-1
R UL 10 15 20 25 30 35 40 Ex
I 3 9 .0 -
I  38,0 -
36.0-1
R UL 10 15 20 25 30 35 40 Ex
Time (min) Time (min)
Fig. 5.3. Rectal temperature (top panel), mean skin temperature (middle panel) and mean 
body temperature (bottom panel) in the Cr (left side) and placebo (right side) supplemented 
groups. *; indicates a significant difference between pre (•) to post (o) supplementation, f: 
indicates a significant greater change in the Cr group compared with the placebo group. 
Values are given as mean (s.d.).
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E stim ated Cr uptake
Estimated Cr uptake was calculated by subtracting the total Cr excreted, corrected 
for the increase in Cm excretion, from the total amount supplemented per day.
Estimated intramuscular [Cr] (mmol-kg'^-dry weight muscle) was calculated based 
on an estimated muscle mass amounting to 40 % of body mass and average muscle 
water approximating 77 % of wet weight (Bergstrom et aL, 1971). hi the Cr group, 
Cm excretion increased from 1.4 ± 0.4 g-day"  ^ pre-supplementation to 2.4 ± 1 . 0  
g-day'^ on the final day o f supplementation. There was no increase in Cm excretion 
in the placebo group (1.5 ± 0.4 g-day“^ to 1.4 ± 0.4 g-day”^ ). Cr excretion increased 
from 8.7 ± 3.7 g’day'^ pre-supplementation to 17.4 ±1.9 g-day”^ ; no Cr was detected 
in the urine of the placebo group. Estimated Cr uptake was maximal on the first day 
of Cr supplementation (12 (6-15) g, 61 (32-77) % being retained) and was lowest on 
the final day (3 (-2-4) g, 16 (-8-21) % being retained). The total amount of Cr 
retained over the supplementation period was 39 ± 14 g, with an estimated increase 
in intramuscular [Cr] of 51 (21-61) mmol-kg'^-dry weight muscle. Based on these
estimates, 3 subjects were classified as ‘non-responders’ (21 (21-25) mmol kg"^  dry 
weight muscle) and the remaining 8 subjects were classified as ‘responders’ (53 ± 5
mmohkg"^ dry weight muscle).
Ratings o f  perceived exertion (RPE)
A  progressive increase in RPE both for breathlessness and perceived leg fatigue was 
found during exercise reaching near maximum ratings at exhaustion (Fig. 1). 
Significantly (3-way interaction, F(2,g)== 2.548; P  = 0.013) lower ratings of perceived 
leg fatigue were found in the Cr group after 10 min (P = 0.043) and 25 min (P = 
0.01) of exercise, with tendencies at 15 min (P -  0.076); no such effect was found in 
the Pic group. There was also a tendency (3-way interaction, F(2,s) = 1.727; P  = 
0.097) for subjects in the Cr group to report a feeling of less breathlessness 
following Cr supplementation; no such effect was observed in the Pic group. The A 
RPE for breathlessness and perceived leg fatigue was not different between Pic and 
Cr groups. Five out of the eleven subjects in the Cr group reported that they found 
the post-supplementation trial easier, while two out of the ten subjects in the Pic 
group rated the post-supplementation trial to be easier. All other subjects rated both 
trials similarly.
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Fig 5.4. RPE (breathing) (top panel) and RPE (legs) (bottom panel) in the Cr (left side) and 
placebo (right side) supplemented groups during exercise. *: indicates a significant 
difference between pre (•) to post (o) supplementation. Values are given as mean (s.d).
P lasm a am ino acids, prolactin  and  fre e  fa tty  acids concentrations
There were no significant differences between Pic and Cr groups in plasma total 
[Trp], [Tyr], [large neutral amino acids] (LNAA) (Table 5.2), total [Trp]:[LNAA] 
ratio, total [Trp]:[Tyr] ratio, free-[Trp]:LNAA ratio, and ftee-[Trp]:[Tyi'] ratio 
(Table 5.3). The A plasma total [Trp], [Tyr] and [LNAA] and the ratios of total 
[Trp]:[LNAA], total [Trp]:[Tyr] and free-[Trp]:[LNAA] were also not different 
between the groups. Plasma free-[Trp] was sigiificantly lower in the post-Cr 
supplementation trial in the Cr group (x^ = 33.909, df = 5, P  < 0.0005) and in the 
‘responders’ (x^ = 25.786, df = 5, P  < 0.0005) when compared to the pre­
supplementation trial (Table 5.2). The A ffee-[Trp] was also significantly lower 
during exercise in the Cr group (x^ = 15.881, df = 1, P  = 0.017) and in the 
‘responders’ (x^ = 14.582, df = 1, P  = 0.019) when compared with A Pic group. In 
‘responders’, the plasma fi'ee-[Trp]:[Tyr] ratio was significantly lower at rest and 
during exercise post-Cr, relative to the pre-supplementation trial, (x^ -  13.071, df = 
5, P  = 0.023) (Table 5.3). Plasma total [Trp], [Tyr], [LNAA], free-[Trp]:[LNAA] 
ratio, total [Trp]:[LNAA] ratio, and total [Trp]:[Tyr] ratio were not different
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between pre- and post-supplementation trials in both Pic and Cr gioups as well as in 
the ‘responders’. Plasma [Prl] was not different between the Pic group and the Cr 
gi'oup as a whole and between pre- and post-supplementation trials in both Pic and 
Cr gioups (Table 5.4). In addition plasma [Prl] was not different at the end of 
exercise between ‘responders’ and ‘non-responders’ and between ‘responders’ and 
placebo groups {P > 0.05). In all trials, [Prl] increased significantly over time at all 
time-points when compared to the resting levels. A plasma [Prl] was also not 
different between the groups and between pre- and post-Cr supplementation trials. 
Plasma [FFA] was not different between Pic and Cr groups or between pre- and 
post-Cr supplementation trials (Table 5.4).
Table 5. 2: Concentrations of total Tip, Tyr, LNAA and free-Trp before and after 
Supplementation. Values are given as median (IQR)._________________________
Blood collection time (min)
Group Trial Rest 40 End
[Tyr] (gm obl ')
[LNAA] (pmol-r^)
Pic Pre 58.3(12) 56.7(22) 63.9(11)
Post 55.2(14) 67.7(22) 75.5(16)®
Cr Pre 47.8(14) 71.1(16)® 69.9(17)®
Post 53.4(5) 62.3(7)® 71.7(21)®
Resp Pre 47.5(6) 65.8(15)® 68.7(18)®
Post 53.6(7) 62.4(8)® 71.6(20)®
Pic Pre 85.3(18) 94.8(12) 116(24)®
Post 76.9(41) 86.5(33) 104.1(36)
Cr~ Pre 71.9(37) 111.5(41)® 121.7(46)®
Post 81.3(34) 104.9(31)® 112.4(52)®
Resp Pre 70.3(31) 112.1(36)® 118.3(45)®
Post 74.6(33) 109.8(31)® 114.5(51)
Pic Pre 831(29) 902(211) 986(254)
Post 873(233) 897(171) 994(375)
Cr Pre 744(334) 1076(340) 945(326)
Post 812(189) 806(372) 933(361)
Resp Pre 732(279) 1051(273) 962(267)
Post 764(187) 864(473) 871(322)
Pic Pre 2.5(0.6) 3.1(0.7)® 3.3(0.8)®
Post 2.6(1.2) 3.2(0.7)® 3.6(0.9)®
Cr Pre 2.4(0.7) 2.9(0.6)® 3.5(0.5)®
Post 2.4(0.5) 2.6(0.5)*® 3.0(0.7)*®
Resp Pre 2.6(0.9) 3.1(0.6) 3.4(0.6)®
Post 2.3(0.7) 2 .7(0 .6)* 3.0(0.5)*®
*: Indicates a significant difference from pre-supplementation values.
Indicates a significant difference over time compared with the resting values 
IQR: hiterquartile range.
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Table 5. 3: Total Trp:LNAA, total Tip:Tyr, free-Trp:LNAA and free-Trp:Tyr ratios 
before and after supplementation. Values are given as median (IQR)._____________
Group Trial Rest 40 End
Total [Trp]:[LNAA] ratio Pic Pre .069(.016) .071(.015) ■076(.016)
Post .070(.012) ,072(.017) ,084(,022)
Cr Pre ,062(.013) .069(.010) .075(.012)
Post .073(.016) .080(.016) .082(.007)®
Resp Pre .062(.012) .069(.010) .076(.014)
Post .076(.016) .077(.019) .082(.006)®
Total [Trp]:[Tyr] ratio Pic Pre 0.65(.24) 0.61(.09) 0.58(.17)
Post 0.71 (.07) 0.68(.18) 0.74(.19)
Cr Pre 0.64(.14) 0.63(.07) 0.61(.15)
Post 0.65(.16) 0.62(.14) 0.65(.09)
Resp Pre 0.66(.20) 0.62(.09) 0.61(.17)
Post 0.71(.16) 0.62(.20) 0.62(.09)
Free-[Trp]:[LNAA] ratio Pic Pre .0030(.0007) .0040(.0010) ,0036(.0020)
Post .0031(.0024) .0038(.0014) .0048(.0012)
Cr Pre .0034(.0021) .0032(.0015) .0037(.0016)
Post .0028(.0015) .0038(.0017) .0028(.0027)
Resp Pre .0042(.0020) .0034(.0010) .0045(.0012)
Post .0027(.0015) .0039(.0017) .0043(.0025)
Free-[Tip]:[Tyr] ratio Pic Pre .032(.017) .035(.008) .027(.014)
Post .035(.018) .039(.012) .043(.013)
Cr Pre .034(.027) .032(.013) .027(.012)
Post .028(.016) .028(.013) .024(.019)
Resp Pre .042(.025) .033(.011) .032(.013)
Post .032(.017)* .026(.015)*® ,029(.018)
Indicates a significant difference from pre-supplementation values.
®: Indicates a significant difference over time compared with the resting values.
IQR: Interquartile range
Table 5.4: Concentrations of plasma prolactin and FF A before and after 
supplementation. Values are given as median (IQR). _____________
Blood collection time (min)
Group Trial Rest 40 End
Plasma [Prolactin] (mnoM'^) Pic Pre 0.13(.04) 0.51(.38)® 0.94(.83)®
Post 0.14(.06) 0.53(.24)® 0.93(.14)®
Cr Pre 0.15(.07) 0.84(.58)® 1.07(.63)®
Post 0.15(.05) 0.79(.51)® 1.14(.56)®
Resp Pre 0.15(.04) 1.14(.39)® 1.27(.44)®
Post 0.14(.04) 0.98(.46)® 1.39(.36)®
Plasm a [FFA] (mmol 1' )^ Pic Pre 0.53(0.47) 0.37(0.18) 0.40(0.34)
Post 0.38(0.10) 0.28(0.14) 0.23(0.19)
Cr Pre 0.42(0.26) 0.29(0.11) 0.31(0.18)
Post 0.48(0.27) 0.32(0.14) 0.34(0.18)
Resp Pre 0.48(0.24) 0.28(0.10) 0.30(0.15)
Post 0.42(0.20) 0.29(0.10) 0.32(0.16)
®: Indicates a significant difference over time compared with the resting values. 
IQR: Interquartile range.
109
Correlation analysis
There were no significant correlations between plasma free-[Trp] and Tree, between 
free-[Trp] and RPE, between free-[Trp] and plasma [FFA], between T,-ec and [Prl] 
and between free-[Trp] and [Prl], when examined for each time-point separately.
5.4 Discussion
The present study utilized prolonged exercise in the heat to examine modulators of 
brain 5-HT and DA function in association with perceptual, metabolic and 
thermoregulatory responses and endurance exercise performance after 7-days of Cr 
supplementation. Cr was used as a ‘vehicle’ to increase hydration status and reduce 
thennal stress. The most significant observations of this study were the effectiveness 
of Cr to directly or indirectly attenuate thermal stress (e.g. Tree, sweat rate, HR), 
increase hydration (ICW, TBW), reduce effort perception and influence selected 
modulators of brain serotonergic and dopaminergic function (i.e. lower plasma free- 
[Trp] and free-[Trp]:[Tyr] ratio). These responses may therefore have contributed to 
enhancing endurance exercise performance in the heat in the ‘responders’ to Cr 
supplementation.
It is well established that there are ‘responders’ and ‘non-responders’ to Cr 
supplementation, with some researchers proposing an ergogenic threshold for
intramuscular Cr uptake of 20 mmohkg'fdry muscle weight following Cr 
supplementation (Casey et aL, 1996; Greenhaff et aL, 1994). In previous studies 
(Kilduff et aL, 2002; 2003), subdividing the Cr subjects into ‘responders’ and ‘non­
responders’ on the basis of physiological measurement (e.g., estimated muscle Cr 
uptake) confirmed the ergogenic potential of Cr supplementation. However 
assigning a specific threshold value was not possible as Cr uptake was only 
estimated in these studies (Kilduff et aL, 2002; 2003). The present results provide 
support for this contention, again with results showing two very distinct groups (21
(21-25) mmol-kg'^ dry weight muscle ("non-responders" n=3) and 53 + 5 mmol-kg"
^'dry weight muscle ("responders" n=8) as previously reported (Kilduff et aL, 2002; 
2003). Failure to discriminate between those who respond to Cr supplementation 
and those who do not could therefore mask any effect due to Cr supplementation. 
This may help account for some of the confounding reports in the literature with
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regard to the ergogenic potential of Cr supplementation. However, it is not 
established yet why some people respond positively and some others negatively to 
Cr (Kilduff et al., 2004; Lemon, 2002). Consequently, more studies are needed to 
establish why some subjects respond positively and some others negatively to Cr.
In the present study, subjects who had supplemented with Cr reported significantly 
lower ratings of perceived leg fatigue after 10 min of exercise, suggesting they were 
able to discern the benefit of this putative hyperhydration strategy. Five out of the 
eight ‘responders’ to Cr reported that they foimd the post-supplementation trial to be 
easier. These same five subjects also showed the largest estimated Cr uptake and 
performance gains (intramuscular Cr uptake: ‘non-responders’, n = 3: 21 (21-25)
mmol-kg"^-dry weight muscle; ‘responders’, n = 8: 53 ± 5 mmol-kg'^-dry weight 
muscle). Time to exhaustion was significantly improved post-Cr supplementation 
and, although A performance failed to reach statistical significance in the 
‘responders’ (P = 0.066), the significant positive correlation between estimated 
muscle Cr uptake and A performance (r = 0.75, n = 11; P  = 0.008), is further 
indication that Cr can enhance prolonged exercise performance in the heat. Power 
tests calculations (Bolton, 1997) utilizing the performance data obtained fiom the Cr 
group as a whole (i.e., both ‘responders’ and ‘non-responders’) revealed that n = 39 
subjects (90 % power) would be required in order to observe a significant 
performance effect, distinguishing the Cr group fi*om the Pic group (P < 0.05). 
However, the power calculation utilizing the performance data obtained firom only 
the ‘responders’ suggested that n = 9 subjects (90 % power) would be required to 
achieve statistical significance (P < 0.05).
In contrast to the present results, a previous study did not report an improvement in 
endurance perfonnance following Cr supplementation when exercise was carried out 
in a relatively thermoneutral environment (Engelhardt et aL, 1998), This failure of 
Cr to enhance endurance exercise performance in such an environment would seem 
to preclude an increased intramuscular [Cr] or [PCr] being responsible for the 
ergogenic effect of Cr on endurance performance. In the absence of any differences 
between trials in blood metabolites, cardiovascular responses (with the exception of 
HR), changes in plasma volume and total sweat rate in the present study (see above: 
Results section; summarizing results from Kilduff et aL, 2004), the reduction in 
effort perception and the improvement in endurance performance in the heat in
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‘responders’ to Cr supplementation may be due, in pait at least, to the responses 
observed in the putative modulators of brain 5-HT and DA function. It has been 
suggested, for example, that a high brain [5-HT]:[DA] ratio increases effort 
perception (i.e. central fatigue) during prolonged exercise while a low [5-HT]:[DA] 
ratio may favor increased arousal and central neural motivation (Davis et aL, 1993; 
2003; Davis and Bailey 1997). Furthennore, high hypothalamic dopaminergic 
activity has been shown to be a reasonable predictor of exercise tolerance during 
prolonged submaximal exercise in the heat (Bridge et aL, 2003). As oral Cr 
supplementation can increase brain DA synthesis (Klivenyi et aL, 1999; Mathews et 
aL, 1999), the finding of a lower plasma free-Trp:Tyi" ratio (and by extrapolation a 
lower [5-HT]:[DA] ratio since both precursors share the same L-system transport 
across the blood brain barrier; Fernstrom and Wurtman 1972) may have contributed 
to attenuating effort perception and enliancing exercise perfonnance in the 
‘responders’ to Cr; no such response was observed in Pic trials. Previous studies 
have shown that DA microinjections into the hypothalamus and substantia nigra of 
the rat produced hypothermia through an increase in [DA] (Brown et aL, 1982; Cox 
and Lee, 1980). This notion is further supported by the recent work of Hasegawa et 
aL, (2000). These authors examined the role o f monoamines in thermoregulation 
during prolonged exercise and observed that exercise in the heat did not influence 
brain [5-HT] and [5-HIAA], but elevated DA levels in the hypothalamus and 
substantia nigra and augmented heat loss mechanisms.
In a recent study, brain uptake of Trp and Tyr as well as brain DA release were not 
affected by hyperthermia, therefore failing to support the classic ‘5-HT-central 
fatigue hypothesis’ and the involvement of brain DA function in thermoregulation 
during exercise in the heat (Nybo et aL, 2003). These authors suggested that brain 
glycogen depletion may have contributed to central fatigue during exercise in the 
heat. However, the results presented by these authors do not preclude the 
involvement of putative modulators of brain 5-HT function in central fatigue during 
exercise in the heat as a correlation was found between arterial ffee-[Trp] and brain 
Tip uptake (Nybo et aL, 2003). Brain Tip uptake has been shown on numerous 
occasions to be the rate-limiting step of 5-HT synthesis (Bloxam et aL, 1980; 
Fernstrom, 1990), thus an involvement of 5-HT during exercise in the heat as 
classically proposed cannot be excluded; 5-HT was not measured in the study by 
Nybo et aL (2003).
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Although plasma free-[Trp] was significantly lower following Cr supplementation, 
[LNAA] and the ratios of free and total Trp:LNAA were unchanged; hence, the 
similar plasma [Prl] found during exercise in the heat in all trials is not entirely 
unexpected. According to Wurtman (1988) in order to elicit a reduction in brain Trp 
uptake and, therefore, attenuation in brain 5-HT turnover, a 5- to 6-fold elevation in 
plasma [LNAA] is required. In addition, Leathwood and Fernstrom (1990) 
suggested that a 13- to 26- fold elevation in total Tip:LNAA ratio is required to 
induce a change in the brain stem [5-HT] in monkeys. The association however, 
between peripheral modulators of brain 5-HT function and circulating [Prl] duiing 
exercise has not been fully explained. Fischer et aL, (1991) for example, observed 
an increase in [Prl] during exercise in proportion to the rise in plasma free-[Tip]. 
Other investigators found a positive correlation between serum [Prl] and Wee (e.g. 
Brisson et aL, 1986; 1991) during exercise in the heat and this relationship has been 
used to justify brain monoamine system involvement in regulating Wee and Prl 
secretion (e.g. Pitsiladis et aL, 2002). However, in the present study, W-ec was lower 
in the post-Cr supplementation trial and Wee and plasma [Prl] were not correlated. 
These results are in agreement with a number of previous studies (e.g. Struder et aL, 
1996) that showed that Prl secretion is not always related to plasma free-[Trp] and 
this may be more evident during exercise in the heat.
hi the present study, Cr was effective in directly or indirectly attenuating thermal 
stress (e.g. Wee, sweat rate, HR) and increasing hydration (ICW, TBW) but Prl levels 
were unaffected. The effects of dehydration on brain neurotransmission and 
hypothalamic Prl secretion has previously been examined and conflicting results 
have been reported. For example, Scacchi et aL, (1989) found that water deprivation 
elevated hypothalamic [5-HT] in the rat. On the other hand, rehydration (injection of 
0.5 ml 10% saline solution) was found to decrease plasma [Prl] in rats (Nagy et aL
1992). Several other studies do not support the association between dehydration and 
changes in osmolality and plasma [Prl] but report a positive correlation between 
elevated body heat storage and plasma [Prl] (Brisson et aL, 1986; Falk et aL, 1991; 
Melin et aL, 1988; Laatikainen et aL, 1988; Pitsiladis et aL 2002). hi particular, 
Brisson et aL, (1986; 1991) demonstrated that a body-temperature threshold value 
had to be reached for heat stress to induce a significant blood Prl response during 
active or passive heat exposure. These authors estimated this mean Wee threshold to 
be approximately 1.3°C - 1.7°C above normal body temperature values, hi the
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present study, the rise in Wee induced by exercise in the heat, far exceeded this 
tlireshold in both pre- and post-supplementation trials, thus resulting in a similar 
elevation in serum [Prl] (Table 4). Consequently, although Cr was effective in 
significantly reducing thermal stress, this reduction was insufficient to significantly 
alter plasma [Prl]. However, this finding does not necessarily preclude a difference 
in hypothalamic Prl secretion between Pic and Cr trials.
Another possible explanation for the reduction in effort perception and for the 
enhancement in endurance performance observed in ‘responders’ to Cr group is the 
attenuation in muscle contraction-stress with Cr, which may prevent an early ATP 
depletion (Guerrero and Willimann, 1998). Recently, for example, Terblanche and 
Nel (1998), using animal models, examined the effect of heat, submaximal exercise 
(10 min mmring x 3 in 30°C with 2 min recovery between exercise) and acclimation 
programme on the activity of creatine kinase (CK) in several tissues including 
kidneys, skeletal and heart muscles. They found that prolonged exercise in the heat 
has significantly reduced the activity of CK in all these tissues concluding that 
exercise in the heat may produce tissue damage. In the present EXP, it is possible 
that Cr has enhanced brain DA function (see Klivenyi et ah, 1999; Matthews et ah,
1999) that contributed to reducing thermal-stress (e.g. Hasagewa et ah, 2000), and 
therefore attenuating the negative effect of heat-stress on CK activation on skeletal 
muscle. However, more controlled human studies are needed in order to examine 
this particular speculation. In addition, it is possible that the increased in exercise 
performance observed in the ‘responders’ group to be due to the increased aerobic 
capacity that might have been elevated as a results of Cr supplementation. 
Unfortunately, the oxygen uptake capacity was not measured when subjects were on 
Cr supplementation regime.
A number of previous studies have reported a significant correlation between plasma 
[FF A] and plasma free-[Trp] primarily due to FF A displacing Trp from its binding 
to albumin (e.g. Curzon et ah, 1973; Spector et aL, 1975). In the present study, the 
rise in plasma [FFA] was modest and not different between trials but plasma ffee- 
[Trp] was lower during exercise and at exhaustion on the post-Cr supplementation 
trial. This somewhat surprising result, in conjunction with the lack of a significant 
correlation between plasma [FFA] and plasma free-[Trp] would suggest a more 
complex control o f plasma ffee-[Trp] during exercise in the heat than previously
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described. The exact mechanism(s) responsible for the obseiwed reduction in plasma 
free-[Trp] and free-Trp:Tyr ratio after Cr loading (despite no difference in plasma 
[FF A]) and the significance of these observations remain to be determined.
It is possible that Cr to enhance tryptophan-2,3-dioxygenase (TDO) and/or 
indoleamine-2,3-dioxygenase (IDO) activation during exercise in the heat, via a 
protection against thermal-stress which otherwise induces liver metabolic 
dysfunction. This possible effect of Cr against thermal stress may enhance the 
conversion of Trp to kynurenine leading to a reduction in plasma free-[Trp]. It has 
been previously found that hyperthermia impaired liver activation by augmenting a 
non-specific proton leaking across the inner mitochondrial membrane, and the 
resultant degraded energy state offsets temperature stimulation of pyruvate 
carboxylase (Willis et aL, 2000). For this reason the pyruvate carboxylation rate of 
intact liver mitochondria may fail to exhibit a Qio effect (Willis et aL, 2000). 
However, Cr supplementation was found to enhance liver function by elevating 
plasma transaminases, lactate dehydrogenase (LDH) and CK activation (Kreider et 
aL, 1998). Similarly, Cr was found to enhance others organs function, such as 
kidneys and heart by elevating CK activation during exercise in the heat (Terblanche 
and Nel, 1998). On the other hand, it has been shown that exercise activates the 
kynurenine pathway of Trp metabolism and made nicotinamide adenine dinucleotide 
(NAD) which will be concerned with energy metabolism in mitochondria (Ito et aL, 
2003). Trp-NAD pathway was initiated by cleavage of indole-ring of Trp by TDO in 
the liver and IDO in other organs (Ito et aL, 2003). However, the hypothesis of Cr- 
induced an acceleration of kynurenic metabolic pathway during exercise in the heat 
by elevating CK-liver activation is only speculative on since no studies have 
examined yet any effect of Cr supplementation on TDO or IDO.
Conclusion
In conclusion, the possible effectiveness of Cr to alter key modulators of brain 5-HT 
and DA function and/or to increase TBW and hyperhydration may have contributed 
to the reduced thermal stress and effort perception during exercise in the heat and to 
the enhancement of endurance performance in the ‘responders’ to Cr 
supplementation. Although further research is warranted, these results provide some 
evidence of a centrally-mediated process of fatigue during strenuous exercise in the 
heat.
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Chapter six
(Experiment 4)
Putative brain serotonergic and dopaminergic modulators in clironic 
fatigue syndrome: the effect o f  graded exercise stress
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6.1 Introduction
As stated in Chapter 1 (section 1.2.9), chronic fatigue syndrome (CFS) is a 
debilitating condition, the precise pathology of which remains largely undefined, 
with both peripheral and central neural mechanisms hypothesised. CFS patients are 
reported to have lower physical fitness and quadriceps muscle strength and higher 
body mass ratio relative to sedentary and depressed controls (Fulcher and White,
2000). However, although these results may suggest peripheral incapability, they do 
not necessarily imply peripheral factors in the pathogenesis and maintenance of 
CFS. Alternatively, these peripheral responses may be due to the chronic physical 
deconditioning, which is common in this population (e.g. Montague et aL, 1989; 
Fulcher and White, 2000; Riley et aL, 1990). Other studies for example suggested 
no differences in Vo^ capacity, HR and lactate metabolic responses between CFS 
and sedentary control groups during graded exercise, precluding the significant role 
of peripheral mediated-factors being responsible in the pathogenesis of CFS (e.g. 
l lo y é e ta L ,  1988; 1991; Sargent a/., 2002).
In contrast also to the heterogeneity in studies on muscle metabolism, an 
exacerbated effort perception has been consistently associated with CFS, with 
patients reporting higher effort perception compared to healthy controls, during both 
submaximal and graded exercise (Cook et aL, 2003; Riley et aL, 1990; Gibson et aL,
1993). In addition, neuroendrocrinological studies support centrally-mediated 
factors in the pathogenesis of CFS implicating specifically, a metabolic up-
1986) and hypothalamic function (Komaroff and Buchwald, 1998). This evidence, 
however, is based predominantly on neuroendocrine challenge tests, with known 
methodological limitations. The extensive use for example, of brain 5-HTia- 
receptors agonist drug, Buspirone, has been suggested to be of doubtftil 
pharmacological specificity (Sharpe et aL, 1996). This probably occurs because 
Buspirone has been suggested to be not only a 5-HTiA-receptors agonist drug but 
also a Di-receptors antagonist drug (Bridge et ah, 2003). In addition, a double-blind 
trial suggested that Fluoxetine may be less tolerated in patients with CFS than those 
with major depression (Vercoulen et aL, 1996).
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regulation of brain 5-HT synthesis (e.g. Cleare et aL, 1995; Sharpe et aL, 1997), 
which may play a role in the development of central fatigue (e.g. Acworth et aL,
It is also interesting to note that most of the treatments in CFS, mainly 
antidepressants, have been suggested to be generally ineffective (e.g. Whiting et aL,
2001). The only evidence available to support relative effective treatments in CFS 
includes cognitive behavioural therapy (Prins et aL, 2001) and graded exercise 
(Fulcher and White, 2000). However, cognitive behavioural therapy has been 
extensively criticised because it does not prevent physical deconditioning, which 
contributes in maintaining and exacerbating CFS symptoms (e.g. Chaiidhuri and 
Behan, 2001; Vercoulen et aL, 1997).
Although during resting conditions, clinical studies suggest a brain serotonergic 
system involvement in CFS, no studies to date have been conducted to examine, 
elucidate and understand the role of putative modulators of brain serotonergic and 
dopaminergic function during exercise in CFS. The aim therefore o f the fourth and 
final experiment was to elucidate the role of putative modulators of central fatigue in 
CFS patients by examining circulating amino acids, which have been previously 
suggested to modify central serotonergic and dopaminergic functions, to evaluate 
the association between these modulators with perceptual and metabolic responses 
in CFS patients and to compare their results to those of matched sedentary controls.
6.1 Methods 
Subjects
Twelve patients (ten female and two male) with a diagnosis of CFS [females: age, 
39 ± 11 years (mean ± s.d.); height, 165 ± 8 cm; body mass, 71 ± 11 kg; male 1 : age, 
45 years; height, 177 cm; mass, 85 kg; male 2: age, 33 years; height, 167 cm; mass, 
66 kg) and 11 sedentary Controls (nine females: age, 38 ± 12 years; height, 163 ± 8 
cm; mass, 62 ± 9 kg; male 1: age, 48 years; height, 168 cm; mass, 76 kg; male 2: 
age, 33 years; height, 175 cm; mass, 65 kg) provided written informed consent prior 
to their participation in the study. For more infoimation regarding the subjects 
medical screening, CFS patients’ and controls’ selection criteria, pre-exercise 
medical examination for CFS patients, and study approval see Chapter 2.
Experim ental design and Procedures
The experimental equipments used are described in Chapter 2. The schematic 
illustration of the experimental design is presented in Figure 6.1.
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Figure 6.1. Schematic illustration of the experimental protocol in EXP 4
Prior to the experiments subjects were asked to keep their normal diet tlrroughout 
the experimental period, were advised to consume the same weighted amoimt and 
same items prior to each trial and to consume their last meal the same time, (at least 
3 hours) before each experimental trial. Subjects were advised to avoid consuming 
items that involve caffeine and alcohol for at least 48 hours prior to each 
experiment.
Subjects underwent a ramp-incremental exercise test on an electronically-braked 
computer-controlled cycle ergometer to limit of tolerance. Gas exchange variables 
and Vo 2 peak were determined using breath-by-breath mass-spectrometer analyser 
(QP9000, Morgan Medical, Gillingham, Kent, UK) based on previously derived 
algorithms (Beaver et aL, 1973) (see Chapter 2, section 2.3 for more details). The 
following criteria were used to define volitional fatigue in the present EXP; 1) near 
or maximal values of perceived exertion, 2) near or maximal HR, 3) inability to 
maintain a cadence of ~ 50 rpm. The incrementation rate for individual subjects 
varied between 3-10 W'min"\ so as to elicit exhaustion within 10-15 min (Figure 
6.1). The work-incremental rate has been deteimined for each subject separately 
based on medical history and physical activity questionnaires completed a week 
before the exercise testing. Subjects reported to the laboratory 1.5 lirs prior to the 
start of the tests. Following a brief familiarisation session with equipment and
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procedures, subjects’ body mass was measured and electrodes were introduced on 
five positions on the chest for on-line HR recording and cardiovascular medical 
examination inspection. Subsequently, subjects were seated comfortably with their 
right hand and forearm immersed for 15 min in warm water. Arterialised-venous 
blood samples were subsequently drawn at rest, unloaded exercise (Uni), exhaustion 
(Exh) and at 6 min of recovery (Rec). For artérialisation of the venous blood at rest 
and during exercise, cannulation, blood sampling, HR and RPE recording, the 
experimental protocol for the removal, treatments and analyses of blood and plasma 
as well as gas exchange measurements and statistical methods used see Chapter 2.
6.3 Results
Plasm a am ino acids concentrations
Table 6.1; Plasma concentrations of amino acid serotonergic and dopaminergic 
modulators in CFS and control groups; values: mean ± s.d.
Rest Unloaded Exercise Exhaustion Recovery
Total Trp (pm ol-r')
CFS 41.5+6.6 38.3+6.5 38.8+5.6 37.9+7.6
Contiols 42.2+4.3 41.3+5.2 41.2+4.8 37.4+5.1
Free Trp (pmoM'^)
CFS 4.2±L4 4.7+1.1 5.1+1.4 5.7+1.2
Controls 3.9+0.9 3.8+1.1 3.8+0.8* 4.6+1.0*
BCAA (pm ol-r')
CFS 351.9+74.2 338.9+71.6 348.7+50.7 343.5+73.5
Controls 391.9+68.6 391.6+78.9 394.4+51.1* 397.8+74.7
LNAA (pmol-r^)
CFS 531.6+97.5 506,8+95.1 526.5+61.3 516.9+95.8
Controls 587.4+87.9 584.4+103.7 596.1+66.4* 602.8+100.5*
Tyr (pmol-r^)
CFS 49.4+14.3 45.8+12.9 49.5+11.0 47.1+11.0
Controls 62.8+9.1* 61.9+10.0* 66.1+8.8* 65.0+13.1*
* indicates a significant difference between CFS and controls; p < 0.05
Plasma ffee-[Trp] was raised in the CFS group throughout the protocol, being highly 
significant at both Exh and Rec, with a tendency at Uni (F < 0.1); total [Trp], 
however, was not significantly different between groups at any o f the time points 
(Table 6.1). [BCAA] and [LNAA], both of which compete with free Trp for entry 
into the brain, were lower in the CFS patients tlrroughout, with highly significant 
differences at Exh, and for [LNAA] also in Rec (Table 6.1). Consequently, the 
central serotonergic modulators ffee-[Trp] : [BCAA] and ffee-[Trp] ; [LNAA] were
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higher in the CFS group, significantly at all time points except at rest (Fig. 6.2). On 
the other hand, significantly lower plasma [Tyr] was found in the CFS patients at all 
time points (Table 6.1). As a result, fi'ee-[Trp]:[Tyr] was significantly higher in the 
CFS group at all time points (Fig. 6.2).
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Fig. 6.2 The ratios of free-[Trp]:[BCAA] (top panel), hee-[Tip];[LNAA] (middle panel) 
and free-[Trp]:[Tyi'] (bottom panel) (mean ± s.d.) in CFS and control groups for Rest, Uni, 
Exh, and Rec. * indicates a significant difference between groups.
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Plasma FFA and blood metabolites concentrations
There were no differences between CFS and control groups for plasma [FFA], blood 
[glucose] or blood [lactate] (with the exception of a significantly lower Rec value in 
the CFS group) (Fig. 6.3).
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Fig. 6.3. Plasma [free fatty acids] (top panel), blood [glucose] (middle panel) and [lactate] 
(bottom panel) (mean ± s.d.) in CFS and control groups for Rest, Uni, Exh, and Rec. * 
indicates a significant difference between groups.
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Cardiopulm onary and percep tua l responses
V o 2 peak in the CFS gi'oup (21.2 ± 6.3 ml ■ min  ^ • kg'^) was significantly lower than 
in the control group (28.3 ± 6.4 ml • min'^-kg'^). Peak heart rate was lower in the 
CFS group than in the control group, although this difference was not statistically 
significant (CFS, 160 ± 29 beats * m in ‘; control, 176 ± 1 3  beats • min'^; P  = 0.12); 
this corresponded to 88% of the maximal age-predicted value for the CFS patients, 
compared with 97% for the controls. The peak RER was significantly lower in the 
patients (0.98 ± 0.06) than in the control group (1.15 ± 0.40). RPE was significantly 
higher in the CFS group at all time points, compared with controls: rest: CFS, 14 (2- 
63) [median (range)]; control, 2 (0-6); unloaded exercise: CFS, 24 (2-99), control, 2 
(0-8); at exhaustion (near-maximal values): CFS, 98 (91-100), control, 90 (51-100) 
(Table 6.2). The total work-load completed was significantly lower in CFS relative 
to Control group; CFS: 62 ± 8.5, Conti'ol: 106 ± 12; F  < 0.1).
Table 6.2: Perception o f effort in CFS and Control groups. Values are given as 
median (range)
Effort perception Rest Unloaded Exercise Exhaustion
CFS 14(2-63) 24(2-99) 98(91-100)
Controls 2.0(0-6) * 2.0(0-8) * 90(51-100)*
* indicates a significant difference between CFS and controls; p < 0.05 
Correlations
Significant positive correlations were found between free-[Tip] and [FFA] for all 
time points collectively, both for the CFS gi'oup (r = 0.44) and the control group (r -  
0.47). Significant positive correlations were found between Vo 2 peak and the putative 
central 5-HT modulators, i.e. free-[Trp] (r=0.73, n=12, F=0.011), hee- 
[Trp]:[BCAA] (r=0.80, n-12, F=0.003) and free-[Tip]:[LNAA] (r=0.78, n=12, 
F=0.005), at exhaustion in the CFS gioup, but not in the control group. Significant 
negative correlation was found between RPE and [tyi'osine] at rest (r=-0.60, n-12, 
F=0.05) and during unloaded exercise (r=-0.65, n=12, F=0.029) in the CFS group 
only. Vo 2 peak and free-[Trp]: [tyrosine] ratio were also significantly correlated at 
exhaustion in the CFS group (r=0.69, n=12, F=0.018), but not in the control group.
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6.4 Discussion
In the present experiment, significant differences between CFS patients and healthy 
sedentary controls were observed in a nmnber of key central serotonergic and 
dopaminergic modulators both at rest and during exercise. This point towards a 
possible role for central neural mechanisms of physical and perceptual fatigue and 
probably contributes, in part at least, to the pathogenesis of CFS.
CFS patients showed marked exercise intolerance, associated with an exacerbated 
RPE result that is consistent with previous studies (e.g. Riley et aL, 1990). The 
demonstration of lower values for HR and RER at peak exercise in the CFS patients 
relative to controls, in combination with an almost maximal value for RPE, is 
consistent with the involvement of a centrally mediated increase in RPE (rather than
0 2 transport) being the limitation to exercise performance (e.g. Gibson et aL, 1993). 
That is, it appears likely that the abnonnally high RPE may translate into an inability 
or unwillingness to effect the power outputs necessary to achieve maximal 
performance (Inbar et aL, 2001), thus precluding the ‘classic’ criteria for attainment 
of maximal effort from being fulfilled. Thus the limit of tolerance provides a 
symptom-limited peak V o 2 peak value, rather than a tme maximum.
The raised plasma free-[Trp] in CFS patients during exercise and subsequent 
recovery, in combination with the high baseline levels of free-[Trp] reported by 
Castell et a l (1998) imply increased concentrations of Trp in the brain (Davis and 
Bailey, 1997) and, potentially, an increase in 5-HT turnover. As we saw in Chapter
3 and 4, the association between increased 5-HT turnover and the subjective feeling 
of fatigue is one that is widely documented. Increases in brain [5-HT] have been 
associated with lethargy, sleepiness and mood changes (Young, 1986), all of which 
have also been linked to increase RPE (Davis and Bailey 1997). It was also 
demonstrated that elevated levels of plasma free-[Trp] and, consequently, of brain 5- 
HT are associated with decrements in physical performance (Blomstrand et aL, 
1989). Free Trp, however, shares the same mechanism for transport into the brain as 
other LNAAs with consequent competition for entry into the brain. In the present 
experiment, LNAA levels were lower at Exh, and also in Rec in CFS patients. The 
resulting increases observed in the ratios of free~[Trp]:[BCAA] and free-
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[Trp]:[LNAA] in CFS group strengthens the proposed hypothesis linking fatigue in 
CFS with an abnormally high brain 5-HT activity (Bakheit et aL, 1992).
The dopaminergic system has also been implicated in central fatigue during exercise 
(Heyes et aL, 1985; Bailey et aL, 1993b). It is of interest, therefore, that we found 
significantly lower levels of tyrosine, the rate-limiting dopaminergic precursor, in 
the CFS group at all time-points, including rest. To our knowledge, this is the first 
study to demonstrate low DA precursor levels in patients with CFS. Since fatigue 
during prolonged physical activity has been shown to be associated with increased 
brain 5-HT and reduced brain DA levels (Bailey et aL, 1993a) a high 5-HT:DA ratio 
should favour reduced exercise performance and indeed, the ratio of the precursors 
of 5-HT and DA, free-[Trp]:[Tyr], was consistently higher in CFS patients at all 
time-points when compared to the control group. The increased baseline [free 
Trp]:[Tyr] ratio may also explain the evident fatigue and associated high RPE, even 
prior to physical exertion, in this patient population.
It should be noted that although the patient group has shown different plasma amino 
acid ratios (free-[Trp]: [BCAA], free-[Trp] : [LNAA] and free-[Trp] :[Tyi']) relative to 
control group none of these ratios seem to change massively with exercise. 
Consequently, based on these responses someone could argue that this makes it 
difficult to relate these differences in amino acid ratios to any problem with exercise 
its self. However, the correlation analysis revealed a significant positive conelation 
between VO^peak and the putative central 5-HT modulators, i.e. free-[Trp], free- 
[Tip]:[BCAA] and free-[Trp] : [LNAA], at exhaustion in the CFS group, but not in 
the control group. In addition, a significant negative correlation between RPE and 
[Tyr] was observed at rest and during unloaded exercise and between and Vo^peak 
and free-[Trp]:[Tyr] ratio at exhaustion in the CFS group only.
At present, the physiological mechanisms underlying the apparent 5-HT over­
activity and the concurrent depression of the dopaminergic system in CFS (the latter 
possibly being a direct result of the inhibitory effect of increased serotonergic 
activity; Bailey et aL, 1993a) cannot be readily explained. The altered levels of 
circulating amino acids demonstrated in the present study may indicate a 
dysfunction in amino acid metabolism, either within the CNS or peripherally (e.g., 
uptake by liver or skeletal muscle). One cannot, therefore, entirely exclude 
involvement of peripheral mechanisms, which could ultimately affect levels of the
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amino acids measured in the present study, in the pathogenesis of CFS. Although 
plasma concentrations of serotonergic and dopaminergic modulators have been 
shown to be closely associated with brain 5-HT and DA levels, respectively 
(Meeusen and De Meirleir, 1995) we did not measure the latter and, thus, can only 
speculate on a ‘true’ central component in the disorder. Plasma levels o f free-[Trp] 
have also been shown to be highly dependent on plasma [FF A], FF A having been 
shown to displace Trp from binding to albumin (Curzon et aL, 1973). However, 
there were no differences in the correlations between free-[Trp] and [FFA], between 
CFS and control groups. This close association between free-[Tip] and [FFA] in 
both groups would imply normal Trp-albiunin binding properties.
Conclusion
In conclusion, the significant differences between patients with CFS and healthy 
controls that have been observed with several key CNS serotonergic and 
dopaminergic modulators, especially during resting conditions, suggest that central 
neural mechanisms may contribute to the increased RPE and impaired exercise 
tolerance in CFS. However the precise role of the serotonergic and dopaminergic 
systems in the pathogenesis of CFS remains to be elucidated.
12 6
Chapter seven
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7. General discussion
The primary objectives of experiments (EXPs) 1-4 were to i) clarify and improve the 
current understanding of the role of putative brain 5-HT and DA modulators and 
therefore brain serotonergic and dopaminergic function in exercise fatigue 
development; ii) elucidate the relationship among these brain 5-HT and DA 
modulators and function, perceptual, metabolic and cardiovascular responses; and, 
iii) differentiate between the mechanism(s) responsible for peripheral and central 
fatigue development in health and exercise-intolerance patients. The general 
observations of these EXPs are discussed in the present chapter, and where possible, 
conclusions are drawn regarding the factors that may affect brain 5-HT and DA 
modulators and indices, perceptual and metabolic responses and exercise capacity.
7.1 Putative central components affecting fatigue in health and disease
No relationship between brain 5-HT modulators, indices, RPE or exercise 
performance was observed in EXPs 1 and 2 after co-ingestion of caffeine with a 
high fat meal. Only in well-trained cyclists in the heat, following Cr 
supplementation (EXP 3), and in CFS patients (EXP 4) was there a relationship 
between modulators of brain 5-HT and DA function (being lower and higher 
respectively in trained humans and reverse in CFS), RPE or exercise tolerance.
In EXPs 1 and 2, these results may suggest that elevating circulating plasma [FFA] 
by a pre-exercise high fat meal have effectively contributed to a similar 
displacement of Trp from plasma albumin and a parallel adjustment of plasma 
[amino acid] and substrate oxidation in both F and FC trials. This is supported by 
the observation that there were no differences between the trials in key brain 5-HT 
and DA modulators (plasma free and total Trp, LNAA, Tyr) as well as in the rate 
and total CHO and fat oxidation. However, although a differentiation between 
putative metabolic and CNS effects of caffeine was achieved following caffeine co­
ingestion with a high fat meal, (as RPE was reduced with caffeine despite the 
elevation in cardiopulmonary and metabolic responses, but there were no differences 
in substrate utilisation and no improvement in exercise performance), caffeine had 
no effect on peripheral brain 5-HT and DA modulators or any positive action on 
incremental and endurance exercise performance. Consequently, brain 5-HT and DA 
systems are unlikely to play an important role in the exercise fatigue process of
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well-trained humans and this may be more evident when exercise is performed 
without significant thermal stress, thus enabling fatigue development to occur due to 
cardiovascular and/or peripheral limiting factors (i.e. glycogen depletion). The limit 
therefore in endurance exercise capacity in low temperatures is most likely 
accounted for by glycogen depletion since the rate and total substrate oxidation were 
not different between the trials (EXP 2).
In EXPs 1,3, and 4, it is rmlikely that substrate oxidation limited exercise capacity 
as muscle glycogen depletion does not limit performance during incremental 
exercise (EXPs 1, 4) (Coyle et al., 1986) or during prolonged exercise in the heat 
(EXP 3) (Galloway and Maughan, 1997). It has been shown that the reduction in 
exercise capacity in the heat is highly associated with elevated core/brain 
temperature (Nielsen et al., 1993; 1997; Nybo and Nielsen, 2001b; Nybo et al.,
2002). In addition, evidence suggests that the reduction in central neural-drive 
motivation to exercise, during exercise in the heat, is highly associated with 
progressive increase in hyperthermia-induced alterations in brain activation (Nybo 
and Nielsen, 2001c), and in particular, with an up-regulation o f brain serotonergic 
function (Bridge et al., 2003; Marvin et al., 1997; Pitsiladis et al., 2002).
In the present EXP 3, plasma free-[Trp] and free-[Trp]:[Tyr] ratio, were 
significantly lower (even at rest) following Cr supplementation indicating that the 
subjects in the Cr trial may have had the advantage of feeling more motivated to 
exercise than the subjects in the Pic trial. These results may suggest that a down- 
regulation of brain Trp uptake and/or an up-regulation of brain DA function may 
have contributed to increase central motivation to exercise and enhanced endurance 
perfoimance in the ‘responders’ to Cr supplementation during exercise in the heat. It 
is possible that this brain DA metabolic up-regulation has contributed in reducing 
thennal-stress (T^c) during exercise in the heat. Clinical studies for example, have 
demonstrated that two weeks of oral Cr administration was able to increase brain 
DA synthesis and function in rats (Klivenyi et al., 1999; Mathews et al., 1999). 
Subsequently, in the same species an increased brain DA synthesis was found to 
reduce core temperature during passive or active heat exposure (Feldberg and 
Myers, 1964; Hasegawa et al., 2000; Lin et al., 1998; Sugimoto et a l, 2000). 
However, the exact mechanism(s) of the reduction in thermal-stress during exercise
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in the heat following Cr supplementation (through a possible elevation in brain DA 
function) remains to be determined.
It should be noted that the enhancement in exercise performance observed in the Cr- 
‘responders’ group relative to Pic should be treated with caution. Although a 
positive correlation was found between estimated Cr uptake (Cr group including 
‘responders’ and ‘non-responders’) and A exercise performance (r=0.75, n= l l ;  
P=0.008) and power calculation revealed n=9 ‘responders’ for securing significant 
differences in performance; the weak statistical power of the present EXP 3 should 
not be ignored (for review see Lemon, 2002).
hi EXP 4, plasma baseline [Tyr] was lower and the ratios o f Ifee-[Trp]:[Tyr] and 
free-[Trp]:[LNAA] were higher in the CFS relative to the control group. These 
results coupled with the higher RPE, even at rest, and with exercise intolerance in 
CFS group. This indicates that CFS patients had a poor central neural motivation to 
start exercising and it may explain, in part at least, the lack of engagement in any 
kind of physical activity characterising CFS patients. Consequently, in line with 
several other studies (e.g. Cleare et al., 1995; Dimitrack et al., 1992), the putative 
brain 5-HT modulators results may reflect a metabolic up-regulation of brain 5-HT 
synthesis in CFS. In addition, the novel observation of the concurrent lower plasma 
baseline [Tyr] could suggest a down-regulation of brain DA function, which may 
contribute to exercise intolerance, pathogenesis and maintenance o f CFS symptoms.
In the EXPs 1-3, a dissociation between brain 5-HT and DA modulators and plasma 
Prl was observed. In EXP 2 for example, plasma free-[Trp]:[LNAA] ratio was 
significantly higher with caffeine and there was a tendency for plasma fi*ee-[Trp] {P 
= 0.064) and fi'ee-[Trp]:[Tyr] ratio {P = 0.066) to be higher with caffeine but plasma 
[Prl] results was close to H = 0.9 between the trials. Similarly, in EXP 3, plasma 
free-[Trp] and free-[Trp]:[Tyr] ratio were significantly lower with Cr but plasma 
[Prl] was not different between Cr and Pic trials. In addition, in all EXPs 1-3 there 
was no correlation between plasma free~[Trp] and plasma [Prl]. The lack of positive 
correlation however, between modulators and indices o f brain 5-HT and DA 
function is consistent with some previous studies. For example, Biggio et al., (1977) 
found an increased intestinal [Trp] but a reduced brain 5-HT synthesis. Teff and 
Young (1988) found a decline in plasma [Trp] (21%) but 5-HT was unaffected.
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Similarly, Stmder et al., (1995) observed an elevation in plasma free-[Trp] and free- 
[Trp]:[BCAA] ratio after endurance activity but plasma [Prl] was not affected.
In the present study, it is possible that the dissociation between modulators and 
indices of brain serotonergic and dopaminergic functions is due to the high fitness 
levels of the subjects participating in these experiments. It has been suggested, for 
example, that the HP A axis is both stimulated by muscle exercise and subjected to 
adaptations with endurance training (Luger et al., 1987). Well-trained endurance 
athletes may therefore have a metabolic down-regulation o f Trp uptake and brain 5- 
HT synthesis (Jakeman et al., 1994). This probably occurs because they have 
developed, through the chronic exercise training, the appropriate physiological 
adaptations to cope from the negative consequences of exercise-induced elevation of 
5-HT turnover. Trained rats for example, have delayed to develop onset of central 
fatigue, associated with elevation in brain 5-HT, during prolonged exercise when 
compared with untrained rats (Acworth et al., 1986). Consequently, although it is 
possible that exercise-stress, caffeine and Cr administrations have influenced brain 
5-HT and DA modulators and functions, this was not to the extent to significantly 
affect plasma [Prl] in well-trained humans.
The lack of changes in plasma [Tyr] observed in EXPs 1-3 after caffeine and Cr 
administration does not necessarily mean that both treatments could not directly 
affect brain DA metabolism irrespective o f their influence on plasma DA precursor 
or brain 5-HT synthesis. For example, caffeine (e.g. Bridge et al., 2000; Cole et al., 
1996; Jacobson et al. 2000; Laurent et al., 2000; Motl et al., 2003) and Cr 
administrations (e.g. Kern et al., 2001; Volek et al., 2001) were found to attenuate 
effort perception during exercise in thermoneutral or hot environments respectively. 
It is not unreasonable therefore, to imply a direct elevation in brain DA function 
with caffeine and Cr treatments. Davis et al. (2003), for example, found a reduction 
in rats brain 5-HT:DA ratio after caffeine administration and Mathews et al. (1999) 
found an enhancement in mice’s brain DA metabolism resulting in a neuroprotective 
effect under specific stress following an oral Cr administration. However, in the 
present study, this claim is speculative since plasma [Prl] was the only index of 
hypothalamic 5-HT and DA metabolic interaction (Ben-Jonathan et al., 1989; 
Freeman et al., 2000).
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It is possible that caffeine and Cr reduced subjective fatigue (i.e. in EXPs 1-3) by 
increasing brain DA metabolism in other brain areas than the hypothalamus without 
being able to significantly inhibit hypothalamic Prl release. Studies using animal 
models for example, have demonstrated an up-regulation o f brain 5-HT synthesis 
during exercise not only into the hypothalamus (Bailey et al., 1993a) but also in the 
midbrain, hippocampus, striatum and frontal cortex (Bailey et al., 1993b; Chaouloff 
et al., 1989; Gomez-Marino, 2001; Meeusen and De Meirleir, 1995; Meeusen et al., 
1996). Consequently, plasma [Prl] in the present EXPs should not be considered to 
reflect changes of the whole brain 5-HT and DA synthesis. For these reasons, more 
in vivo studies, using predominantly human volunteers, are warranted to examine a 
possible direct effect of caffeine and Cr administration on DA metabolism in various 
brain regions.
The reason however, why only in CFS patients (EXP 4) an association between 
brain 5-HT and DA precursors (being significantly higher and lower respectively in 
CFS relative to control group) and an early elevation in subjective and objective 
fatigue was observed is not easy to explain. CFS patients have been suggested to 
have a metabolic up-regulation of brain 5-HT synthesis (Behkeit et al., 1992; Cleare 
et al., 1999). This response may be due to the elevation in plasma Trp uptake by the 
brain per se (Cleare et al., 1995) or in combination with the increased plasma and 
brain [5-HT] both of which were found to induce BBB permeability and 
neurotoxicity (Bested et al., 2001). Supporting this contention, several studies 
observed a positive correlation between plasma/brain [5-HT] and BBB permeability 
mider various stressors such as summer-heat and forced-swimming (Sharma and 
Dey, 1986; 1987; Sharma er a/., 1996).
Nevertheless, a metabolic down-regulation of plasma Tyr uptake by the brain should 
not be imderestimated in the development of an early onset of fatigue and increased 
effort perception in CFS. Acute tyrosine depletion for example, was found to inhibit 
brain DA synthesis and function in humans (Montgomery et al., 2003). 
Subsequently, the reduction in brain DA metabolism, tlirough an acute tyrosine 
depletion, was found to reduce mood-state, motivation to physical activity, exercise 
tolerance (Avraham et al., 2001) and motor co-ordination in humans (Meeusen and 
De Meirleir, 1995). It is possible therefore, that in CFS the pathogenesis of the 
disease is the concomitant result of both down-regulation of plasma Tyi* (which may
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induce Tyr deficiency) and up-regulation of brain 5-HT function. As a result, the 
altered levels of circulating amino acids demonstrated in the EXP 4 may indicate a 
dysfunction in amino acid metabolism, either within the CNS or peripherally (i.e. 
uptake by liver or skeletal muscle). Consequently, one cannot entirely exclude the 
involvement of peripheral mechanisms (which could ultimately affect levels of the 
amino acids measured in the present study) in the pathogenesis of CFS. More 
studies are needed to examine the association between circulating 5-HT levels, brain 
neurotoxicity rate and ‘central fatigue’ development in CFS.
One of the attempts in EXP 1 was to examine whether anaerobic exercise, reflected 
by elevation in muscle lactate production during incremental exercise, may stimulate 
5-HT synthesis and therefore Prl secretion (De Meirleir et al., 1985a, b; Newsholme 
and Blomstrand, 1996; Shangold et al., 1981) and if this could be reversed by a 
positive action of caffeine on brain DA metabolism (Davis et al., 2003). However, 
blood [lactate] was significantly higher on the FC relative to F trial during constant­
load exercise, at exhaustion and recovery after incremental exercise but neither 
exercise performance nor plasma [Prl] was different between the trials. In addition, 
similar pattern between blood [lactate] and plasma [Prl] have observed in EXP 2 at 
exhaustion. In this EXP, at the end of exercise, especially on the FC trial, blood 
[lactate] indicates anaerobiosis (blood lactate > 4 mMol) but plasma [Prl] was not 
different between the trials. These results may therefore dispute the hypothesis of a 
linear relationship between blood [lactate] and brain 5-HT stimulation during 
exercise. However, these results do not preclude that muscle acidosis may stimulate 
hypothalamic 5-HT synthesis via an autonomic nervous system information supplied 
irrespectively from blood [lactate] per se. For example, in the studies by De Meirleir 
et al., (1985a and b) where a positive correlation between blood [lactate] and 5-HT 
synthesis was observed, the blood [lactate] may represent an absolute muscle lactate 
production and not an attenuation in blood lactate clearance due to caffeine 
ingestion for example (see Graham et al., 2000).
As stated in Chapter 3, blood [lactate] does not necessarily indicate muscle lactate 
production and/or muscle acidosis especially in well-trained subjects implying an 
attenuation effect of caffeine on blood lactate clearance (e.g. Graham et al., 2000). 
Consequently, it is possible that anaerobiosis stimulates brain 5-HT synthesis only 
when an early muscle acidosis is developed irrespective of blood [lactate] and this is
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probably more evident in untrained subjects. It has been well established that during 
high-intensity exercise untrained individuals can develop muscle acidosis earlier 
relative to well-trained individuals due to the lack of anaerobic enzymatic capability 
and glycolytic adaptations in type IIA and IIB muscle fibres (Jansson et al., 1990). 
This, in association with the observation that untrained subjects do not have the 
training adaptations to down-regulate brain 5-HT synthesis (Acworth et al., 1986; 
Jackeman, 1996) might have caused the inconsistency between the present study and 
those by investigators who tested untrained subjects (e.g. De Meirleir et al., 1985a, 
b; Newsholme and Blomstrand, 1996; Shangold et al., 1981).
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7.2 Plasma FFA and displacement o f tryptophan from albumin 
Release of FFA from adipose tissue appears to be the primary factor underlining the
prolonged exercise-induced elevation of plasma free-[Trp]. Trp is liberated from its 
binding to albumin when the plasma [FFA] rises and competes with Trp for the 
binding to albumin (Curzon et al., 1973; Spector, 1975). The higher plasma free-
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[Tip] observed at rest, during exercise or recovery in CFS group relative to control 
in EXP 4 are unlikely to be associated with the displacement o f Trp fr'om albumin 
by plasma FFA. This is because there were no differences in plasma [FFA] between 
CFS and Control groups and there was a positive correlation between plasma free- 
[Trp] and [FFA] in both CFS and Control groups. Similarly, in EXP 2, although 
significantly higher plasma [FFA] was found, at rest and during exercise following 
caffeine ingestion, there was only a tendency for plasma free-[Trp] to be higher in 
the same trial. In EXP 3 also although plasma [FFA] was not different between the 
pre- and post-Cr supplementation trials, plasma free-[Tip] was lower with Cr.
The reason for this dissociation between plasma [FFA] and [Trp] observed in all
EXPs is intriguing. In EXP 2, although a small increase in plasma free-[Trp] was
observed with caffeine at the beginning and at the end (increased 11.3% and 15.5%
respectively) of exercise relative to Pic counteract time points, the lack of significant
differences in free-[Trp] between F and FC trials {P = 0.064) may be explained by
*the pre-exercise high fat meal employed in both trials. This concentration probably 
of the artificially elevated plasma FFA can occupy the biding site o f plasma albumin 
to its higher threshold binding to FFA attenuating any further displacement of Trp 
fi'om albumin (Struder et al,, 1996).
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In the present EXPs 1 and 2, the elevation in plasma [FFA] following the high fat 
meals was at around 0.6mmol/l at rest, 0.35mmol-r’ during exercise and 0.8mmol/l 
at the end of exercise. In contrast, Struder et al. (1996) observed that circulating 
plasma [FFA] was ~3.3mmoM'^ following soy oil/heparin administration, 
Consequently, due to the different diet manipulation protocol between Struder et al. 
(1996) study (which caused this massive elevation in circulating plasma [FFA]) and 
the present EXPs 1 and 2, the study by Struder et al. (1996) cannot be in general 
comparable with present EXPs. It should be noted that this high amount of the 
artificially elevated plasma [FFA] (hyperlipemia) is characterised by negative 
muscle metabolic and cardiovascular physiological responses elevating the risk of 
sudden-death (Newsholme and Leach, 1991).
The reason however, why plasma ffee-[Trp] was significantly higher and lower in 
CFS group (EXP 4) and in Cr group (EXP 3) respectively but plasma [FFA] was not 
different between the groups may implicate the role of liver function in this 
dissociation. It is well established that Trp is taken up and metabolised by the liver 
(Newsholme and Leech, 1983). Consequently, in CFS patients the dissociation 
between plasma [FFA] and ffee-[Trp] may suggest an abnormal liver Trp metabolic 
regulation leading to an inhibition of plasma free-Trp uptake. This may elevate 
plasma free-[Trp] irrespectively from plasma [FFA]. This possible liver dysfunction 
concerning Trp metabolism may be the same reason for the lower plasma [Tyr] 
observed in CFS group. This may lead to a metabolic down-regulation of plasma 
[Tyr] inducing lower brain Tyr uptake and DA synthesis. Consequently, there is a 
possibility that one of the pathogenic factors in CFS is due to the liver dysfunction 
enabling an elevation in plasma fi-ee-[Trp] and brain 5-HT up-regulation. On the 
other hand, it is possible that Cr supplementation contributes to enhancing liver free- 
Trp uptake and re-conversion of free-Trp to total Trp resulting in lowering plasma 
free-[Tip] irrespectively from plasma [FFA]. However, this possible liver re­
conversion o f free-Trp to total Trp was not to the extent to elevate plasma total [Trp] 
because free-Trp generally approximates to about only 10% of the total Trp levels 
(Curzon et al., 1973). More controlled studies are needed in order to examine the 
role of liver on Trp metabolic regulation in CFS and in health after Cr 
supplementation at rest and during exercise.
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7.2.1 One step forward into the role of Trp metabolism in ‘central fatigue’
As stated in Chapter 1 (section 1.2.1), after the Trp uptake by the liver, Trp can enter 
tlii'ee main metabolic pathways. These include Trp metabolism i) to kynurenine, in 
periphery and brain (Lapin, 1980; Stone and Connick, 1985; Moroni, 1999), ii) to 
brain 5-HT (Newsholme et a l, 1987) and iii) to tryptamine in the brain, which is 
further converted to kynurenine (Stone and Darlinghton, 2002). It has been reported 
that only 1% - 5% of dietary Tip is metabolised to brain 5-HT and more than 95% is 
converted to kynurenine (Stone, 1993).
One o f the significant reactions after the conversion o f Tip to kynurenine in the liver 
is that, kynurenine can be easily transfeired to cerebrospinal fluid or directly cross 
the BBB and distributed in various brain regions by the LNAA-camer (Fukui et a l, 
1991; Heyes and Quearry, 1990). For this reason, its levels may be elevated into the 
brain. It was previously fomid for example, that around 60% of the brain 
[kynurenine] has a peripheral origin (Gal and Sherman, 1980). In the brain, after the 
conversion of Trp to kynurenine, the latter can further be metabolised to kynurenic 
acid, to quinolinate acid (Stone and Darlinghton, 2002) or to anthamilic acid 
(Amirkhani et a l, 2002). The significance o f this kynurenine sub-conversion is that 
kynuienic acid was found to be neuroprotective but quinolinate acid is highly 
neurotoxic and may cause mitochondrial dysfunction, increase free-radical 
generation and produce neuronal damage in vivo (for review see Stone and 
Darlinghton, 2002). However, what is not known to date is whether kynurenine 
metabolites, especially quinolinate acid, could affect central fatigue in health and 
CFS, especially during prolonged exercise. It is possible therefore that kynurenine 
metabolites play a role in the development of central fatigue during exercise in the 
heat for example, and in the pathogenesis, exercise intolerance and exacerbated 
effort perception in CFS patients. More controlled studies are needed to examine the 
Trp rate conversion to kynurenines in periphery and brain at rest and during exercise 
at various temperatures in humans and to elucidate the role of kynurenine 
metabolites in putative central fatigue in health and CFS patients.
7.3 Brain 5-HT and DA modulators and perceptual responses
Several observations linking effort perception with peripheral sensory cues include 
(apart from sensations arising from the exercising muscles and joints) blood lactate
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levels (Ekblom and Goldbarg, 1971; Mihevic, 1981; Noble et al., 1983). Other 
mediators in the effort perception development include body core and skin 
temperatures and sensation of thermal-stress (Noble and Robertson, 1996). 
However, the association between increased 5-HT turnover and the subjective 
feeling of fatigue is one that is widely documented but less well understood, 
hicreased brain [5-HT] has been associated with lethargy, sleepiness, poor mood 
(Young, 1986) and increased core temperature (Feldberg and Myers, 1964; Lin et 
al., 1998; Sugimoto et al., 2000). All these responses have also been linked to 
reduction in cential motivation to exercise and rise in effort perception during 
exercise in thermoneutral (Davis et al., 1993; Davis and Bailey, 1997) or hot 
environments (Bridge et al., 2003; Nybo and Nielsen, 2001c; Pitsiladis et al., 2002).
In EXPs 1 and 2, leg muscular discomfort was significantly lower during constant­
load exercise following caffeine ingestion but this reduction was not found to be 
associated with brain 5-HT modulators as previously proposed (e.g. Blomstrand et 
al., 1997; Davis et al., 1993; Davis and Bailey, 1997). During exercise in the heat 
however, the reduction in leg muscular discomfort could be attributed to the lower 
plasma h*ee-[Trp] and free-[Trp]:[Tyr] ratio, observed following Cr 
supplementation, leading to a reduction in brain 5-HT synthesis and/or to an 
enhancement in brain DA metabolism. However, the lack of correlation between 
plasma ffee-[Trp] and [Prl] and between plasma free-[Trp] and effort perception, 
does not preclude an alternative mechanism in this effort perception reduction.
The reduction therefore, in effort perception in EXP 3 may be due to the effect o f Cr 
supplementation in reducing thermal-stress and dehydration rate (since both A T,-ec 
and sweat rate were lower during exercise with Cr than without). This contention is 
consistent with some previous reports (e.g. Kem et al., 2001; Noble and Robertson, 
1996). Another possible explanation for this reduction is the attenuation in muscle 
contraction-stress with Cr, which may prevent an early ATP depletion (Guerrero and 
Willimann, 1998). Although this prevention was not to such an extent to enhance 
endurance perfoimance in the heat in the whole Cr group, it was effective to 
increase perfoimance in the estimated ‘responders’ to Cr supplementation. Recently, 
for example, Terblanche and Nel (1998), using animal models, examined the effect 
of heat, submaximal exercise (10 min running x 3 in 30°C with 2 min recovery 
between exercise) and acclimation progi'amme on the activity o f creatine kinase
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(CK) in several tissues including kidneys, skeletal and heart muscles. They found 
that prolonged exercise in the heat has significantly reduced the activity of CK in all 
these tissues concluding that exercise in the heat may produce tissue damage. In the 
present EXP 3, it is possible that Cr has entranced brain DA function (Klivenyi et 
al., 1999; Mathews et al., 1999) that contributed to reducing thermal-stress (e.g. 
Hasagewa et at., 2000), and therefore attenuating the negative effect of heat-stress 
on CK activation on skeletal muscle. This may have contributed to the reduction in 
effort perception. However, more controlled human studies are needed in order to 
examine this particular speculation.
It is difficult however, to explain why the subjects in the EXPs I and 2 perceived it 
easier to exercise with caffeine than without. Particularly when one considers the 
accompanying elevation in key blood metabolites and cardiovascular responses (see 
Chapters 3 and 4) that typically would be expected to augment, rather than attenuate 
the response (Borg, 1982; Noble et al., 1983). Although, as stated in chapter 3, the 
reduction in effort perception may be due to the effect of caffeine on enhancing the 
secretion of endorphins (e.g. Laurent et al., 2000), which is well known to reduce 
pain perception and promote euphoria (e.g. Harber and Sutton, 1984) alternative 
mechanisms should not be precluded. Caffeine has the potential to easily cross the 
BBB and serves as a central competitive antagonist of adenosine (e.g. Fredholm et 
al., 1999). The net effect could then be to increase brain DA synthesis by 
antagonising the inhibition o f adenosine on DA activity (Davis et al., 2003) (For 
more details see Chapter 1, section 1.2.6.3). However, the similar plasma 
modulators and indices o f brain 5-HT and DA functions observed between the trials 
in EXPs 1 and 2 in association with the lack of performance improvement but lower 
effort perception found in both EXPs are in contrast to the hypothesis that 
physiological caffeine doses attenuates brain 5-HT synthesis and enhance exercise 
performance in well-trained humans. It is therefore possible that caffeine may 
significantly reduce brain 5-HT;DA ratio only when is directly administrated in 
small animals’ brain (Lim et al., 2001; Davis et al., 2003); or circulating [Prl] may 
not be as sensitive a marker o f 5-HT and DA metabolic interaction as previously 
proposed (e.g. Ben-Jonathan et al., 1989; De Meirleir et al., 1985a; b).
Alternatively, the inconsistency between the present EXPs 1 and 2 and some other 
animal studies on caffeine (e.g. Davis et al., 2003; Lim et al., 2001) may be due to
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different mechanistic action of caffeine between animals and humans (see Chapter 
1, section 1.2.6.2). In animals for example, caffeine administration leads to high 
CNS [theophylline] and in humans [paraxanthine] (Fredholm et al., 1999). 
Theophylline is a more potent inliibitor factor of brain adenosine receptors than 
caffeine itself or paraxanthine (Benowitz et al., 1995). Consequently, this could 
cause a discrepancy between studies that used animals or humans to examine the 
effect of caffeine on brain 5-HT:DA ratio and/or exercise performance. In addition, 
it was reported that caffeine half-life, for doses lower than lOmg'kg”^ range from 
0.7 to 1.2 hours in rat and mouse, 3 to 5 hours in monkey and 2.5 to 4.5 hours in 
humans (Fredholm et al., 1999). For these reasons, more control studies are 
required, utilising the same exercise protocol and same amount of caffeine ingestion, 
to determine possible different actions of caffeine in humans and animals 
particularly during exercise.
Only in CFS patients was effort perception significantly higher at exhaustion 
relative to sedentary control subjects (EXP 4). In the EXPs 1-3, although effort 
perception was significantly lower during prolonged exercise there were no 
differences between the trials and gi'oups in perceptual and cardiovascular responses 
at exhaustion. These results may imply a central neural component being 
responsible for the inability and/or imwillingness of CFS patients to achieve peak 
performance. Conversely, in EXPs 1-3 the effort perception results at exhaustion 
may suggest a similar central neural components being responsible for effort 
perception development in all trials irrespectively from caffeine and Cr 
administration. These may indicate that both caffeine and Cr administrations can 
effectively increase central motivation to exercise in thermoneutral, mild-cold and 
hot environments before the fatigue point is reached. However, when the metabolic 
and cardiovascular systems are stressed in the heat or in the cold neither caffeine nor 
Cr contributes in attenuating peak subjective fatigue.
7.4 General conclusions
From this series of EXPs a number of conclusions could be drawn. These 
conclusions apply specifically to protocols where constant-load or incremental 
exercise is performed to volitional fatigue in well-trained individuals and CFS 
patients. It is unknown to what extent the results obtained from these experiments
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and conclusions drawn could successfully be applied to different exercise protocols, 
to untrained or less-fit subjects and to different kind of exercise-intolerance patients 
other than CFS.
For the present experiments it maybe concluded:
i) a dissociation between effort perception, putative modulators of brain 
5-HT function, and exercise fatigue development in well-trained humans 
during exercise (EXPs 1-2).
ii) a lack of implication of brain 5-HT and DA modulators and functions 
in exercise fatigue process (EXPs 1-2), especially in a low temperature 
where the primary cause of fatigue during prolonged exercise is due to 
glycogen depletion (EXP 2).
iii) a lack of caffeine effectiveness in enhancing incremental and 
endurance exercise performance following an acute pre-exercise muscle 
metabolic adjustment with a high fat meal (EXPs 1-2).
iv) a dissociation between metabolic responses and effort perception 
development during constant-load exercise in the heat, thermoneutral and 
low temperatures in well-trained humans (EXPs 1-3) and during grated 
exercise in CFS patients (EXP 4).
v) an association between increased effort perception and exercise 
intolerance and increased effort perception and metabolic up- and down- 
regulation of brain 5-HT and DA modulator respectively in well-trained 
humans during exercise in the heat (EXP 3) and in CFS patients at rest 
and during grated exercise to volitional fatigue (EXP 4).
Overall, the results obtained from all four EXPs may suggest that neither brain 5-HT 
nor DA systems are implicated in the fatigue process when exercise is performed 
without significant thermoregulatory stress thus enabling fatigue development 
during exercise to occur due to peripheral factors (i.e. cardiovascular factors and 
glycogen depletion). Consequently, the increased central drive motivation to 
exercise (reduction in effort perception) per se is not capable to contribute in 
enlaancing exercise performance of well-trained humans in relatively thermoneutral 
temperatures. The exact mechanism therefore for the attenuation of effort perception 
with caffeine is unlikely to be brain 5-HT-mediated but a DA-mediated effect
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should not be precluded. However, the effectiveness of Cr supplementation to 
reduce brain 5-HT modulators and/or directly elevate brain DA function may have 
contributed to ameliorate thermal-stress, reduce RPE and enhance endurance 
performance in the ‘responders’ to Cr supplementation during exercise in the heat. 
Similarly, a metabolic up- and down-regulation of brain 5-HT and DA hinctions 
respectively may be involved in the early elevation in RPE and in onset of exercise 
intolerance in CFS and these may be important aspects even for the pathogenesis 
and maintenance of the disease. The present study was the first to demonstrate 
significantly lower baseline DA precursor levels in patients with CFS when 
compared with sedentary control.
7.5 Direction for firture research
A. The EXP 4, was the first that demonstrated abnormalities in precursors and 
peripheral modulators of brain 5-HT and DA functions, even in resting 
conditions. These results implicate the involvement of central neural 
mechanisms in the increased effort perception and impaired exercise 
tolerance in CFS, and warrant future intervention strategies aimed at 
correcting these abnormalities. Tyr depletion for example, was found to 
attenuate DA function in health (Harmer et a l, 2001). It is possible that Tyr 
supplementation contributes in enhancing central motivation to exercise and 
exercise tolerance and progressively attenuating the acute CFS symptoms. 
However, no studies to date have examined this particular hypothesis.
B. One of the metabolic pathways of Trp in the liver and brain leads to 
conversion of kynurenine, which is further converted mainly to kynurenic 
acid and quinolinate acid. What is not known to date is whether kynurenine 
metabolites, especially quinolinate acid, which is highly neurotoxic (causing 
mitochondrial dysfunction, increase free-radical generation and produce 
neuronal damage in vivo), could contribute in central fatigue process in 
health and CFS either at rest or during prolonged exercise in the heat. In 
addition, whether those kynurenine metabolites play a role in the 
pathogenesis, exercise intolerance and exacerbated RPE in CFS. More 
controlled studies are required to examine the rate of Trp conversion to 
kynurenines in periphery and brain at rest and during exercise in various
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temperatures in humans and to elucidate a possible role of kynurenine 
metabolites in central fatigue in health and CFS patients.
C. Further research is required to examine the effect of Cr supplementation on 
putative modulators of brain 5-HT and DA systems at rest but especially 
during prolonged exercise to fatigue in the heat.
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CENTRE FOR EXERCISE SCIENCE AND MEDICINE 
M E D T C A T . H IS T O R Y
t'
(CONFIDENTIAL)
Please read.
It is important to take a record of your medical history. You may 
have, or may have once had a condition that would make this type of 
testing unsuitable for you. For this reason we ask you to be as 
truthful and detailed as possible. At no point will this information be 
made available to any one other than the principal investigators for 
this study. If you have any doubts or questions, please ask.
SUBJECT DETAILS:
NAME:
AGE:
SEX (M/F):
GP NAME & ADDRESS:
D.O.B:
SMOKING:
Never Smoked 
Not for >6 months . 
Smoke <10 per day 
Smoke >10 per day
ILLNESSES:
ALLERGIES:
HOSPITALISATIONS:
MUSCULO SKELETAL DISORDER:
(Ai'thritis, Joint Pain, Fractures, Sports injury, Others)
CARDIOVASCULAR DISORDER: (Fever, Heart Murmurs, Chest Pain, Palpitations, High Blood 
Pressure, Others)
RESPIRATORY DISORDER: (Asthma, SOB, Cough, URTI, Others)
GASTROINTESTINAL DISORDER: (Jaundice, Bleeding, Others)
DIABETES:
CNS DISORDER: (Fits, Blackouts, Tremor, Paralysis, Epilepsy, Other)
PSYCHIATRIC TREATMENT:
FAMILY HISTORY: (Sudden death in a first degree relative-under the age of 35 years)
 - . Y ;r.:5
ARE YOU CURRENTLY TAKING ANY MEDICATION? No / Yes*
(*Please specify)________ __________________________________________
ARE YOU CURRENTLY TAKING ANY SUBSTANCES TO HELP IMPROVE YOUR TRAINING 
OR CONTROL YOUR WEIGHT i.e. CREATINE, PROTEIN SUPPLEMENT? No / Yes*r
(*Please specify)
ARE YOU CURRENTLY TAKING ANY OTHER SUPPLEMENTS i.e. FOOD SUPPLEMENTS, 
VITAMINS? No/Y es*
(*Please specify)________________________________________________________________________
CAN YOU THINK OF ANY OTHER REASON WHY YOU SHOULD NOT TAKE PART IN ANY OF 
OUR TESTS?
SYIVIPTOMS:
Do you experience any of the following, particularly on exercise?
Breathlessness No / Yes
Chest Pain No / Yes
Dizzy Fits/Fainting No / Yes
Palpitations No / Yes
Please note that if  you feel unwell on the day of the proposed test, or have been feeling poorly over 
the preceding day or two, please inform the investigators and DO NOT TAKE PART in the 
exercise test.
DECLARATION:
I have completed this questionnaire fully and truthfully. I have not kept any information from the 
investigators that may put myself at risk during high-intensity exercise, or affect the results that they 
obtain. I understand that I may withdraw from any one test or the study as a whole if I feel unwell, or feel 
uncomfortable with any part of the testing procedure.
(Signature).................
(Date)
PHYSICAL EXAM:
WEIGHT:
PULSE (Resting):
HEIGHT:
BP (Resting):
Screened by: 
(Signature) . (Date)
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CONSENT FORM
TITLE OF PROPOSED STUDY
Name of volunteer: ... 
Principle Investigator: Dr. Y. P. Pitsiladis
I have read the volunteer information foim on the above-mentioned study and I have 
had the opportunity to discuss the details and ask relevant questions. The nature and 
the puipose of the experimental tests to be undertaken have been explained to me. I 
understand fully what is proposed to be undertaken.
I have agreed to take part in the study as it has been outlined to me, but I understand 
that I am completely free to withdraw from the study at any time I wish.
I understand that these practical trials are part of a research project design to promote 
scientific and medical knowledge, which has been approved by the Joint Ethical 
Committee, and may be of no benefit to me personally.
I hereby fully and freely consent to take part in the study, which has been explained to 
me.
Signature o f volunteer
Date
I confirm that I have fully explained to the volunteer named above, the nature and 
purpose of the experimental tests to be undertaken.
Signature of investigator ............................................................
Date
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APPENDIX C
HPLC buffers, mixed-reagent and calibration standard preparation
Buffer A- 0.04 NaAc + 0.25% THF (IL)
0.03M NaAc 2.46g IL
pH ~7.5 -  adjust to 7.2 with dilute Acetic Acid, add 2.5ml THF 
Buffer B -  200ml 0.1 NaAc + 800ml Acetonitrile 
0. IM 1.64g NaAc in 200ml HzOa 
Calibration Standard 0.25mM:
5mM L-Tryptophan 50pl
2.5mM Sigma lOOpl
2.5mM internal standard lOOpl (0.0045g L-Methionine Sulfme in 10ml)
O.lmMHCl 750pl
Reagent C -  500mg OPA in 10ml methanol
Increase volume to 100ml with borate buffer
Add 500 pi of 2-mercaptoethanol (MCE).
Running samples composition:
80pl plasma + 20pl (1.375) / 0.25 ISl + lOpl PGA (3.3mM)
Calibration Std O.OOSmM:
0.25 % Dilution factor = 0.005
Dilution factor = 0.02 i.e., 50 times dilution
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APPENDIX D1
Glucose Method
The following is an enzymatic method for the measurement o f blood glucose on the 
Cob as Mira (ABX Mira Plus Spectrophotometer; ABX Diagnostics, UK).
Reagent:
Add contents o f 1 bottle of Glucose PAP (unimate 7) to lOOmls of distilled water 
Standard:
5.56 mmol/L standard (Sigma diagnostics)
Use Standard neat
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APPENDIX D2
Lactate Method
The following is an enzymatic method for the measurement o f blood lactate on the 
Cobas Mira (ABX Mira Plus Spectrophotometer; ABX Diagnostics, UK).
Reagents:
Hydrozine buffer: 5g Hydrozine hydrate + 0.2g EDTA disodium (Diaminoethanetetra- 
acetic acid disodium salt) + 1.3g Hydi'ozine sulphate. Make up to 85ml using distilled 
water. Check pH is 9 (using HCL to ip H  and KOH to tpH ). Top up to 100ml with 
distilled water.
NB: Calibration of pH meter. Use pH 7 to set offset. Rinse with distilled water. Use 
pH 4 to set slope. Rinse with distilled water.
Lactate reagent; 10ml Hydrozine buffer + 0.02g NAD + 150pl Lactate 
dehydrogenase (mix well).
Standards:
Lactate standard 3mmol: 9,970pl distilled water + 30pl L-Lactat(e) standard Imol 
(Boeluinger Mannheim).
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APPENDIX D3
Pyruvate M ethod
The following is an enzymatic method for the measurement of blood pyruvate on the 
Cobas Mira (ABX Mira Plus Spectrophotometer; ABX Diagnostics, UK).
Reagents:
Main Reagent solution: Trizma base solution (Sigma)
Start Reagent solution 1: 2mmol/LNADH (Roche). 14mg (0.014g) ofNADH 
dissolved in 10ml of distilled water.
Start Reagent solution 2: Lactate dehydrogenase (Boehringer Mannheim)
Both main reagent and start reagent 2 are used neat from the bottle.
Standards: Pymvate acid standard (450umol/L)
Use standard neat
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APPENDIX D4
Glycerol M ethod |
The following is an enzymatic method for the measurement of plasma glycerol on the 
Cobas Mira (ABX Mira Plus Spectrophotometer; ABX Diagnostics, UK).
Reagents:
Reagent 1 - 2-amino-2-methylpropan-l-ol Buffer (O.lmol/L, pH 9.9)
891.4mg (0.8914g) 2-amino-2-methylpropan-1 -ol 37.2mg (0.0372g) EDTA 
Disodium salt
ImL hydrazine hydrate
Dissolve in approx 90mL distilled was, adjust pH to 9.9 with HCl and dilute to lOOmL.
Reagent 2 -  Phosphate Buffer 0.lmol/1 pH 7.4 | |II0.1778g potassium orthophosphate I0.7628g di-sodium hydrogen orthophosphate
"IDissolve in 100ml distilled water and check pH is 7.4 3"A.
’Î Î
- fCo-enzyme -  Dissolve 25mg (0.025g) NAD in 1ml phosphate buffer (reagent 2)
Enzyme -  Use Glycerol Dehydrogenase (GDH) from Boehringer (Cat No. 258555)
Working Enzyme Reagent:
Add 150pl of NAD solution (co-enzyme) and 30pl of GDH (enzyme) to 8.1 ml of 
amino methyl propanol buffer (reagent 1)
Standards:
2.29 mmoEL (1.14mmol/L) (Precimat Glycerol, Roche)
a
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APPENDIX D5
Free Fatty Acid Method
The following is an enzymatic method (colorimetric method, Roche Diagnostics 
GmbH, Germany) for the measurement of FF A on the Cobas Mira (ABX Mira Plus 
Spectrophotometer; ABX Diagnostics, UK).
Reagent:
Using Free fatty acid, Half-micro test (Boehringer Mannheim). Prepare reaction 
mixture A {Main reagent) -dissolve one tablet of bottle 2 in bottle 1 (NB. Use forceps 
to take tablets out of bottle 2).
Start reagent:
Using Free fatty acid. Half-micro test (Boehringer Mannlieim). Prepare reaction 
mixture B {Sri)- dissolve one tablet of bottle 5 in bottle 4 (NB. Use forceps to take 
tablets out of bottle 5). Mix reaction mixture B with an equal volume from bottle 3.
Palmitic acid standard
l.Smmol: 0.0384g Palmitic Acid (Sigma) / 100ml = 1.5mmol. Transfer Palmitic acid 
into 100ml volumetric flask and dissolve in 25ml warm ethanol (exact volume not 
crucial, make sui'e stopper is in place on flask to prevent evaporation). Make volume 
up to 100ml with Triton X solution, stining throughout. Continue to stir for a further 
30mins.
Triton X solution: Warm 80ml distilled water to approx. 30°C - 40°C (microwave 
30s). Pipette in 7.5ml Triton X (NB. Triton X is difficult to pipette i.e. very thick, 
pipette slowly accuracy is not cmcial). Leave to cool to room temperature then top up 
to 100ml mark.
Ethanol: Warm 25ml of ethanol. Seal in a beaker (Parafilm) and leave for 5 minutes 
in a basin of warm water.
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